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Osteoarthritis (OA) is a heterogeneous disease involving the whole synovial joint. 
It is characterised by progressive degeneration of articular cartilage and changes in 
subchondral bone and bone at joint margins. Soft tissue structures such as synovium, 
ligaments and bridging muscles are also involved. OA can affect any joint, but the 
hand joints are among the most frequently involved joint sites.1,2 
At present there are no treatments to cure or delay the progression of structural 
abnormalities in OA (structure modifying treatments). Treatment options are limited to 
patient education and symptom alleviation aiming at control of pain and maintaining 
or improving joint function. 
Hand osteoartHritis, clinical asPects and 
imPact
Clinically, hand OA is characterised by joint pain, morning or inactivity stiffness, variable 
degrees of inflammation and limited motion leading to functional limitations. Clinical 
hallmarks are Heberden and Bouchard nodes or bony enlargement with or without 
deformities affecting characteristic target joints. Structural abnormalities in the affected 
joints can be assessed by radiographic methods, with the plain radiograph as recommended 
measure.3 Radiographic features of hand OA are the presence of osteophytes on joint 
margins, joint space narrowing, subchondral sclerosis, bony cysts and an altered shape of 
bony ends.4 In a subset of patients subchondral erosions are present. 
Hand OA often affects multiple hand joints.5-7 Symmetrical involvement is the 
strongest pattern of joint involvement, followed by clustering by row and clustering 
by ray. This was found for radiographic as well as symptomatic hand OA. Hand OA 
does not only cluster within hand joint groups, but also occurs with OA at other joint 
sites.8-10 The strongest and most consistent association was found between hand 
OA and knee OA. This polyarticular disease is known as generalised OA, although a 
widely accepted definition is lacking.11 
The disease burden of hand OA is variable but can be considerable and similar to 
that of rheumatoid arthritis (RA).12,13 In a study on the usefulness of the questionnaire 
Score for Assessment and quantification of Chronic Rheumatic Affections of the 
Hands (SACRAH) patients from secondary care with OA and RA had similar levels of 
pain and functional limitations, which were much worse than for healthy controls.12 
Interestingly, physicians considered RA patients more severely affected by their 
disease than OA patients. In another study in hand OA patients in secondary care, 
health related quality of life was worse in patients with hand OA than in healthy 
controls and similar to RA patients.13
ePidemiology of Hand osteoartHritis
The prevalence of hand OA increases with age and is higher in women than in 
men.1,14 Distinction is made between radiographic and symptomatic hand OA, the 
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latter being of most clinical and public health interest. The best known classification 
criteria for symptomatic hand OA are the criteria developed by the American College 
of Rheumatology (ACR).15 These criteria identify subjects with clinical hand OA using 
hand pain or stiffness as major criterion. In contrast, radiographic OA is defined 
based only on radiographic features of OA seen on radiographs. 
In a population study in Rotterdam among 917 women aged 55 to 70 years the 
prevalence of radiographic hand OA was 69%.16 The prevalence of symptomatic hand 
OA is as high as 26% in women over 70 years of age.17 The age- and sex-standardised 
incidence rates of symptomatic hand OA were 100 per 100,000 person years.1 The 
distal interphalangeal (DIP) joints are most commonly affected hand joint group, 
followed by the proximal interphalangeal (PIP) joints and the first carpometacarpal 
(CMC-1) joints (figure 1).2,17,18
aetiology of Hand osteoartHritis
OA is a multifactorial disease with systemic factors and local biomechanical factors 
playing a role in its development. In each patient a combination of these factors 
leads to activation of biochemical pathways resulting in the development of OA in a 
particular joint site (figure 2). 
Well-known systemic risk factors for hand OA are age and female sex.19,20 Obesity 
is associated with the development of hand OA, although the level of evidence is 
moderate.21 This suggests a role for metabolic processes, such as the production 
of adipocytokines. The role of genetic factors in OA susceptibility is generally 





accepted.22 A hereditary basis for hand OA has been documented already in the 
1940s by Stecher23 and it was later confirmed and extended to generalised OA by 
Kellgren et al.24 Heritabilities are reported to be as high as 65%.25,26 
The role of local biomechanical risk factors in hand OA development is less 
clear. Certain occupations with repetitive hand movements and prior hand injury 
were associated with an increased risk for hand OA development.20 It seems that 
the effect of mechanical factors differs between finger and thumb base joints. 
Interphalangeal OA was more prevalent in the dominant hand, whereas thumb base 
OA was found more often in the non-dominant hand.18,27 Articular hypermobility was 
positively associated with thumb base OA, while it was found to be protective for 
interphalangeal joint OA.28,29 
As is the case for OA development, OA progression is also thought to be 
multifactorial. However, even less is known about the factors that play a role in 
progression than in development, especially concerning hand OA. There is some 
evidence that risk factors for OA progression differ from those for OA development.30 
It remains unclear which hand OA patients are at risk for rapid progression of their 
disease. This lack of knowledge has hampered the development of new treatments 
and complicates patient information on prognosis.
Pain in osteoartHritis
Another issue of interest is the source of pain in OA. Cartilage is aneural and therefore 
cannot be the tissue that directly generates pain. Other joint structures such as 
subchondral bone, synovium and ligaments are richly innervated and could be the 
source of nociceptive stimuli. The relationship between radiographic hand OA signs 
and pain is only modest31, indicating that mechanisms not visible on radiographs play a 
role. With ultrasound a dose-response relationship was shown between inflammatory 
ultrasound features and pain.32 MRI studies give the opportunity to assess the role of 
subchondral bone, but have not yet been performed in hand OA. There is some evidence 
suggesting that both local and central pain sensitisation of pain pathways result in 
normal stimuli becoming painful in OA.30 Finally, it is well recognised that personal and 
environmental factors modulate the experience of pain and disease outcome on pain 
and disability (figure 2). This multidimensional character of the disease is illustrated by 
the International Classification of Functioning, Disability and Health (ICF) developed by 
the World Health Organization describing disease impact on a patient as a dynamic 
interaction between disease, personal and environmental factors.33
Hand osteoartHritis suBsets
Because of the heterogeneous character of hand OA, different subsets have been 
proposed based on different risk factors, associations and outcomes, although evidence 
is limited.3,20 Recognised subsets are interphalangeal joint OA (with and without nodes), 
thumb base OA and erosive OA. As described earlier, there is evidence suggesting that 
interphalangeal joint OA and thumb base OA have different risk factors. 
11
Chapter 1
erosive Oa is a radiographic subset based on the presence of subchondral erosions 
mainly affecting the interphalangeal joints.34 the prevalence was estimated 2.8% 
in the general population, rising to 15.5% in symptomatic hand Oa.35 the clinical 
course of erosive Oa is characterised by episodes of inflammatory signs and symptoms 
that finally fade out leaving deformities and functional disability.36 although it is 
assumed that erosive Oa has a higher burden and worse outcome than non-erosive 
Oa, evidence is limited.
apart from lack of data on disease outcome and pathogenesis of these subsets, 
it is unclear how these subsets are delineated. an example is the relationship 
between erosive Oa and nodal Oa. research on hand Oa subsets is therefore 
part of the agenda of the european League against rheumatism (eULar) Oa task 
Force.20 Characterisation and differentiation between subsets gives insight in their 
pathogenesis and may contribute to individualised patient management according to 
localisation and type of Oa.
Natural course of haNd osteoarthritis
Despite its high prevalence and disease burden little is known about the natural history 
of hand Oa. We can distinguish between the course of symptoms and signs of Oa 
Figure 2. Schematic representation of relationship between systemic and local biomechanical risk 




and the radiographic course. Besides information on the disease course it is important 
to identify determinants of clinical and radiographic outcome. This will contribute 
to more accurate patient information and to the development of new treatments. 
With respect to the development of structure modifying treatments, insight in the 
relationship between the clinical and radiographic course is of particular interest. 
Few studies have reported on the clinical course of hand OA. Earlier we reported 
on the course of hand OA over a period of 2 years, showing that around half of 
the population had an increase in self-reported pain and functional limitations and 
approximately 75% had an increase of pain on physical examination.37 Change in 
symptoms was not related to radiographic progression. A study with assessment after 
3 and 8 years found that over both periods around half of the population reported 
worse overall OA condition, whereas about a quarter reported improvement.38 
Another study showed that the average change in self-reported pain and functional 
limitations after 4 years was small, but again almost half of the individuals reported 
worsening of hand symptoms.39 
The radiographic course of hand OA has been studied more extensively, but still 
the number of studies is limited. Most studies have been conducted in samples from 
the general population.40-45 In our own hand OA patient population followed over the 
relatively short period of 2 years, we showed that 20% had radiographic progression 
in terms of osteophytes as well as joint space narrowing.37 In a long-term study over 
10 years in 169 hand OA patients 90% had progression of osteophytes and 74% had 
progression of joint space narrowing.46
How can we document the disease course in hand OA? A core concept of outcomes 
and outcome measures in hand OA studies is specified in the Osteoarthritis research 
Society International (OARSI) recommendations.3 Pain, functioning and radiographic 
abnormalities belong to the inner core set. Importantly, outcome measures and 
instruments need to be valid, reliable and sensitive to change. Questionnaires like 
the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) or a visual analogue 
scale (VAS) have shown to be valid and reliable self-reported measures for change 
in pain and functioning.3 Although pain obtained during physical examination and 
hand performance reflect different aspects compared to self-reported measures, 
standardised outcome measures are lacking. Serial radiographs are the recommended 
outcome measure for structural abnormalities. Various semi-quantitative radiographic 
scoring methods are available to assess the severity and progression of structural 
damage in hand OA.4,44,47-50 However, there is no consensus on the preferred method 
since comparative studies between methods are scarce.
All together, our knowledge on the disease course of hand OA is insufficient, 
especially when the clinical course and determinants of outcome are concerned. One 
of the reasons may be that the available instruments are not sensitive enough to 
detect change or do not assess processes essential in hand OA progression. This 
warrants assessment of existing measures and development of new methods.
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aim of tHe tHesis
The aim of this thesis is three-fold:
1 To investigate characteristics of the hand OA subsets thumb base OA, erosive OA 
and nodal OA.
2 To describe the long-term disease course of hand OA and identify determinants of 
outcome.
3 To determine the reliability, validity, sensitivity to change and feasibility of outcome 
measures in hand OA.
The ultimate goal of increasing our knowledge on hand OA subsets and 
factors involved in hand OA progression is identification of potential targets for 
the development of new treatments that alter the disease course or even prevent 
its development. In addition, it will contribute to better patient information and 
individualised patient management. 
tHe garP study
The Genetics ARthrosis and Progression (GARP) study is a collaborative research project 
by the departments of Rheumatology, Molecular Epidemiology, Clinical Epidemiology 
and Radiology of the Leiden University Medical Center. The study population consists 
of 192 Caucasian sibling pairs with symptomatic OA at multiple sites including the 
hands, knees, hips and spine.51 Hand OA is present in the majority of this population. 
Patients were included for baseline assessment between August 2000 and 
March 2003. Sibling pairs with at least one subject with symptomatic hip or knee 
OA were followed for 2 years to assess short-term disease progression at the lower 
extremity as well as the hand. This study showed that over a relatively short period 
there was already deterioration of both symptoms and structural abnormalities in a 
considerable part of the population. 
OA is, however, a slowly evolving disease and therefore the long-term disease 
course is of special interest. Therefore, the OA status was evaluated once more in 
the period April 2007 to June 2008. Participants assessed after this mean period of 6 
years comprise the main study population described in this thesis. 
tHesis outline
In part I the proposed hand OA subsets thumb base OA, erosive OA and nodal OA 
are investigated. Characterisation and differentiation between these subsets gives 
insight in their pathogenesis and contributes to individualised patient management 
according to localisation and type of OA.
In chapter 2 we assessed the impact of thumb base OA compared with 
interphalangeal joint OA by comparing pain and functional limitations between these 
subsets. Chapter 3 describes the clinical burden of erosive OA by comparing patients 
with erosive OA and patients with non-erosive OA with respect to pain, functioning 




burden is attributable to the erosive disease directly or to the presence of nodal OA. 
To enhance our knowledge on the development and progression of erosions in hand 
osteoarthritis we investigated the evolution of subchondral erosions over 6 years as 
well as local and systemic factors associated with this process in chapter 4. 
Part II concerns the natural course of hand OA over a period of 6 years and 
determinants of outcome over that period. As pointed out earlier, little is known about 
the natural history of hand OA and determinants of outcome. Knowledge of these topics 
contributes to better patient information and to the development of new therapies. 
The clinical and radiographic course of hand OA over 6 years as well as determinants 
of poor clinical outcome and radiographic progression are reported in chapter 5. 
Here we evaluate the clinical and radiographic determinants of outcome. Other risk 
factors for the progression of hand OA are assessed in subsequent chapters. 
As described earlier hand OA clusters in multiple hand joints and may occur as 
component of generalised OA. Most evidence supporting these concepts is based 
on cross-sectional data. Chapter 6 describes the progression of lower extremity OA 
after 6 years as well as its clinical and radiographic determinants in the same patient 
population. Subsequently, we investigated the relationship between radiographic 
progression in the joint groups within the hand as well as the relationship between 
hand OA progression and progression of OA at the knee in chapter 7. 
Little is known on the role of genetics in OA progression. In the GARP study we 
showed that over 2 years familial aggregation in OA progression is present, indicating 
a role for genetics in OA progression.52 In chapter 8 we investigated three single 
nucleotide polymorphisms (SNPs) known to be related with OA susceptibility for 
their association with radiographic progression of hand OA. Identification of genetic 
factors involved in OA progression gives insight in its pathophysiology and may reveal 
potential targets for new treatments.
According to the ICF patients’ perceptions regarding their disease are part of 
the personal factors that modify disease outcome. Chapters 9 and 10 report the 
relationship between illness perceptions and outcome of pain and disability in OA. 
This is of importance with a view to illness perceptions as potential targets for therapy 
aiming at better clinical outcome.
Loss of localised bone mineral density (BMD) has been shown to indicate 
inflammatory bone involvement in RA.53,54 In chapter 11 we investigated the 
association between accelerated BMD loss and radiographic progression of hand OA 
over a 2-year period. This gives insight in the relationship between BMD and OA, and 
may add to the role of inflammation in the pathophysiology of OA.
In part III the clinimetric properties of clinical and radiographic outcome measures 
for hand OA are evaluated.
Although there are validated self-reported outcome measures for pain, there is 
no standardised method for the assessment of pain on physical examination. Self-
reported and physician obtained pain score may reflect different aspects of disease. 
In chapter 12 we evaluated the reliability, feasibility and validity of the Doyle Index55, 
a measure that could serve this purpose. 
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There is no consensus on the preferred method for assessment of structural 
damage in hand OA. Therefore, we evaluated the reliability, sensitivity to change and 
feasibility of three semi-quantitative radiographic scoring methods in chapter 13. 
Recently a method for the measurement of joint space width in hand joints was 
developed.56 Chapter 14 describes the validity of this method by comparing the 
relationship to pain and disability between this method and semi-quantitative 
measurement of joint space narrowing. 
Finally, we summarised the results of the studies in this thesis and present our 
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thumb base involvement 
in symptomatic hand 
osteoarthritis is associated 
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Objective. To assess the impact of different subsets of symptomatic hand osteoarthritis 
(OA) on pain and disability. 
Methods. From 308 patients with hand OA a group with carpometacarpal joint 
(CMCJ) symptoms only (group I, n=20) was identified as well as groups with 
symptoms at the interphalangeal joints (IPJs) only (group II, n=138) and symptoms 
at both sites (group III, n=150). Hand pain and function, assessed with the AUSCAN, 
were compared between groups using linear mixed models. Radiographic OA was 
assessed using the Kellgren-Lawrence grading scale. 
Results. Mean (SD) AUSCAN scores for group I, II and III were 23.1 (11.7), 18.3 (11.9) 
and 26.4 (12.5), respectively. After adjustment for age, gender, body mass index, 
family effects and number of symptomatic hand joints, significant differences in 
AUSCAN scores of 7.4 (95%CI 1.8 to 13.0) between group I and II, and 5.7 (95%CI 
2.7 to 8.6) between group II and III were found. AUSCAN scores were 5.8 (95%CI 3.1 
to 8.6) higher for patients with versus patients without CMCJ symptoms. Kellgren-
Lawrence scores did not differ between groups.
Conclusion. In symptomatic hand OA, CMCJ OA contributes more to pain and 
disability than IPJ OA. Hence, treatment of CMCJ OA should be emphasised, even if 
it coincides with IPJ OA. 
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introduction
Hand osteoarthritis (OA) is a common musculoskeletal disorder, leading to variable 
degrees of pain and disability.1 It typically affects the distal interphalangeal joints (DIPJs), 
followed by the proximal interphangeal joints (PIPJs) and the first carpometacarpal 
joints (CMCJs).1,2
Different subsets of hand OA have been proposed based on different risk factors, 
associations and outcomes, although evidence is limited.3,4 Recognised subsets are 
IPJ OA (with or without nodes) and CMCJ OA. Articular hypermobility was positively 
associated with CMCJ OA, while it was found to be protective for IPJ OA.5,6 In 
addition, IPJ OA was found more often in the dominant hand, whereas CMCJ OA 
was found more often in the non-dominant hand.7 Few data are available on health 
outcomes in these subsets.8
The impact of functional limitations in the IPJs can differ from that in CMCJs, 
because IPJ OA causes limitations in movement of the fingers, whereas CMCJ OA 
affects closure of the first web. Therefore, different treatment strategies may be 
required. Current EULAR recommendations state that treatment of hand OA should 
be individualised according to its localisation.9
In the present study we take advantage of the presence of different subsets of 
symptomatic hand OA in a relatively large cohort. A group of patients with CMCJ OA 
only was identified as well as patients with IPJ OA only and patients with OA at both 
joint sites. We compared pain and disability between these subsets, which may have 
implications for the importance of treatment for each joint group. This study can 
contribute to the further distinction between subsets of hand OA and recommended 
management strategies. 
Patients and metHods
Study design and patient population
The Genetics ARthrosis and Progression (GARP) study is a cohort study, aimed at 
identifying determinants of OA susceptibility and progression.10 A total of 192 
Caucasian sibling pairs with OA at multiple sites in the hands or in two or more sites 
being hand, knee, hip or spine, were included after giving informed consent. Details 
on the recruitment and selection have been published elsewhere.10 The study was 
approved by the medical ethics committee.
Patients were eligible for the present study if they fulfilled the American College 
of Rheumatology (ACR) criteria for clinical hand OA11 or if they had hand pain or 
stiffness on most of the days of the preceding month in addition to multiple bony 
swellings in the selected joints from the American College of Rheumatology (ACR) 
criteria, or a Kellgren-Lawrence score ≥2 in any hand joint. 
A standard diagram of the hand joints was used to identify painful and stiff joints. 
Based on the location of these self-reported symptoms patients were assigned to 
three groups: group I with CMCJ symptoms only, group II with IPJ symptoms only 
and group III with symptoms at both sites. The number of symptomatic joints 




Self-reported hand pain and function were assessed with the pain (5 items) and 
physical functioning (9 items) subscales, as well as the total score (15 items) of the 
Australian/Canadian Osteoarthritis Hand Index LK 3.0 (AUSCAN) on a five-point 
Likert scale (0=none to 4=extreme).12 
Hand radiographs (dorsal-volar) were obtained by a single radiographer, employing a 
standard protocol. Radiographic hand OA was evaluated by an experienced radiologist 
(HMK) using the Kellgren-Lawrence grading scale.13 Intrareader reproducibility was high.10
Statistical analysis
Data were analysed using SPSS, version 14.0 (SPSS, Chicago, Illinois, USA). Demographic 
characteristics, AUSCAN and Kellgren-Lawrence scores were compared between the 
three groups using one-way ANOVA for normally distributed variables, the Kruskal-
Wallis test for not normally distributed variables, and chi-square test for proportions. 
For post hoc analysis the Bonferroni test and Mann-Whitney U test were used. All tests 
were two-tailed and p-values <0.05 were considered statistically significant.
Hand pain and function measured by the AUSCAN were compared between 
groups using linear mixed models adjusting for age, gender, body mass index (BMI) 
and number of symptomatic hand joints. A random intercept was used to adjust 
for family effects, meaning resemblance between siblings of one family. First the 
initial three groups were compared, followed by comparison of patients with CMCJ 
symptoms (group I + III) and those without CMCJ symptoms (group II). Estimates of 
fixed effects are reported with 95% confidence intervals (95%CI). 
results
Population description
Of the 308 eligible patients 20 (6.5%) were assigned to group I (CMCJ symptoms only), 
138 (44.8%) to group II (IPJ symptoms only) and 150 (48.7%) to group III (symptoms 
at both sites). The mean age was 60 years, the majority were women and fulfilled the 
ACR criteria for clinical hand OA (table 1). Group III consisted of significantly more 
women compared to groups I and II. Other demographic characteristics did not differ 
between the groups. The mean (SD) AUSCAN total score for the whole population was 
22.5 (12.8). AUSCAN was positively associated with the number of symptomatic joints.
Hand pain and function 
Mean (SD) AUSCAN total scores were 23.1 (11.7) for group I, 18.3 (11.9) for group 
II, and 26.4 (12.5) for group III (table 1). Multivariable analysis showed differences 
in AUSCAN total scores of 7.4 (95%CI 1.8 to 13.0) between groups I and II, and 5.7 
(95%CI 2.7 to 8.6) between groups II and III. Differences between group I and III were 
not significant. AUSCAN pain and function scores showed the same pattern.
Comparing patients with and without CMCJ symptoms (groups I + III vs group II) 
showed that AUSCAN total scores were 5.8 (95%CI 3.1 to 8.6) higher for patients 
with CMCJ symptoms compared to patients without CMCJ symptoms; AUSCAN pain 
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scores were 2.1 (95%Ci 1.2 to 3.1) higher and ausCan function scores were 3.6 
(95%Ci 1.8 to 5.5) higher. 
Radiological damage
median Kellgren-lawrence scores for the total hand did not differ between the 
groups (table 1). Considering the CmCJs showed that group ii had lower scores than 
groups i and iii (p<0.01). 
DISCUSSION
in this study it was found that symptomatic CmCJ oa contributes substantially to 
the level of self-reported pain and disability in patients with symptomatic hand oa. 
Patients with iPJ symptoms only reported the lowest levels of pain and disability, 
followed by patients with CmCJ symptoms only. Patients with symptoms at both sites 
Table 1. demographic characteristics, australian/Canadian osteoarthritis hand index (ausCan) and 










age, mean (sd) years 60.1 (7.3) 59.0 (5.7) 60.7 (7.6) 59.7 (7.4) ns
Women, %  86.4  75.0  81.2  92.6 <0.01 iii vs i0.01 iii vs ii
Post-menopausal, % 88.7 66.7 91.2 89.2 ns
bmi, mean (sd) kg/m2 26.9 (4.6) 28.2 (5.9) 26.6 (4.3) 26.9 (4.6) ns
aCR criteria hand oa, % 87.0 75.0 84.8 90.7 ns
Right handed only, % 78.7 75.0 77.4 79.3 ns
symptomatic hand oa only, % 12.1 21.7 11.7 10.9 ns
no. painful hand joints‡ 5 (2-10) 2 (1.3-2) 4 (2-8) 7 (4-12) ns
no. stiff hand joints‡ 5 (0-16) 0 (0-0) 6 (0-16) 7 (2-17) ns
no. bony swellings‡ 9 (6-14) 6 (4-12.3) 9 (5-14) 9 (6-14) ns
ausCan, mean (sd)
Total (0-60) 22.5 (12.8) 23.1 (11.7) 18.3 (11.9) 26.4 (12.5) <0.01 ii vs iii
Pain (0-20) 7.5 (4.4) 7.8 (3.9) 6.1 (4.1) 8.9 (4.2) <0.01 ii vs iii
Function (0-36) 13.2 (8.5) 13.9 (8.0) 10.6 (8.0) 15.6 (8.5) <0.01 ii vs iii
Kellgren-lawrence‡
Total (0-120) 15 (8-25) 16.5 (11-24) 14 (7.8-23) 16 (8-27) ns
iPJ (0-72) 12 (6-22) 12.5 (8-20) 13 (6.8-22) 11.5 (6-22.3) ns
CmCJ (0-8) 2 (0-4) 4 (2.3-5) 1 (0-3) 3 (1-5) <0.01 ii vs i and ii vs iii
Group i=symptoms at first CmCJs only, group ii=symptoms at iPJs only, group iii=symptoms at first 
CmCJs and iPJs. ausCan was unavailable for 10 patients assigned to group ii and 16 patients 
assigned to group iii.
‡median (iQR).
*P-value derived from one-way anova, mann-Whitney u test or Chi-square test.
abbreviations: CmCJ: carpometacarpal joint; iPJ: interphalangeal joint; bmi: body mass index; aCR: 
american College of Rheumatology. 
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experienced the highest levels of pain and disability. After adjustment for the number 
of symptomatic joints, which was associated with pain and disability, the levels of 
pain and disability reported by patients with CMCJ symptoms remained significantly 
higher compared to patients without CMCJ symptoms. This suggests that treatment 
aiming at CMCJ symptoms in patients with symptomatic hand OA is important, even 
if it coincides with IPJ symptoms. 
This is one of the first studies comparing patients with symptomatic CMCJ OA to 
patients with symptomatic IPJ OA. Spacek et al. compared disability and perceived 
handicap in hand OA between patients with predominantly thumb base symptoms and 
patients with predominantly IPJ symptoms.8 They found that disability and perceived 
handicap levels were comparable between the groups. However, they classified patients 
based on the location with most severe symptoms. Thus, patients in the thumb base 
group could experience IPJ symptoms and vice versa. This classification may be the reason 
why no differences between the groups were found. The classification criteria used in 
the present study were stricter, resulting in a more pronounced distinction between the 
groups. In general, no classification criteria for subsets of hand OA are available. We 
chose self-reported symptoms as classification criteria because symptomatic hand OA 
is considered the disease of clinical and public health interest. 
Several limitations of this study have to be considered. The first is the small 
number of patients in the group with CMCJ symptoms only. However, this small 
number may reflect the clinical reality where isolated symptomatic CMCJ OA is not 
very prevalent. Second, patients in the present study had familial OA at multiple 
sites. Whether the results can be generalised to patients with hand OA only, in a less 
selected population, has to be investigated. 
Based on these results it seems that CMCJ OA adds more to pain and disability 
in symptomatic hand OA than IPJ OA alone. This may be explained by the prominent 
role of the thumb in hand functioning. CMCJ symptoms therefore may be perceived 
as more severe and as having more impact on functioning than symptoms at the IPJs. 
Although no cut-off values are available for the AUSCAN, differences on the function 
subscale between those with and without CMCJ symptoms seem clinically relevant.14
The findings of this study suggest that treatment of CMCJ symptoms may 
substantially reduce levels of pain and disability, even if there is concurrent IPJ 
involvement. The results support expert opinion on the use of intra-articular corticoids 
and thumb orthosis for CMCJ OA.9 Occupational factors involving repetitive thumb 
use or heavy load on the thumb are modifiable factors that can contribute to CMCJ 
OA. Therefore, they should be taken into account when education and lifestyle 
advice are considered.15 Future research should aim at elucidating the efficacy of 
interventions targeted at the CMCJ in symptomatic hand OA. 
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Objective. To describe the clinical burden of erosive osteoarthritis (EOA) of the 
hand in terms of pain, functioning and health-related quality of life (HRQL), and its 
relationship to nodal osteoarthritis (OA). 
Methods. Patients with EOA (n=42) and non-EOA (n=194) were compared. Pain 
was assessed with the Australian/Canadian Osteoarthritis Hand Index (AUSCAN), 
Michigan Hand Outcome Questionnaire (MHQ) and pain intensity upon palpation. 
Functioning was evaluated with AUSCAN, MHQ, grip strength, pinch grip and hand 
mobility tests. HRQL was measured with the Short Form-36. Patient satisfaction with 
hand function and aesthetics were evaluated. The presence of nodal OA as well as 
its extent reflected by the number of nodes was assessed. Mean differences between 
patient groups were estimated with linear mixed models. To determine whether 
differences were independent of the nodal character of disease, adjustments were 
made for the number of nodes. 
Results. Patients with EOA experienced more pain, more functional limitations, 
less satisfaction with hand function and aesthetics and worse hand mobility than 
patients with non-EOA. HRQL was similar for the two groups. Patients with EOA 
had more nodes. A higher number of nodes was associated with worse outcome. 
After correction for the number of nodes, only hand mobility and patient satisfaction 
remained different between the groups.
Conclusion. Patients with EOA have a higher clinical burden than those with non-
erosive disease. This higher burden is only partly attributed to erosive disease itself, 
but mainly to the nodal character of the disease. 
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introduction
Hand osteoarthritis (OA) is a common musculoskeletal disorder characterised 
by degradation of cartilage and changes in subchondral bone.1 Because of its 
heterogeneous character, different subsets have been proposed based on different 
risk factors, associations and outcomes, although evidence is limited.2,3 Proposed 
subsets affecting the interphalangeal (IP) joints are erosive OA (EOA) and nodal OA.
The term EOA was first introduced by Peter et al.4 in 1966, but its clinical and 
radiographic features had already been described.5,6 EOA is a radiographic subset 
based on the presence of subchondral erosions which lead to deformities and 
sometimes to bony ankylosis.7 Although it is assumed that EOA has a higher clinical 
burden and worse outcome than non-EOA, there are very few studies on this topic.8,9 
In addition, the relationship between EOA and the presence of nodes is unclear. 
Whether EOA comprises a separate disease with specific risk factors and 
pathogenesis or a more severe subset of hand OA is unclear and therefore part of the 
research agenda of the EULAR OA Task Force.2 A first step is to further characterise 
EOA. In addition, insight in the relationship between EOA and nodal OA can contribute 
to our knowledge on these subsets.
To obtain a clearer view of the clinical burden of EOA we compared patients with 
EOA and non-EOA with respect to pain, functioning and health-related quality of life 
(HRQL). In addition, we determined whether this clinical burden is attributable to the 
erosive character of the disease or to the presence of nodal OA.
Patients and metHods
Study design and patient population
The Genetics ARthrosis and Progression (GARP) study population comprises 192 
Caucasian sibling pairs with symptomatic OA at multiple sites in the hands or in two 
or more of the following joint sites: hand, knee, hip or spine. Details on recruitment 
and selection have been published elsewhere.10 Patients from this population with 
hand OA evaluated after 6 years were included in the present study.
Diagnosis of hand OA
Hand OA was defined by the American College of Rheumatology (ACR) criteria for clinical 
hand OA11 or the presence of bony swelling in ≥2 of the 10 selected joints from the ACR 
criteria and a Kellgren-Lawrence score ≥2 in any IP or first carpometacarpal (CMC-1) joint. 
EOA was defined as the presence of erosive radiographic features according to 
the Verbruggen-Veys system in ≥2 IP joints.12,13 Erosive features were assessed on 
standardised hand radiographs by consensus opinion of two experienced readers (JB, 
IW). Intrareader reproducibility for the presence of EOA was excellent (kappa=1.0). 
In addition, osteophytes were graded 0-3 using the Osteoarthritis Research Society 
International (OARSI) atlas.14
Nodal OA was defined as Heberden’s or Bouchard’s nodes assessed by palpation 




Self-reported pain, functioning and HRQL
Hand pain and functional limitations were assessed with the pain (5 items) and 
function (9 items) subscales of the Australian/Canadian Osteoarthritis Hand Index 
(AUSCAN), on a five-point Likert scale (0=none to 4=extreme).16 
In addition, the Michigan Hand Outcome Questionnaire (MHQ) was used.17,18 
This hand-specific questionnaire includes 6 subscales: overall hand function, 
activities of daily living (ADL), pain, work performance and patient satisfaction 
with hand function and aesthetics. Subscale scores are calculated by summing the 
five-point Likert scale responses and normalizing them to 0-100.17 Higher scores 
indicate better hand function, except for the pain subscale on which higher scores 
correspond to more pain. 
The number of self-reported painful joints was assessed on a standard diagram 
including 30 hand joints (distal interphalangeal (DIP), proximal interphalangeal (PIP), 
first interphalangeal (IP-1), metacarpophalangeal (MCP) and CMC-1 joints).
HRQL was assessed with the Physical Component Summary scale (PCS) and Mental 
Component Summary scale (MCS) of the Medical Outcomes Study Short Form-36 
(SF-36) derived using norm based data from the Dutch population.19,20 Higher scores 
indicate better HRQL.
Physician-obtained measures 
Pain upon joint pressure was graded 0-3 in the 30 hand joints mentioned above (0=no 
pain, 1=complaining of pain, 2=complaining of pain and wincing, 3=complaining of 
pain and withdrawal of the joint). This pain intensity score ranges from 0 to 90.
Performance
Grip strength and pinch grip were measured with a hydraulic hand dynamometer 
and hydraulic pinch gauge (Saehan corporation, Masan, South-Korea), respectively. 
Hand mobility was assessed with the Hand Mobility in Scleroderma test (HAMIS) 
and fingertip to palm distance during maximal finger flexion.21,22 Using the HAMIS the 
nine movements included in the range of motion of the hand are graded 0 (normal) 
to 3 (unable to do) for each hand and summed. The total score is the mean of two 
hands. Fingertip to palm distance in millimeters was measured from the finger pulp 
to the distal palmar crease for each finger and summed. 
Statistical analysis
Data were analysed using SPSS, version 16.0 (SPSS, Chicago, Illinois, USA). 
Demographic and disease characteristics were compared between EOA and non-EOA 
patients using t-test and chi-squared test. Mean differences between these groups 
in measures of pain, functioning and HRQL, as well as the number of nodes, were 
estimated with a linear mixed model correcting for age, sex, body mass index (BMI) 
and with a random intercept to adjust for family effects within sibling pairs. Estimates 
are reported with 95% confidence intervals (95%CI). 
To determine whether differences between the groups can be attributed to the erosive 
or nodal component of the disease, the number of nodes was taken into account. By 
32
3
CILINICAL BURDEN OF EROSIVE HAND OA
doing so, its influence on differences in outcome can be assessed as well as the effect 
of erosiveness, independent of the nodal aspect. First, the association between outcome 
measures and the number of nodes was determined using linear mixed models, adjusting 
for age, sex, BMI and family effects. Estimates indicate the change that is accompanied by 
the presence of one additional node. Secondly, mean differences with 95%CI for measures 
of pain, functioning and HRQL between EOA and non-EOA groups were estimated using 
linear mixed models adjusting for the number of nodes in addition to age, sex, BMI and 
family effects. These estimates reflect the influence of erosiveness on clinical measures 
independent of the nodal disease character. 
We evaluated the radiographic appearance of nodes by assessing the presence 
and severity of osteophytes in IP joints with nodes. In addition, the above mentioned 
analysis was performed with correction for osteophytes instead of nodes.
results
Population description
Of the 236 patients with hand OA included, 42 (18%) were classified as having 
EOA. Nodal OA was present in 215 (91%) patients. All patients with EOA were 
also classified as having nodal OA, compared to 89% of the patients with non-EOA 
(p=0.031). The mean number of nodes in patients with EOA and non-EOA was 15.0 
(range 6-18) and 10.6 (range 2-18), respectively (p<0 001).
The mean age was 64.8 years and 83% were women (table 1). All patients with 
EOA fulfilled the ACR criteria for clinical hand OA. Demographic characteristics did 
not differ between patient groups (data not shown). 
Pain
Patients with EOA reported more pain and a higher number of painful joints than 
patients with non-EOA (table 2). There was a trend towards a higher pain intensity 
score in patients with EOA.
Table 1. Patient characteristics of 236 patients with hand osteoarthritis (OA). 
Age, mean (SD) years 64.8 (6.9)
Women, no (%) 195 (83)
Postmenopausal women, no (%) 185 (95)
Body mass index, mean (SD) kg/m2 28.3 (5.8)
ACR criteria hand OA, no (%) 206 (87)
Right handed, no (%) 187 (79)
Symptom duration, mean (SD) years 17.0 (8.2)
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Functioning
Self-reported hand function measured with the AUSCAN and MHQ subscales overall 
function, ADL and work performance was worse in patients with EOA (table 2). Grip 
strength and pinch grip did not differ between the groups. Hand mobility measured 
with the HAMIS and finger-palm distance was worse in patients with EOA. 
Health related quality of life 
Although no difference in PCS between the patient groups was found, a score below 
50 indicates that physical health was lower than the general population. The MCS 
was also similar for the groups, but not different from the general population. Patient 
satisfaction with hand function and aesthetics was lower in those with EOA (table 2). 
Association between outcome measures and number of nodes
A higher number of nodes was related to more pain and self-reported functional 
limitations (table 3). Grip strength and pinch grip were not related to the number 
of nodes, whereas worse hand mobility was related to the number of nodes; for 
each additional node, the fingertip to palm distance increased 3.7 mm and the 
HAMIS increased 0.24 points. No relationship between the SF-36 and the number of 
nodes was found. Lower patient satisfaction with hand function and aesthetics was 
associated with the presence of more nodes.
Table 3. Association between outcome measures and the number of nodes for 
total population expressed as β-coefficient (95%CI). 
Association with number of nodes*
Pain
AUSCAN pain 0.26 (0.12 to 0.39)
MHQ pain 1.37 (0.77 to 1.98)
Number of painful joints 0.50 (0.29 to 0.71)
Pain intensity 0.29 (0.09 to 0.48)
Functioning
AUSCAN function 0.33 (0.09 to 0.58)
MHQ overall function -0.77 (-1.20 to -0.35)
MHQ ADL -0.56 (-1.06 to -0.06)
MHQ work performance -0.34 (-1.07 to 0.39)
Grip strength, kg -0.17 (-0.39 to 0.05)
Pinch grip, kg 0.02 (-0.02 to 0.06)
HAMIS 0.24 (0.17 to 0.31)
Fingertip to palm distance, mm 3.71 (2.79 to 4.64)
Health related quality of life
SF-36 PCS -0.04 (-0.29 to 0.21)
SF-36 MCS 0.06 (-0.23 to 0.35)
MHQ function satisfaction -1.51 (-2.20 to -0.81)
MHQ aesthetic satisfaction -0.79 (-1.24 to -0.33)
*Adjusted for age, sex, BMI and family effects.
Abbreviations see table 2.
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Pain, functioning and HRQL adjusted for number of nodes
Mean differences in pain, functioning and HRQL were estimated with additional adjustment 
for the number of nodes (table 2). The estimated mean difference for all outcome measures 
was lower after this adjustment. Only hand mobility and patient satisfaction with hand 
function and aesthetics remained significantly different between patients with EOA and 
non-EOA. Adjustment for osteophytes instead of nodes did not change the results.
Structural abnormalities in IP joints with nodes
In the total population 13% (340/2682) of the IP joints with nodes had osteophytes 
grade 2-3 reflecting severe structural changes (table 4). For patients with EOA and 
non-EOA these proportions were 40% (255/628) and 4% (85/2054), respectively. 
discussion
This study was one of the first to investigate the clinical burden of EOA by comparing pain, 
functioning and HRQL between patients with EOA and non-EOA. It was found that patients 
with EOA experience more pain, report more functional limitations, have worse hand 
mobility and are less satisfied with hand function and aesthetics than those with non-EOA. 
HRQL was comparable for the patient groups. Patients with EOA had more nodes, which 
was also found to be a determinant of clinical outcome. Taking into account the number 
of nodes, only hand mobility and patient satisfaction remained different between the 
groups. These findings demonstrate that the clinical burden of EOA is higher compared to 
its non-erosive counterpart. However, it seems that this higher burden cannot exclusively 
be attributed to the erosive character but also to the nodal character of the disease.
Our results are in line with a study showing that patients with EOA reported more 
pain during ADL tasks than patients with non-EOA, but that grip strength did not 
differ between the groups.9 Maheu, et al. showed that patients with EOA reported 
more functional limitations, more aesthetic damage, similar HRQL and similar pain 
levels compared to those with non-EOA.8 This last finding is in contrast with our 
results, which may be due to difference in outcome measures. 
Hand mobility was assessed with the HAMIS and fingertip to palm distance. The 
HAMIS was developed for scleroderma patients. However, it can be regarded as a 
Table 4. Osteophyte grades for interphalangeal (IP) joints with and without nodes for the total 
population as well as erosive OA (EOA) and non-erosive OA (non-EOA) patient groups. 
Total population
Number of IP joints
EOA
Number of IP joints
Non-EOA













Osteophytes grade 0 1237 1215 143 95 1094 1120
Osteophytes grade 1 1105 336 230 31 875 305
Osteophytes grade 2-3 340 4 255 1 85 3
Total 2682 1555 628 127 2054 1428
36
3
CILINICAL BURDEN OF EROSIVE HAND OA
generic test since it evaluates all movements included in the range of motion of the 
hand, which was supported by a study showing that the HAMIS was valid for patients 
with rheumatoid arthritis.21,23 HAMIS and fingertip to palm distance showed the same 
results, indicating construct validity of both measures. 
For both groups it was found that physical health was lower compared to the 
general population, which is in line with a study by Slatkowsky-Christensen, et al.24
Patient satisfaction with hand function and aesthetics in hand OA comprises a 
domain not studied before. Although aesthetic damage is considered of potential 
importance in the evaluation of hand OA3, a recognised outcome measure is lacking. 
We have shown that the MHQ could serve this purpose.
There are a number of potential limitations to address. First, the GARP study 
was not designed to investigate differences between EOA and non-EOA. As a 
consequence the number of patients with EOA is relatively small, although it is the 
largest group of patients with EOA studied to date. This may reflect clinical practice 
in which, in our experience, EOA is not very prevalent. Data on the prevalence of 
EOA in a hospital population are unavailable. Cavasin, et al. showed that 8.5% of 
the general population of the Venetian area in Italy with signs or symptoms of hand 
OA had EOA.25 Second, patients in the present study had familial OA at multiple sites. 
Whether this specific phenotype affects our findings is unclear, and therefore similar 
studies in other OA phenotypes are warranted. 
We found that a higher number of nodes was associated with more pain, more 
functional limitations and less patient satisfaction. This is in line with a study reporting 
that Heberden’s nodes were positively related to hand pain.26 Only part of the nodes 
had high-grade osteophytes and this proportion was higher in patients with EOA 
than in those with non-EOA. This suggests that nodes do not only reflect severe 
structural abnormalities. The pathogenesis and role of nodes in IP joint OA is not 
fully understood. Nodes develop from mesenchymal stem cells from the periosteum 
or synovium by chondrogenesis and endochondral ossification induced by growth 
factors from the transforming growth factor β (TGF-β) family.27 Erosions are the 
product of increased osteoclast activity induced by inflammatory cytokines.28 Hence, 
processes involved in node and erosion formation seem to be different. 
After taking the number of nodes into account, pain and self-reported functional 
limitations between the patient groups were no longer different. This implies that the 
higher levels of these outcomes in patients with EOA cannot exclusively be attributed 
to erosiveness. Differences in hand mobility and patient satisfaction, however, 
remained significant after correction for the number of nodes meaning that they can 
also be attributed to erosiveness. A possible explanation is that hand mobility is a 
mechanical feature with structural underlying pathology, as seen in EOA.7 
This study showed that the clinical burden in patients with EOA is higher than 
in those with non-EOA. This higher burden seems to be due to the nodal character 
and only partly to the erosive character of the disease. Further research on disease 
characteristics, risk factors and the pathogenesis of EOA is needed to determine 
whether it comprises a separate disease and, more importantly, to enable the 
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Objective. In order to gain insight in the pathogenesis of erosive hand osteoarthritis 
(OA), the evolution of erosions in hand OA and risk factors involved were investigated.
Methods. The 6-year evolution in radiographic Verbruggen-Veys anatomical phase 
was assessed in interphalangeal joints of 236 patients with hand OA (mean age 
59 years, 83% women) from the Genetics ARthrosis and Progression (GARP) sibling 
pair study. Erosive evolution comprised phase transitions from non-erosive to erosive 
phases and from active erosions to remodelling. Clustering of erosive evolution 
within patients was assessed using the chi-squared test. Familial aggregation was 
evaluated in sibling pairs by estimating odds ratios (OR) for siblings and probands 
sharing erosive evolution. Local baseline determinants and the effect of high-sensitive 
CRP were assessed using generalised estimating equations. 
Results. Erosive evolution took place in 181 of 4120 interphalangeal joints at risk 
(4.4%), corresponding to 60 patients (25.4% of study sample). Erosive evolution 
was found more often in multiple interphalangeal joints in one patient than would 
be expected by chance (chi-square 373.0, p<0.001). The adjusted OR (95%CI) for a 
sibling having erosive evolution if the proband had erosive evolution was 4.7 (1.4 to 
15.8). Systemic inflammation was not associated with erosive activity. Independent 
local determinants were joint space narrowing (OR (95%CI) 8.9 (4.8 to 16.4)) and 
self-reported pain (OR (95%CI) 2.3 (1.1 to 4.7)). 
Conclusion. Erosive evolution was clustered within patients and families. Local factors 
were also involved in the evolution. This increase in insight in the pathogenesis of 
erosive hand OA will contribute to the development of new treatments. 
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introduction
Hand osteoarthritis (OA) is a common musculoskeletal disorder characterised by 
degradation of cartilage and changes in subchondral bone leading to pain and disability.1 
Because of its heterogeneous character, different subsets have been proposed, erosive 
OA (EOA) being one such subset that has attracted interest in OA research.2,3 
EOA is a radiographic subset based on the presence of subchondral erosions 
mainly affecting the interphalangeal (IP) joints.4 The prevalence of EOA was estimated 
to be 2.8% in the general population, rising to 15.5% in those with symptomatic 
hand OA.5 Recently we have shown that the clinical burden of EOA is higher 
compared to non-EOA, mainly due to its nodal character.6 The clinical course of 
EOA is characterised by episodes of inflammatory signs and symptoms that finally 
fade out leaving deformities and functional disability.7 Radiographically, a dynamic 
erosive process takes place with loss of joint space, mostly accompanied by other OA 
features, preceding active erosions that ultimately become remodelled.8,9 
Little is known on the risk factors associated with the development and progression 
of erosions in OA. Knowledge on these factors will increase understanding in the 
pathophysiological pathways involved in the erosive process of EOA, which is of 
importance when development of new therapies is considered. Therefore, we 
investigated the evolution of erosions in IP joints over time as well as systemic and 
local factors associated with the development and progression of erosions in a cohort 
of patients with hand OA followed for 6 years. Because the population comprises 
sibling pairs, it was possible to assess the role of familial factors.
Patients and metHods
Study design and patient population
The Genetics ARthrosis and Progression (GARP) study is a cohort study aimed at 
identifying determinants of OA susceptibility and progression. The study population 
comprises 192 Caucasian sibling pairs with symptomatic OA at multiple sites in the 
hand or in at least two of the following sites: hand, knee, hip or spine. Details about 
the recruitment and selection have been published elsewhere.10 In brief, probands 
were recruited from rheumatologists, orthopaedic surgeons and general practitioners. 
Subsequently, affected siblings were recruited via the probands. Both proband and 
sibling were required to have OA at multiple sites. The GARP study was approved by 
the medical ethics committee. 
Patients were included for baseline assessment between August 2000 and 
March 2003. From April 2007 to June 2008 participants who consented for a follow-
up evaluation were assessed. All consenters completed questionnaires and part of 
them visited the outpatient clinic for physical examination and radiographic evaluation. 
Patients were eligible for the present study if they had hand OA as defined hereafter 
and if radiographic follow-up data were available. Hand OA was defined by the 
American College of Rheumatology (ACR) criteria for clinical hand OA11 or the presence 
of either bony swelling in at least two of the ten selected joints from the ACR criteria or 




Hand radiographs (dorsal-volar) were obtained at baseline and follow-up by a 
single radiographer, employing a standard protocol with a fixed film focus distance 
(1.15 m). Radiographs were scored paired in chronological order blinded for patient 
characteristics by consensus opinion of two experienced readers (JB, IW) using the 
anatomical phase score developed by Verbruggen and Veys.8,9 In addition, osteophytes 
and joint space narrowing (JSN) were graded 0-3 using the Osteoarthritis Research 
Society International (OARSI) atlas.12 
The Verbruggen-Veys anatomical phase score comprises five phases representing 
the evolution of hand OA as a dynamic process. The first phase represents joints 
without OA signs (N, normal). In the stationary (S) phase joints have a classic OA 
appearance with osteophytes and possible JSN. The third phase comprises total loss 
of joint space (J) in the whole or part of the joint. In the next phase the subchondral 
plate becomes eroded (E). This is followed by the remodelling (R) phase when new 
irregular subchondral plates are formed and a new joint space becomes visible. Each 
phase incorporates the structural abnormalities that occur in that phase. Intrareader 
reproducibility for the evolution of joint phases over 6 years based on 25 randomly 
selected pairs of radiographs was very good (kappa=0.81). 
Determinants of outcome measured at baseline
Non-local factors included age, sex and body mass index (BMI). In addition, we assessed 
clustering of erosive evolution in multiple IP joints of the same patient as well as familial 
aggregation of the erosive process. Baseline serum high sensitive CRP (S-HsCRP) levels 
were used a measure for systemic inflammation. Serum samples were collected in 
the morning, processed within 4 hours upon collection and stored at -80°C until 
measurement. S-HsCRP was assayed using an ultrasensitive immunonephelometry 
method (N Latex CRP mono; Behringwerke AG, Marburg, Germany) on a BNA Behring 
nephelometer by a specialised laboratory (Synarc, Lyon, France).
Local factors on the joint level were the presence of self-reported pain and stiffness, 
pain upon lateral joint pressure, nodes, limited motion, osteophytes and JSN. Self-
reported pain and stiffness were assessed using a standard diagram including all hand 
joints on which the patient marked painful and stiff joints. The presence of pain upon 
lateral joint pressure, nodes and limited motion were assessed by a single observer 
during physical examination. For analysis we distinguished between osteophytes and 
JSN grade 0-1 and grade 2-3 as measured with the OARSI atlas. On the patient 
level self-reported hand pain and functional limitations were assessed with the pain 
(5 items) and function (9 items) subscales of the Australian/Canadian Osteoarthritis 
Hand Index (AUSCAN), on a five-point Likert scale (0=none to 4=extreme).13
Statistical analysis
Data were analysed using SPSS, version 16.0 (SPSS, Chicago, Illinois, USA). Only IP joints 
were included in the analyses since EOA is said to predominantly affect the IP joints.4 
For each IP joint the evolution of the anatomical phase over 6 years was obtained.
The E- and R-phases were considered as EOA. Although the J-phase could be 
regarded as a destructive phase, we felt that it comprises a phase that precedes the 
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true erosive phase. To assess the effect of this classification, sensitivity analysis was 
carried out including J-phase joints as erosive. Joints in the R-phase at baseline were 
not included in the analysis since they are no longer at risk for ongoing evolution. 
Erosive evolution was regarded a dynamic process defined by phase transitions from 
the N-phase, S-phase or J-phase to erosive phases (E-phase or R-phase) and from the 
E-phase to the R-phase. 
To test whether erosive evolution is likely to cluster in multiple IP joints of the same 
patient, we obtained the prevalence of erosive evolution for each IP joint. Using these 
observed frequencies the numbers of patients expected to have an erosive transition 
in 0, 1, 2, or at least 3 joints were calculated, assuming that the occurrence of erosive 
evolution in different IP joints of a patient is independent. Observed frequencies of 
involved joints were compared to the expected distribution using the chi-squared test. 
To assess whether familial factors play a role in the erosive process we compared 
siblings of probands who had erosive evolution in least one IP joint with siblings of 
probands without erosive evolution. This analysis requires availability of follow-up 
data for both proband and sibling. Odds ratios (ORs) were estimated for erosive 
evolution in siblings given erosive activity in the probands using logistic regression 
analyses. Additionally, we estimated the dose-response relationship between erosive 
evolution in the siblings and the number of joints with erosive evolution in probands. 
Adjustments were made for age, sex and BMI.
Risk factors for erosive evolution were assessed using generalised estimating 
equations (GEE) to take into account intra-patient and intra-family correlation. 
Additional adjustment was made for the anatomical phase at baseline. Multivariable 
analysis was carried out to assess the independent effect of determinants found to 
be associated with the outcome in univariable analysis adjusted for anatomical phase 




Of the 357 patients fulfilling the hand OA criteria at baseline, 300 (84%) consented 
to participate in the follow-up study of which 242 visited the outpatient clinic and 
58 completed questionnaires only. Consent was not given by 43 (12%) patients, 12 
(3.3%) were deceased and 2 (0.6%) were lost to follow-up. Most frequent reasons 
for non-consent were loss of interest (n=13), health problems not related to OA (n=7), 
unavailability of transport (n=7) and emigration (n=2). Of the 242 eligible patients 
236 had radiographic data available at baseline and follow-up and were included in 
the present study, comprising 4232 IP joints. There were 87 sibling pairs with follow-
up data for both proband and sibling for the analysis on familial aggregation. The 
mean follow-up time was 6.1 years (range 5.0-7.8 years). 
Baseline characteristics for the whole study sample as well as for the complete 
sibling pairs are shown in table 1. There were no differences between probands 
and siblings. Patients not included in the present study were somewhat older. Other 
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clinical and radiographic baseline parameters did not differ between consenters and 
non-consenters (data not shown).
Erosive evolution
At baseline 203 IP joints (4.7%) in 48 patients were classified as EOA, little more than 
half being in the remodelling phase (table 2). After 6 years 315 IP joints (7.4%) in 65 
patients were in erosive phases, of which two-third had reached the remodelling phase. 
Of the 4120 IP joints at risk at baseline (4232 minus 112 in R-phase), 181 (4.4%) 
had development or progression of erosions, comprising 60 patients (25.4% of study 
sample). This erosive evolution took place in 14 of the 2542 normal IP joints (0.6%), 
76 of the 1450 joints in S-phase (5.2%), 22 of the 37 joints in J-phase at baseline 
(59.5%), and 69 of the 91 joints with active erosions (76.0%). Phase transitions were 
most frequent in the distal interphalangeal (DIP) joints, except for the newly developed 
stationary OA, which occurred more often in the proximal interphalangeal (PIP) joints. 
Systemic determinants of erosive evolution
There was clear evidence for clustering of erosive evolution within patients (table 3). 
There were 31 patients with at least three IP joints showing erosive evolution, compared 
to 3 patients expected in this category. 
The adjusted OR (95%CI) for a sibling having erosive evolution if the proband had 
erosive evolution was 4.7 (1.4 to 15.8) (table 4). A dose-response relationship was found 
between the number of IP joints with erosive evolution among the probands and the 
presence of erosive evolution in siblings, although patient numbers were small (table 5). 
Age, sex, BMI and S-HsCRP levels were not associated with development or 
progression of erosions. The ORs (95%CI) adjusted for anatomical phase at baseline 
and family effects were 0.97 (0.94 to 1.01) for age, 1.13 (0.40 to 3.19) for female 
sex, 0.98 (0.92 to 1.04) per point BMI and 1.00 (0.96 to 1.05) for S-HsCRP.
Table 1. Baseline characteristics of the whole sample of 236 patients with hand osteoarthritis (OA) 




Age, mean (SD) years 58.9 (7.1) 58.9 (6.6) 58.6 (7.5)
Women, no (%) 196 (83) 75 (86) 69 (79)
Postmenopausal women, no (%) 176 (90) 69 (92) 62 (90)
Body mass index, mean (SD) kg/m2 27.1 (5.0) 27.5 (5.4) 26.8 (4.9)
ACR criteria hand OA, no (%) 183 (78) 72 (83) 66 (76)
Right handed, no (%) 188 (80) 67 (77) 68 (78)
Additional OA sites, no (%)
Knee 76 (32) 31 (36) 22 (25)
Hip 49 (21) 20 (23) 19 (22)
Spine 185 (78) 67 (77) 70 (81)
*Sibling pair with follow-up data available for both proband and sibling.
ACR: American College of Rheumatology.
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Table 2. Distribution of anatomical phases at baseline and follow-up and the evolution of anatomical 
phases over 6 years in 4232 interphalangeal (IP) joints from 236 patients with hand osteoarthritis. 
Baseline Follow-up Transition IP joints DIP joints PIP joints*
N-phase 2542 (60.1) 2387 (56.4) N-N 2387 (56.4) 868 (46.1) 1519 (64.6)
N-S/J 141 (3.3) 44 (2.3) 97 (4.1)
N-E/R 14 (0.3) 4 (0.2) 10 (0.4)
S-phase 1450 (34.3) 1501 (35.5) S-S/J 1375 (32.5) 724 (38.5) 651 (27.7)
S-E/R 76 (1.8) 55 (2.9) 21 (0.9)
J-phase 37 (0.9) 29 (0.7) J-J 15 (0.4) 11 (0.6) 4 (0.2)
J-E/R 22 (0.5) 15 (0.8) 7 (0.3)
E-phase 91 (2.1) 91 (2.1) E-E 22 (0.5) 19 (1.0) 3 (0.1)
E-R 69 (1.6) 55 (2.9) 14 (0.6)
R-phase 112 (2.6) 224 (5.3) R-R 112 (2.6) 87 (4.6) 25 (1.1)
Total 4232 4232 4232 1882 2350
*The IP-1 joint was included in the PIP joint group.
N=normal, S=stationary OA, J=joint space lost in part or whole joint, E=erosive, R=remodelled.
Abbreviations: DIP: distal interphalangeal; PIP: proximal interphalangeal.
Table 3. Observed and expected number of patients with 
interphalangeal joints showing erosive phase evolutions over 6 years.
Number of joints  







*Erosive evolution comprises phase transitions from N-phase, S-phase 
or J-phase to the erosive phases and from the E-phase to the R-phase.
Table 4. Odds ratios (OR) for concordance between probands and siblings for the presence of erosive 
evolution* in at least one interphalangeal joint in 87 sibling pairs with hand osteoarthritis.
Erosive evolution proband




Absent 53 6 1 1
Present 19 9 4.2 (1.3 to 13.3) 4.7 (1.4 to 15.8)
*Erosive evolution comprises phase transitions from N-phase, S-phase or J-phase to the erosive 
phases and from the E-phase to the R-phase.
**Adjusted for age, sex and BMI
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Local determinants of erosive evolution
Self-reported symptoms at patient and joint level as well as pain on pressure during 
physical examination were associated with erosive evolution (table 6). The presence of 
a node or limited motion in a joint was also related to this process. The largest effect for 
erosive activity was found for JSN with an OR (95%CI) of 9.8 (5.7 to 16.6). Osteophytes 
and self-reported functional limitations were not associated with erosive evolution. 
Multivariable analysis including all variables found to be associated in univariable 
analysis showed that self-reported pain at the joint level and JSN are independently 
associated with the development and progression of erosions (table 6). Sensitivity 
analysis regarding the J-phase as EOA did not substantially change the estimates from 
both univariable and multivariable analyses.
discussion
This longitudinal study over 6 years is the first to investigate the evolution of erosions 
in hand OA as well as determinants of this process. We found that erosive evolution 
took place in 4.4% of the IP joints at risk, which corresponds to 25.4% of the patients. 
Phase transitions involving this erosive activity were clustered within patients and 
within sibling pairs. JSN and self-reported pain at the joint level were independent 
local predictors for erosive evolution. These findings give insight in the course of EOA 
and contribute to the understanding of its pathogenesis and nature. 
Very few studies report on the evolution of EOA. Verbruggen et al. found that over 
3 and 5 years 5.6% and 9.1% of the IP joints showed erosive evolution, respectively.9 
The difference with our findings may be explained by the higher proportion of 
patients with EOA at baseline and the exclusion of the thumb IP joint in the study 
by Verbruggen et al. Although it is hypothesised that the so-called decompensation 
phase (J-phase or E-phase) will always be followed by remodelling, we found that 
41% of the joints in J-phase and 24% of the joints in E-phase remained in the same 
phase over 6 years. This is in line with the findings by the study on the course of EOA 
mentioned earlier, showing that over 5 years almost a quarter of the J-phase joints 
and almost half of the E-phase joints did not evolve to subsequent phases.9 Since OA 
Table 5. Dose-response relationship between the number of interphalangeal joints with erosive 
evolution* in probands and erosive evolution in siblings.
Number of IP joints with 
erosive evolution in proband




0 53 6 1 1
1 5 1 1.8 (0.2 to 17.7) 1.9 (0.2 to 19.9)
2 6 3 4.4 (0.9 to 22.4) 5.2 (0.9 to 29.0)
≥3 8 5 5.5 (1.4 to 22.4) 6.2 (1.4 to 27.5)
* Erosive evolution comprises phase transitions from N-phase, S-phase or J-phase to the erosive 
phases and from the E-phase to the R-phase.
**Adjusted for age, sex and BMI
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is a slowly progressive disease a longer follow-up period may be needed to confirm 
the hypothesis that decompensation phases always remodel. 
To our knowledge, risk factors for the development and progression of EOA have 
not been studied before. We found that phase transitions involving erosive activity 
were clustered within patients, meaning that EOA is more likely to occur in certain 
patients than in others. In other words, it is likely that only part of all hand OA patients 
will develop EOA. Differences in genetic background may explain this predisposition 
to erosive disease. This is strengthened by the finding that familial factors play a 
role in erosive evolution, although apart from genetic factors shared environmental 
influences may also explain this familial aggregation. We tried to minimise this effect 
by including only one sibling per proband. Stern et al. showed an association between 
EOA and the presence of a single nucleotide polymorphism (SNP) of the interleukin-
1β gene.14 In view of the role of IL-1 as mediator of erosions in rheumatoid arthritis15, 
its association with EOA makes sense. Another study found an increased frequency 
of the MS α1-antitrypsin genotype in EOA patients compared to non-EOA patients.16 
Our data on clustering suggest that EOA is a distinct, more severe OA phenotype, but 
it cannot answer the question whether EOA is a separate disease entity. 
Looking at local processes, we showed that pain predicts erosive evolution. A 
recent study in patients with hand OA showed a strong dose-response relationship 
between pain and signs of inflammation on ultrasound.17 Therefore, it might be that 
local inflammation is involved in the erosive process. A second independent risk factor 
for the evolution of erosions was moderate to high grade JSN. Since JSN is thought 
to reflect articular cartilage loss, all processes involved in cartilage damage may 
potentially contribute to the development and progression of erosions in IP joint OA. 
Table 6. Association between local factors and erosive evolution in 4120 interphalangeal joints from 






Self-reported pain 2.8 (1.7 to 4.7) 2.3 (1.1 to 4.7)
Self-reported stiffness 2.3 (1.3 to 4.0) 1.4 (0.6 to 3.1)
Pain on pressure 2.2 (1.4 to 3.4) 1.1 (0.6 to 1.8)
Node 2.7 (1.7 to 4.5) 1.8 (0.9 to 3.5)
Limited motion 2.6 (1.2 to 5.4) 1.6 (0.8 to 3.1)
Osteophyte grade 2-3 0.7 (0.3 to 2.0) -
JSN grade 2-3 9.8 (5.7 to 16.6) 8.9 (4.8 to 16.4)
Patient level
AUSCAN pain (per point) 1.07 (1.02 to 1.12) 1.00 (0.94 to 1.06)
AUSCAN function (per point) 1.02 (0.98 to 1.06) -
*Taking into account intra-familial effects and anatomical phase at baseline.
**Including all baseline determinants found to be associated in univariable analysis and additionally 
adjusted for family effects, anatomical phase at baseline, age, sex and BMI.
Abbreviations: AUSCAN: Australian/Canadian Osteoarthritis Hand Index, JSN: joint space narrowing.
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We did not find an association between systemic inflammation measured by 
S-HsCRP and erosive transition over 6 years. This may be due to the fact that S-HsCRP 
is an acute phase protein that was measured only at baseline whereas the erosive 
phase transition could have taken place at any moment in the 6 years of follow-up. 
Cross-sectional data on CRP in EOA are conflicting, showing higher as well as lower 
serum levels in EOA compared to non-EOA.18,19 It could be that local inflammation 
has more important role in EOA than systemic inflammation. 
For clinical practice these findings imply that IP joints of hand OA patients with 
moderate to severe JSN on radiographs are at a high risk of developing erosions. The 
same is true for pain although this effect is much smaller. Other factors to consider are 
presence of erosions in other IP joints and a family history of EOA. The identification 
of patients at high risk for development or progression of erosions has consequences 
for treatment since EOA is associated with high disease burden.6
There are a number of potential limitations to address. First, the GARP study was 
not designed to investigate the evolution of EOA. As a consequence the number of 
joints developing this uncommon feature was relatively small, but sufficient to derive 
valid results. The second concerns the possibility of bias due to differences between 
consenters and non-consenters. However, except age there were no differences 
between the two groups. We expect that the age difference has no effect on study 
outcome, since age was not associated with the outcome. Thirdly, our sample 
consists of patients with familial OA at multiple sites. Whether this specific hand OA 
phenotype affects our findings is unclear, and therefore similar studies in other OA 
phenotypes are warranted. On the other hand, this study sample gave the possibility 
to assess familial aggregation. The number of sibling pairs that was available for this 
analysis was relatively small, nevertheless effect sizes were considerable. Finally, the 
Verbruggen-Veys anatomical phase score was initially developed for the assessment 
of EOA. One might argue that this scoring system is not suitable for our sample since 
the majority of patients did not have EOA. However, our goal was to investigate the 
evolution of erosions over 6 years meaning that those without erosions were at risk to 
develop them. Therefore, the anatomical phase score is the appropriate method for our 
purpose. Recently, Verbruggen et al. extended their scoring system by quantification 
of the pathological changes that occur especially in the erosive phases.20
In conclusion, this study gives insight in the evolution of erosions in hand OA. 
We showed that patient, familial and local factors are involved in this process. 
These findings contribute to the unravelling of the pathogenesis of EOA, which is of 
importance when development of new treatment strategies is concerned. Whether 
genetic factors underlie the patient and familial factors is of interest. If so, it could 
provide evidence for EOA as separate disease entity. 
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aBstract
Objective. To investigate the long-term clinical and radiographic disease course of 
hand osteoarthritis (OA) and determinants of outcome. 
Methods. Clinical and radiographic measures were obtained at baseline and after 
6 years in 289 hand OA patients (mean age 59.5 years, 83.0% women). Clinical 
outcomes were self-reported pain and functional limitations assessed with the 
Australian/Canadian Osteoarthritis Hand Index (AUSCAN). Poor clinical outcome was 
defined as a follow-up score not fulfilling the Patient Acceptable Symptom State. 
Radiographic outcome was assessed by osteophytes and joint space narrowing 
(JSN) on standardised hand radiographs using the Osteoarthritis Research Society 
International (OARSI) atlas. Radiographic progression was defined as a change in 
osteophytes or JSN, above the smallest detectable change. Change in outcome 
measures was calculated and baseline determinants for poor clinical outcome and 
radiographic progression were assessed using logistic regression analysis.
Results. Clinical change showed great variation, with half of the population 
reporting deterioration. Poor outcome in pain was related to high levels of functional 
limitations and a high number of painful joints at baseline. Poor outcome on functional 
limitations was related to high baseline pain levels. Radiographic progression was 
present in 52.5% of patients and associated with high baseline levels of pain, nodes, 
osteophytes and the presence of erosive OA and nodal OA. Clinical change and 
radiographic progression were not related.
Conclusion. This study gives insight in the clinical and radiographic course of hand OA 
as well as determinants of outcome. These findings enable better patient information 
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introduction
Osteoarthritis (OA) is a common musculoskeletal disorder characterised by degradation 
of cartilage and changes in subchondral bone leading to pain and disability. The hand is 
a frequently involved joint site.1,2 The prevalence of symptomatic hand OA is estimated 
to be as high as 26% in women over 70 years of age.3 It is therefore a burden not only 
for the individual but also for society, increasing in relevance with an aging population.3,4 
Treatment options are limited to patient education and symptom alleviation. 
Despite its high prevalence and disease burden, little is known about the natural 
history of hand OA and the determinants of outcome. Knowledge of these topics 
enables the clinician to provide the patient with a more accurate prognosis and 
information about the disease. From a scientific point of view insight in the disease 
course and risk factors for an unfavourable outcome may reveal modifiable factors 
and thus enable the development of new therapies, including the much desired 
structure modifying treatments. 
Studies investigating the course of hand OA in patient populations are scarce.5-8 
Earlier we reported on the course of hand OA over a period of 2 years, showing 
that a considerable proportion of patients showed clinical as well as radiographic 
deterioration over this relatively short period.8 Since hand OA is a chronic disease 
and data on its long-term course and outcome are lacking, we assessed the clinical 
and radiographic disease course of hand OA over a period of 6 years as well as 
determinants of poor clinical outcome and radiographic progression in a cohort of 
hand OA patients. In addition, we assessed if changes in clinical symptoms are related 
to radiographic progression.
Patients and metHods
Study design and patient population
The Genetics ARthrosis and Progression (GARP) study is a cohort study aimed at 
identifying determinants of OA susceptibility and progression. The study population 
comprises 192 Caucasian sibling pairs with symptomatic OA at multiple sites in the 
hand or in at least 2 of the following sites: hand, knee, hip or spine. Patients were 
recruited from rheumatologists, orthopaedic surgeons and general practitioners. 
Further details about the recruitment and selection have been published elsewhere.9 
The GARP study was approved by the medical ethics committee. 
Patients were included for baseline assessment between August 2000 and 
March 2003. From April 2007 to June 2008 participants who consented for a follow-
up evaluation were assessed. All consenters completed questionnaires and part of 
them visited the outpatient clinic for physical examination and radiographic evaluation. 
Patients were eligible for the present study if they had hand OA defined according 
to the American College of Rheumatology (ACR) criteria for clinical hand OA10 or if 
structural abnormalities were present. Structural abnormalities were defined as the 
presence of radiographic hand OA based on a Kellgren-Lawrence score of ≥2 in at 
least one interphalangeal (IP) or first carpometacarpal (CMC-1) joint, or the presence 




Self-reported hand pain and functional limitations were assessed with the pain 
(5 items) and physical functioning (9 items) subscales of the Australian/Canadian 
Osteoarthritis Hand Index LK 3.0 (AUSCAN).11 On this hand specific questionnaire 
items are rated from 0 (none) to 4 (extreme) using a 48-hour time frame. Higher 
scores indicate worse pain and more functional limitations.
Radiographic outcome
Hand radiographs (dorsal-volar) were obtained at baseline and follow-up by a 
single radiographer, employing a standard protocol with a fixed film focus distance 
(1.15 m). Radiographs were scored paired in chronological order blinded for patient 
characteristics by consensus opinion of two experienced readers (JB, IW) using the 
Osteoarthritis Research Society International (OARSI) atlas.12 Osteophytes and joint 
space narrowing (JSN) were graded 0-3 in the distal interphalangeal (DIP), proximal 
interphalangeal (PIP), first interphalangeal (IP-1), CMC-1, metacarpophalangeal (MCP) 
and scaphotrapezotrapezoidal (STT) joints with total scores ranging from 0 to 96. 
Intra-class correlation coefficients (ICCs) for intrareader reproducibility based on 25 
randomly selected pairs of radiographs were 0.94 for osteophytes and 0.87 for JSN.
Determinants of outcome
All determinants were measured at baseline. Demographic variables were age, sex, 
body mass index (BMI) and post-menopausal status. 
Clinical determinants were pain and functional limitations measured with the 
AUSCAN, pain intensity score and the number of self-reported painful joints. The pain 
intensity score was obtained by grading pain on joint pressure 0 to 3 in 30 hand joints 
(0=no pain, 1=complaining of pain, 2=complaining of pain and wincing, 3=complaining 
of pain, wincing and withdrawal of joint). The number of painful joints was obtained 
using a standard diagram including 30 hand joints on which the patient marked the 
joints where pain was experienced on most days of the preceding month. 
Determinants reflecting structural abnormalities were osteophytes, JSN and the number 
of nodes in IP joints plus CMC-1 squaring. The latter was assessed by joint palpation. 
In addition, three proposed hand OA subsets were evaluated as outcome 
determinants.13 Erosive OA was defined as the presence of erosive radiographic 
features according to the Verbruggen-Veys score in at least two IP joints.14 Nodal OA 
was defined as the presence of Heberden or Bouchard nodes affecting at least two 
rays of either hand.15 The last subset comprises symptomatic thumb base OA, which 
was defined as the presence of pain or stiffness in the CMC-1 joint on most of the 
days of the preceding month.
The use of medication for OA joint complaints at baseline and follow-up and hand 
surgery performed over the follow-up period were recorded.
Statistical analysis
Data were analysed using SPSS, version 16.0 (SPSS, Chicago, Illinois, USA). Mean 
changes with 95% confidence interval (95%CI) for AUSCAN pain, AUSCAN functional 
limitations, osteophyte and JSN scores were calculated. Cumulative probability plots 
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were used to visualise change in these measures. To evaluate the proportion of patients 
with clinically relevant change in pain and functional limitations, the minimum clinically 
important improvement (MCII) of 1.49 and 1.25, respectively, was used.16 Those with a 
change on AUSCAN pain and functional limitations below -1.49 and -1.25 respectively, 
were classified as improved. Patients with change on AUSCAN pain and functional 
limitations above 1.49 and 1.25, respectively, were classified as deteriorated. For 
osteophytes and JSN the smallest detectable change (SDC) was used to assess change 
above measurement error.17 The SDC was 1.3 for osteophytes and 1.5 for JSN.
Poor clinical outcome was defined as AUSCAN pain and functional limitation 
scores at follow-up above the Patient Acceptable Symptom State (PASS), which 
were 8.2 and 16.1, respectively.18 Generalised estimating equations (GEE) models 
were used to estimate the risk for poor clinical outcome after 6 years for tertiles of 
baseline determinants with robust variance estimators to account for family effects 
within sibling pairs. Adjustments were made for baseline tertiles of AUSCAN pain and 
functional limitations depending on the outcome and follow-up time. 
Radiographic progression was defined as a change in osteophytes or JSN above the SDC. 
The risk for radiographic progression was estimated for tertiles of baseline determinants 
using GEE analysis to account for family effects within sibling pairs. Corrections were 
made for tertiles of baseline osteophyte and JSN scores and follow-up time. 
Odds ratios (ORs) were subsequently transformed to risk ratios (RRs) using the 
approximation formula described by Zhang, et al. because ORs for common outcomes 
in a fixed cohort are not good approximations of RRs.19 
The association between change in symptoms and radiographic progression was 
assessed by estimating mean differences of change on AUSCAN pain and functional 
limitations between patients with and without radiographic progression using linear 
mixed models. Adjustments were made for age, sex, BMI, baseline AUSCAN, baseline 
osteophytes, baseline JSN, follow-up time and family effects within sibling pairs. 
results
Study population
Of the 357 hand OA patients at baseline 300 (84.0%) consented to participate in the 
follow-up study of which 242 completed questionnaires and visited the outpatient 
clinic and 58 completed questionnaires only. Consent was not given by 43 (12.0%) 
patients, 12 (3.3%) were deceased and 2 (0.6%) were lost to follow-up. Most 
frequent reasons for non-consent were loss of interest (n=13), health problems 
not related to OA (n=7), unavailability of transport (n=7) and emigration (n=2). 
Of the 300 eligible patients complete clinical or radiographic follow-up data were 
available in 289 patients. These patients were included in the present study. Of these 
289 patients 18 had no baseline AUSCAN due to delayed validation of the Dutch 
AUSCAN. Of the 242 patients visiting the outpatient clinic, 6 had incomplete data 
due to missing radiographs.
The mean follow-up time was 6.1 years (range 5.0-7.8 years). Baseline 
characteristics are shown in table 1. Patients not included were somewhat older. 
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Other demographic characteristic as well as disease characteristics did not differ 
between these groups (data not shown). Looking at hand OA subsets, 22 patients 
had both erosive OA and thumb base OA comprising 52.4% and 16.2% of the 
patients with erosive OA and thumb base OA, respectively.
Clinical course of hand OA over 6 years
The mean increase in self-reported pain was small (table 2). However, there was 
great variation on the individual level as shown in figure 1A. An increase in pain was 
present in 109 patients (40.2%) whereas 71 patients (26.2%) reported less pain. The 
same was found for change in functional limitations: 136 patients (50.2%) patients 
reported more functional limitations and 71 patients (26.2%) improved (figure 1A).
At baseline and follow-up 137 (47.4%) and 157 (54.3%) patients used medication 
for joint complaints, respectively. Non-steroidal anti-inflammatory drugs (NSAIDs) 
and paracetamol were most frequently used: at baseline by 67.2% and 52.6%, 
respectively and at follow-up by 45.2% and 75.2%, respectively. Hand surgery was 
performed in 46 (15.9%) patients, comprising mostly of surgery for carpal tunnel 
syndrome and in 4 cases of joint surgery. 
Radiographic course of hand OA over 6 years
Osteophyte and JSN scores increased over time (table 2). Progression of osteophytes 
and JSN was present in 106 (44.9%) and 61 (25.8%) patients, respectively 
Table 1. Baseline characteristics of 289 patients with hand osteoarthritis (OA).
Age, mean (SD) years 59.5 (7.4)
Women, no (%) 240 (83.0)
Postmenopausal women, no (%) 220 (91.6)
Time after menopause, mean (SD) years 12.1 (8.4)
Body mass index, mean (SD) kg/m2 27.0 (4.7)
ACR criteria hand OA, no (%) 226 (78.2)
Right handed, no (%) 232 (80.3)
Hand OA subsets
Erosive OA, no (%) 42 (14.5)
Age, mean (SD) years 60.0 (7.5)
Women, no (%) 35 (83)
Nodal OA, no (%) 205 (70.7)
Age, mean (SD) years 59.5 (7.6)
Women, no (%) 180 (88)
Thumb base OA, no (%) 136 (47.1)
Age, mean (SD) years 58.9 (7.2)
Women, no (%) 124 (91)
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Table 2. Baseline, follow-up and change scores on self-reported pain and functional limitations (n=271), 
osteophytes and joint space narrowing (n=236) in patients with hand osteoarthritis followed for 6 years.
Baseline Follow-up Mean change 
(95%CI)Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Self-reported pain (0-20) 6.7 (4.8) 7.0 (3.0-10.0) 7.4 (4.9) 7.0 (4.0-11.0) 0.7 (0.3 to 1.2)
Self-reported function (0-36) 11.8 (8.9) 10.0 (4.0-19.0) 13.9 (8.9) 13.0 (7.0-21.0) 2.1 (1.3 to 2.9)
Osteophytes (0-96) 10.7 (8.2) 9.0 (5.0-14.0) 12.5 (9.4) 10.0 (6.0-16.0) 1.8 (1.6 to 2.1)
Joint space narrowing (0-96) 19.1 (11.3) 18.0 (12.0-24.0) 20.1 (11.8) 19.0 (12.3-25.0) 1.1 (0.8 to 1.3)
Figure 1. Cumulative probability plots of change in self-reported pain and functional limitations, 
osteophytes and joint space narrowing (JSN) in hand osteoarthritis patients over a 6-year period. 
A. Change in self-reported pain and functional limitations. The dotted lines represent the cut-off 
for deterioration and improvement based on the minimum clinically important improvement 
(MCII). Patients above the upper dotted line have deterioration of pain or functional limitations. 
Patients below the lower dotted line have improvement of pain or functional limitations. B. Change 
in osteophytes and JSN. All patients above the dotted smallest detectable change (SDC) line are 
classified as having progression in osteophytes or JSN.
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(figure 1B). In 124 (52.5%) patients radiographic progression, defined as progression 
in osteophytes or JSN, was present. Most change was seen in the DIP joints followed 
by the PIP joints and CMC-1 joints (table 3). 
Determinants of poor clinical outcome in hand OA after 6 years 
Poor outcome in pain was related to high levels of functional limitations and a 
high number of painful joints at baseline (table 4). More pain at baseline, reflected 
by AUSCAN pain and the number of painful joints, was associated with a higher 
risk of poor outcome in functional limitations. Determinants reflecting structural 
abnormalities, demographic characteristics (data not shown) and hand OA subsets 
were not associated with poor clinical outcome. Adjustment for medication use or 
hand surgery did not substantially influence the estimates. 
Determinants of radiographic progression of hand OA over 6 years 
Demographic characteristics were not related to radiographic progression (data not 
shown). Of the clinical variables, high levels of self-reported pain and pain intensity 
were associated with a higher risk of radiographic progression, whereas self-reported 
functional limitations were not (table 5). A high number of nodes and osteophyte 
scores were also related to radiographic progression. Patients with erosive OA had a 
higher risk of radiographic progression than patients with non-erosive OA. Nodal OA 
was associated with a two times higher risk of radiographic progression. Correction 
for medication use or hand surgery did not change these results. 
Table 3. Distribution of changes in osteophytes and joint space narrowing of the hand over 6 
years in 236 patients with hand osteoarthritis. The numbers represent the number of patients with 
corresponding change for each hand joint group.
≤-2 -1 0 1 2 3 4 ≥5
Osteophytes
 DIP joints 0 3 160 41 15 9 4 4
 PIP joints 0 0 169 44 12 4 3 4
 IP-1 joints 0 1 186 44 5 0 0 0
 CMC-1 joints 0 2 169 50 11 5 0 0
 MCP joints 0 2 215 13 4 2 0 0
 STT joints 0 1 229 6 0 0 0 0
Joint space narrowing
 DIP joints 2 8 173 33 11 4 5 0
 PIP joints 3 2 207 11 7 2 1 3
 IP-1 joints 0 3 204 19 9 1 0 0
 CMC-1 joints 4 6 184 32 10 0 0 0
 MCP joints 0 0 219 11 3 2 0 1
 STT joints 0 1 208 21 5 1 0 0
Abbreviations: DIP: distal interphalangeal, PIP: proximal interphalangeal, IP-1: first interphalangeal, 
CMC-1: first carpometacarpal MCP: metacarpophalangeal, STT: scaphotrapezotrapezoidal.
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Relationship between clinical change and radiographic progression in 
hand OA
The mean change in self-reported pain and functional limitations was not different 
between patients with and without radiographic progression, with adjusted mean 
differences (95%CI) of -0.14 (-1.21 to 0.92) and -0.57 (2.36 to 1.22) for pain and 
functional limitations, respectively. This means that clinical change and radiographic 
progression are not related.
Table 5. Risk of radiographic progression of hand osteoarthritis over 6 years for tertiles of baseline 














1.27 (0.86 to 1.69)
1.63 (1.21 to 1.99)
1
1.28 (0.84 to 1.74)









1.17 (0.80 to 1.52)
1.37 (1.00 to 1.71)
1
1.23 (0.85 to 1.60)
1.33 (0.95 to 1.73)








1.64 (1.24 to 1.98)
1.46 (1.05 to 1.84)
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1.63 (1.19 to 2.00)









1.87 (1.39 to 2.28)
1.78 (1.28 to 2.23)
1
1.80 (1.31 to 2.24)
1.70 (1.18 to 2.19)








2.35 (1.80 to 2.81)
2.32 (1.71 to 2.81)
1
2.06 (1.47 to 2.60)









1.21 (0.83 to 1.61)
1.92 (1.51 to 2.22)
1
1.28 (0.87 to 1.70)









0.74 (0.47 to 1.06)
1.47 (1.10 to 1.78)
1
0.71 (0.45 to 1.05)
1.24 (0.82 to 1.63)
Hand OA subsets 
Erosive hand OA 30/35 1.83 (1.50 to 2.01) 1.55 (1.04 to 1.88)
Nodal hand OA 104/164 2.28 (1.74 to 2.74) 1.94 (1.37 to 2.48)
Thumb base OA 64/109 1.18 (0.96 to 1.36) 1.16 (0.91 to 1.36)
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discussion
This study is the first to assess the long-term course of symptoms and radiographic 
abnormalities in hand OA patients and determinants of poor outcome. In contrast to 
the ongoing radiographic progression, both clinical deterioration and improvement 
were observed. Poor clinical outcome after 6 years was associated with high levels 
of pain and functional limitations at baseline. More pain, structural abnormalities 
and the presence of erosive OA and nodal OA were associated with a higher risk 
of radiographic progression over 6 years. Change in symptoms and radiographic 
progression were not related. These findings give insight in the long-term disease 
course of hand OA and factors associated with poor outcome. As a consequence the 
clinician can provide the patient with more accurate information on prognosis. From 
a scientific point of view these findings imply that the clinical and radiographic course 
of hand OA are distinct, making development of structure modifying treatments with 
clinical benefit challenging. 
Very few studies report on the clinical course of hand OA. We found that over 
a period of 6 years 40-50% of patients experienced more pain and functional 
limitations whereas about a quarter improved. These proportions are similar to the 
proportions reported over a 2-year period in the GARP study.8 Our findings are in line 
with a study by Dieppe et al. who found that around half of the population reported 
worse overall OA condition over 3 and 8 years, whereas about a quarter improved 
over both periods.20 Allen et al. showed that the average change on AUSCAN scores 
over 4 years was small, but again almost half of the individuals reported worse hand 
symptoms.21 It seems that the evolution of clinical symptoms is heterogeneous. 
Furthermore, the proportion of patients who deteriorate and improve does not 
differ much in the short and long-term. This may be due to adaptation to a chronic 
condition over time or other psychosocial factors rather than genuine improvement 
of the disease. The follow-up assessment took place at an arbitrary time point. The 
change may therefore not reflect the evolution of the disease over the whole time 
period, although on average it is valid.
The radiographic course of hand OA has been studied more extensively, but still 
the number of studies is limited. Most studies have been conducted in samples from 
the general population. In our patient sample we found that 52.5% of patients had 
radiographic progression: 44.9% had progression of osteophytes and 25.9% had 
progression of JSN. A study over 10 years found that 90% and 74% of hand OA 
patients had progression of osteophytes and JSN, respectively.6 These studies illustrate 
that the radiographic course of hand OA is an ongoing process. 
There are a number of potential limitations to this study. The first concerns 
the possibility of bias due to differences between consenters and non-consenters. 
However, demographic and disease characteristics did not differ between these 
groups, except for a higher age of non-consenters. We expect that this age difference 
has no effect on the study outcome, since age was not associated with any of the 
outcomes. Radiographic follow-up data were not available in all patients since a 
proportion only completed questionnaires. However, baseline radiographic scores did 
not differ between those with and without complete data indicating that selection 
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bias is probably absent. Third, our sample consists of patients with familial OA at 
multiple sites. Whether the results can be generalised to patients with other hand 
OA phenotypes has to be investigated. Another issue concerns the use of the MCII as 
cut-off for improvement and, conversely, for deterioration on the AUSCAN. This was 
done because there are no cut-offs available for clinically relevant deterioration on the 
AUSCAN. Finally, we used a self-reported outcome measure for functioning because 
performance measures were not available. Since performance is thought to reflect 
other aspects of functioning it would be interesting to investigate the evolution of 
hand performance over time as well as determinants of outcome. 
To date, the only information the clinician could provide hand OA patients was 
that their condition would deteriorate over time. At what pace and what the chances 
for worsening of the disease are, was unknown. This study enables more accurate 
information on the disease course and prognosis. We have shown that clinical 
improvement is seen in a substantial proportion of patients and some of the patients 
remain stable, even over a long time period. Thus, clinical deterioration is not inevitable 
for each patient. In contrast, radiographic abnormalities will worsen over time. It is 
important to bear in mind and inform patients that the evolution of symptoms and 
radiographic abnormalities are not related. With respect to patient prognosis, this 
study highlights parameters that are easy to obtain in order to identify patients at risk 
for poor outcome. If patients report high levels of pain and functional limitations at 
presentation they are at risk to have poor outcome on pain and functional limitations in 
the long term. The same is true for patients with more than eight painful joints. Patients 
with high levels of symptoms at presentation, nodal OA, erosive OA or a considerable 
amount of osteophytes are most likely to show progression of radiographic signs of 
OA. Since symptoms are most important to patients and predictive for both clinical and 
radiographic outcome of hand OA, they are of greater value in the evaluation of hand 
OA patients than radiographic OA signs. 
We found that change in symptoms was not related to structural changes. 
This discordance, for hand OA and OA in general, has been known well from 
cross-sectional studies and to lesser extent from longitudinal studies.8,22 This has 
important implications for the development of structure modifying treatments. 
Since symptomatic hand OA is considered the disease of clinical and public health 
interest, it is desirable if these treatments influence symptoms and not just structural 
abnormalities.23 These data show that change in symptoms does not coincide with 
change in structure. Whether the explanation is that there is really no association or 
that the current outcome measures are not sensitive enough is unknown, warranting 
more research. 
In conclusion, this study gives insight in the long-term clinical and radiographic 
disease course of hand OA as well as in determinants of poor outcome. This enables 
more accurate patient information on prognosis. It also shows that the clinical 
and radiographic course of hand OA is distinct, making development of structure 
modifying treatments challenging. Further research on prognostic factors in hand OA 
is needed to confirm and extend our findings as well as research on the relationship 
between change in symptoms and structural abnormalities.
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Objective. To investigate the factors associated with clinical progression and good 
prognosis in patients with lower limb osteoarthritis (OA).
Methods. Cohort study of 145 patients with OA in either knee, hip or both. 
Progression was defined as 1) new joint prosthesis or 2) increase in WOMAC pain 
or function score during 6 years follow-up above pre-defined thresholds. Patients 
without progression with decrease in WOMAC pain or function score lower than 
pre-defined thresholds were categorised as good prognosis. Relative risks (RRs) 
for progression and good prognosis with 95% confidence interval (95%CI) were 
estimated by comparing the highest tertile or category to the lowest tertile, for 
baseline determinants (age, sex, BMI, WOMAC pain and function scores, pain on 
physical examination, total range of motion (tROM), osteophytes and joint space 
narrowing (JSN) scores), and for worsening in WOMAC pain and function score in 1 
year. Adjustments were made for age, sex and BMI.
Results. Follow-up was completed by 117 patients (81%, median age 60 years, 84% 
female); 62 (53%) and 31 patients (26%) showed progression and good prognosis, 
respectively. The following determinants were associated with progression: pain on 
physical examination (RR (95%CI) 1.2 (1.0 to 1.5)); tROM (1.4 (1.1 to 1.6)); worsening 
in WOMAC pain (1.9 (1.2 to 2.3)); worsening in WOMAC function (2.4 (1.7 to 2.6)); 
osteophytes (1.5 (1.0 to 1.8)); and JSN (2.3 (1.5 to 2.7)). Worsening in WOMAC pain 
(0.1 (0.1 to 0.8)) and function score (0.1 (0.1 to 0.7)), were negatively associated with 
good prognosis.
Conclusion. Worsening of self-reported pain and function in 1 year, limited tROM 
and higher osteophyte and JSN scores were associated with clinical progression. 
Worsening in WOMAC pain and function score in 1 year were associated with lower 
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introduction
Osteoarthritis (OA) of the lower limbs accounts for problems in performing lower 
extremity tasks such as walking and stair climbing.1 Some of the patients with lower 
limb OA show progression of their OA with some progressing to total joint failure 
needing joint replacement.2 Knowing those who will progress is important because it 
will improve patient information on the prognosis of OA.
Several studies have investigated determinants of the progression of knee and hip 
OA3-5 and several remarks could be made on these studies. Firstly, none of the studies 
investigated knee and hip together. Investigating knee and hip separately is easy to 
understand, but it does not reflect the clinical practice. In more than 30% of knee OA 
patients, hip OA is present at the same time and up to 78% of patients have bilateral 
OA in knees or hips.6-7 Concomitant presence of OA in lower limb joints will affect the 
experience of pain and influence disability in all lower limb joints. Arguably, it is difficult 
for a patient to allocate complaints to a particular knee or hip joint. The questionnaires 
used in OA, such as Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) asks questions on daily life activities such as climbing the stairs, where knee 
and hip joints are simultaneously needed.8 Secondly, in most studies, progression was 
defined as joint deterioration on a radiograph while from the patient’s perspective clinical 
progression is more important.2,9 Thirdly, almost exclusively baseline determinants of 
progression were investigated. However, OA patients are included in cohort studies at 
varying stages of the OA disease course, which make changes in determinants over a 
short time period of interest as prognostic factors on the long term. 
Clinical progression is relevant for patients, but it is difficult to define. Probably 
this is one of the reasons why data on clinical progression are lacking compared to 
data on radiological progression. At this moment, there is no consensus on how to 
define clinical progression of knee and hip OA.10,11 Obviously, total joint replacement 
should be considered as OA disease progression. However, not all patients with 
worsening of their OA will receive joint replacement because of factors such as 
patient’s comorbidity and surgeon’s preference. Self-reported pain or disability could 
be used to define clinical progression, yet at present no standardised ‘cut-off’ for 
progression on self-reported outcome measures exists. 
To deal with the abovementioned issues, we propose in the present study 
a composite outcome which combines total joint replacement and increase in 
self-reported pain and function during 6 years follow-up above a clinically relevant 
cut-off8 as clinical progression. We sought to identify determinants associated with 
clinical progression and determinants associated with good prognosis of lower limb 
OA (knee and hip OA together). We assessed baseline determinants and determinants 
which were measured repeatedly over time. 
Patients and metHods
Study design and patient population
This study is part of the Genetics ARthrosis and Progression (GARP) study, a cohort 
study aimed at identifying determinants of OA susceptibility and progression.12 In this 
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cohort, 192 Caucasian sibling pairs (384 patients), aged 40 to 70 years were included. 
To be included, patients should have symptomatic OA at multiple joint sites in the 
hands or OA in two or more of the following joint sites: hand, spine (cervical or 
lumbar), knee or hip. Patients were recruited from the rheumatologic, orthopaedic 
and general practice clinics around Leiden, The Netherlands. Patients with secondary 
OA, familial syndromes with a clear Mendelian inheritance, and a shortened life 
expectancy (<1 year) were excluded. Patients underwent baseline assessment between 
August 2000 and March 2003 and filled-in questionnaires 1 year after this baseline 
visit. From April 2007 to June 2008 patients who consented for a follow-up evaluation 
(mean follow-up 6.1 years (range 5.1-7.5 years)) were assessed. 
To be eligible for the present study, patients needed to have OA in either knee or 
hip, or both. Knee OA was defined according to American College of Rheumatology 
(ACR) criteria as pain or stiffness in the knee on most days of the prior month and the 
presence of osteophytes in the tibiofemoral joints.13 Hip OA was also defined according 
to ACR criteria as pain or stiffness in the groin and hip region on most days of prior 
month together with femoral or acetabular osteophytes or joint space narrowing on 
the radiograph.14 There were 168 patients with knee or hip OA in the GARP cohort. Of 
these patients, 23 with prosthesis at baseline were excluded leaving 145 patients eligible 
for follow-up. Patients with prosthesis at baseline were excluded because they could be 
considered as already having progressive disease at baseline and because having first 
prosthesis could influence the decision in having another prosthesis (confounder). This 
study was approved by the medical ethics committee of the Leiden University Medical 
Center. Written informed consent was obtained from all participants. 
Clinical assessment
Demographic data at baseline were recorded using standardised questionnaires. 
Self-reported pain (5 items) and functional limitations (17 items) were evaluated by 
using the Dutch version of the WOMAC in 100 mm visual analogue scale format at 
baseline, at 1 year and at 6 year follow-up. It considered both knees and hips in the 
last 48 hours. Total scores on the pain and function subscales range from 0 to 100, 
higher scores indicating worse outcome. 
Physical health at baseline was assessed with the summary component scales 
for physical health (PCS) of the Dutch validated Medical Outcomes Study Short 
Form-36 (SF-36) derived from norm based data from the Dutch population (mean 50, 
SD 10).15,16 Higher scores indicate better physical health. 
Physical examination was performed at baseline. Pain on passive movement of the 
knee and hip joint was assessed using the modified articular index described by Doyle 
et al.17 (range 0 to 3; 0=no pain, 1=patient expressed tenderness, 2=patient expressed 
tenderness and winced, 3= patient expressed tenderness, winced and withdrew the 
joint). The total pain score ranged from 0 to 12. Flexion and extension of the knee 
and flexion and endorotation of the hip were measured using a goniometer and 
summed up as total range of motion (tROM).
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Radiographs 
Radiographs of the knees (posterior-anterior (PA); weight-bearing, non-fluoroscopic 
fixed-flexion protocol) and hips (PA; weight-bearing) at baseline were taken by a single 
experienced radiographer using a standard protocol with a fixed film focus distance 
(1.30 m). These analogue films were digitised using a film digitiser at a resolution 
corresponding to a pixel size of 100 mu. Using the Osteoarthritis Research Society 
International (OARSI) atlas18, two readers (EY, JB) scored the radiographs by consensus 
opinion. Osteophytes were graded 0-3 in the hip, on the medial and lateral femur and 
in the medial and lateral tibia. Joint space narrowing (JSN) was graded 0-3 in the hip 
and in the medial and lateral tibiofemoral compartments of the knees. Total scores for 
osteophytes ranged from 0 to 24 in the knees and 0 to 6 in the hips. Total scores for 
JSN ranged from 0 to 12 in the knees and 0 to 6 in the hips. Intrareader reproducibility 
based on 25 randomly selected pairs of radiographs was excellent, with intraclass 
correlation coefficients (ICC) of 0.99 for osteophytes and 0.98 for JSN. 
Definition of progression and good prognosis
Clinical progression was defined as: 1) the acquirement of joint replacement during 
follow-up or 2) an increase in self-reported (WOMAC) pain or function from baseline 
to 6 years follow-up above the predefined MPCI (minimum perceptible clinical 
improvement). The joint replacement should be due to OA and not due to other 
forms of arthritis or trauma. MPCI was originally developed as threshold value to 
define treatment response in OA. The threshold values were 9.7 for WOMAC pain 
and 9.3 for WOMAC function.8 
These threshold values with negative sign, were used to define good prognosis. 
Patients without progression who had decrease in WOMAC pain or function score in 
6 years lower than -9.7 or -9.3, respectively, were defined as having good prognosis.
Statistical analysis
Data were analysed using PASW Statistics 17 (SPSS, Chicago, Illinois, USA). Mean 
changes (SD and 95% confidence interval (95%CI)) for WOMAC pain and function, 
PCS and pain on examination scores were calculated by subtracting baseline scores 
from follow-up scores. Mean changes of scores with the 95%CI that did not cross 0 
were considered as significant. The self-reported pain and function change scores of 
every patient were plotted in a cumulative probability plot. 
Determinants of clinical progression were assessed using logistic regression 
analysis. We assessed the following baseline determinants: age, sex, BMI, WOMAC 
pain and function scores, pain on physical examination, total range of motion (tROM) 
and radiographic scores. We also assessed the determinants worsening in WOMAC 
pain and function score in 1 year.
The following baseline determinants were categorised in tertiles: BMI, WOMAC 
pain and function, tROM, osteophytes and JSN. Also categorised in tertiles were 
worsening in WOMAC pain and function in 1 year. Pain on physical examination was 
categorised into presence or absence of pain. In the logistic regression analysis, the 
odds ratios (ORs) were estimated by using the lowest category or the lowest tertile as 
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reference except for tROM where the highest tertile was used as reference. ORs were 
transformed to risk ratio (RRs) using the approximation formula of Zhang et al. because 
ORs of common outcomes in a fixed cohort are not a good approximation of RRs.19 
Since the population of this study consists of sibling pairs, intrafamily effect were taken 
into account by computing robust standard errors using Stata version 8 (Stata, College 
Station, Tx, USA). In the analyses, adjustments were made for age, sex and BMI. 
The significant determinants were included in a multivariable model to investigate 
whether these determinants could independently predict the clinical progression. 
To get an impression on how good these determinants predict clinical progression 
when they presented together, the R2 of this model was determined. Additionally, to 
investigate the discriminative ability of the multivariable model, we fitted a receiver 
operating characteristics (ROC) curve and calculated the area under the curve (AUC). 
We compared the predicted risk of progression with the observed clinical progression 
and good prognosis with the observed clinical progression and good prognosis.
results
Population description
Of the 145 patients eligible for the follow-up, 117 (81%) gave consent for follow-up 
assessment. The reasons for non-consent were: no interest in the follow-up study 
(n=8), unavailability of transport (n=8), health problems not associated with OA (n=4) 
and emigration (n=1). Five patients died during follow-up. 
Baseline characteristics of patients with and without follow-up and excluded patients 
due to joint prosthesis at baseline are presented in table 1. No difference was found 
between baseline characteristics of patients with and without follow-up (table 1). 
Clinical course of lower limb osteoarthritis 
The mean changes (95%CI) of self-reported (WOMAC) pain and function scores of all 
patients were -2.6 (-8.9 to 3.7) and 0.5 (-5.9 to 6.9), respectively (table 2). 
During follow-up, 36 patients (31%) received at least one joint replacement; 15 
for the hip, 16 for the knee and 5 for both knee and hip. In these patients with new 
joint replacements, the mean WOMAC pain score (95%CI) decreased over 6 years 
of follow-up (-8.5 (-17.8 to -0.1)). In the patients without new prosthesis (n=81), 
WOMAC pain and WOMAC function scores did not change significantly over time: 
-0.1 (-8.3 to 8.1) and 1.9 (-6.3 to 10.1), respectively.
Cumulative probability plots show the variation in natural course of self-
reported pain and function in the subgroup of patients without prosthesis (n=81) 
(figures 1a and 1b). Fifteen and 22 patients showed progression of WOMAC pain 
and WOMAC function based on changes above the MCPI, respectively. In total, 
26 patients (19.7%) showed clinical deterioration. Together with the 36 patients 
receiving joint replacement during follow-up, 62 of 117 patients (53.0%) showed 
clinical progression. Thirty-one patients showed good prognosis, based on change 




Disease course lower limb oa
Table 1. baseline characteristics of 168 patients with knee and/or hip osteoarthritis (oa) stratified 





Joint prosthesis at 
baseline (n=23)
age, median (iQr) years 60 (55-66) 62 (53-58) 64 (61-68)
women, no (%) 98 (84) 24 (74) 13 (72)
bmi, mean (range), kg/m2 28.0 (20-47) 27.3 (20-38) 29.3 (22-43)
Patients with oa, no (%)
Knee 74 (63) 18 (55) 3 (17)
Hip 31 (27) 6 (18) 6 (33)
Knee and hip 11 (10) 9 (27) 9 (50)
trom, mean (range),° 258 (133-389) 257 (219-441) 251 (48-360)
Knee flexion 86 (1-55) 86 (0-155) 85 (16-135)
Knee extension -4 (-30-10) -3 (-30-16) -2 (-15-16)
Hip flexion 134 (100-176) 134 (8-166) 133 (8-175)




Knee and hip 1
Pain physical exam, no (%)* 85 (73) 20 (71) 17 (74)
Hip 30 (26) 9 (32) 14 (61)
Knee 64 (55) 16 (57) 11 (48)
*Patients may have oa at multiple joints and can have pain in the knee and hip joint simultaneously.
Table 2. mean (sD) baseline, follow-up and change scores on self-reported pain and function (womac), 
physical health (Pcs), and pain on physical examination (Pe) for the total population and subgroups.
Baseline Follow-up Change (95%CI)
all patients (n=117) womac pain 36.2 (23.5) 33.6 (25.7) -2.6 (-8.9 to 3.7)
womac function 33.1 (24.3) 33.6 (24.8) 0.5 (-5.9 to 6.9)
Pcs 41.8 (9.8)‡ 42.0 (10.1)‡ 0.2 (-2.4 to 2.8)
Pain on Pe 1.7 (1.7) 2.4 (2.4) 0.7 (0.2 to 1.2)‡
Patients receiving prosthesis 
during follow-up (n=36) womac pain 36.5 (18.2) 28.0 (21.0) -8.5 (-17.8 to - 0.1)
‡
womac function 32.4 (20.1) 30.0 (20.6) -2.4 (-12.0 to 7.2)
Pcs 40.8 (9.1)‡ 40.7 (10.0)‡ -0.1 (-4.6 to 4.4)
Pain on Pe 1.8 (1.6) 2.8 (3.1) 1.0 (-0.2 to 2.2)
Patient not receiving prosthesis 
during follow-up (n=81) womac pain 36.1 (25.6) 36.0 (27.2) -0.1 (-8.3 to 8.1)
womac function 33.4 (26.1) 35.3 (26.4) 1.9 (-6.3 to 10.1)
Pcs 42.3 (10.1)‡ 42.6 (10.0)
‡ 0.3 (-2.8 to 3.4)




In the total study sample, in the subgroup of patients with new prosthesis and in 
patients without new prosthesis, physical health summary measures using SF-36 did 
not change during follow-up (table 2). Compared to the general population, physical 
health of patients with lower limb OA was consistently shown to be worse at baseline 
and follow-up.
Pain during physical examination worsened in the total population (table 2). In the 
subgroup with new prosthesis, pain did not worsen.
Determinants of clinical progression of lower limb osteoarthritis
Determinants of clinical progression of lower limb OA are shown in table 3. Age, 
female sex and BMI were not associated with clinical progression. Worsening of 
WOMAC pain and function scores in the first year were associated with 6 year 
progression while WOMAC pain and function score at baseline were not. Subjects 
in the highest tertile of WOMAC pain and function worsening in 1 year had a RR 
(95%CI) of 1.9 (1.2 to 2.3) and 2.4 (1.7 to 2.7), respectively, for clinical progression. 
The presence of pain on physical examination at baseline was associated with clinical 
progression (1.2 (1.0 to 1.5)). Patients in the lowest tertile of tROM had a higher 
risk for clinical progression, RR (95%CI) of 1.4 (1.1 to 1.6). Osteophytes and JSN 
at baseline were associated with clinical progression, RRs (95%CI) for being in the 
highest tertile of osteophytes and JSN scores were 1.5 (1.0 to 1.8) and 2.3 (1.5 to 
2.6), respectively. In a multivariable regression model, WOMAC function worsening 
in 1 year, limited tROM and JSN scores were found as independent determinants 
of clinical progression (table 3). With these variables, explained variance (R2) was 
48.6%. The AUC of the ROC curves was 0.85 (95%CI 0.76 to 0.94).
Determinants of good prognosis of lower limb osteoarthritis
Worsening in WOMAC pain and function score in 1 year were negatively associated with 
good prognosis, i.e. patients in highest tertile of 1-year increase in WOMAC pain and 
function scores had lower risk to have good prognosis (table 4). Patients in the highest 
tertile of worsening of WOMAC pain and function in 1 year, had RRs (95%CI) of 0.1 (0.1 
to 0.8) and 0.1 (0.1 to 0.7), respectively to have good prognosis of their lower limb OA 
compared to patients with WOMAC pain and function change in the lowest tertile. When 
these significant determinants were analysed in one model, only worsening in WOMAC 
function in 1 year was negatively associated with good prognosis. The R2 of this model 
was 43.3% and the AUC of the ROC curves was 0.78 (0.68 to 0.89).
discussion
To our knowledge, the present study is the first which investigated determinants of 
clinical progression of knee and hip together. Clinical outcome is chosen because it 
is essential to patients. Clinical progression was present in 53% of patients; 33% by 
receiving joint prosthesis and 20% by deteriorating of self-reported pain or function. 
Self-reported pain improved over 6 years in patients who received prostheses. Self-
reported function did not change over 6 years regardless of joint replacement. The 
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Table 3. Determinants for clinical progression of lower limb osteoarthritis over 6 years.
Determinant
Number of patients (%) Risk ratio 
(95%CI)*
Risk ratio 
(95%CI)**Progression No progression 
Age > 60 years 59 (50) 50 (43) 1.0 (0.9 to 1.1) NA
Female sex 48 (41) 50 (43) 0.6 (0.3 to 1.0) NA
Body mass index
< 25.5 19 (16) 20 (17) 1 NA
25.5-29.1 16 (14) 21 (18) 0.9 (0.5 to 1.2)
> 29.1 27 (23) 14 (12) 1.3 (0.9 to 1.7)
WOMAC pain 
< 23.2 21 (18) 18 (15) 1 NA
23.2-45.9 20 (17) 18 (15) 0.9 (0.5 to 1.3)
> 45.9 21 (18) 19 (16) 1.1 (0.7 to 1.4)
WOMAC function
< 18.0 20 (17) 20 (17) 1 NA
18.0-40.9 22 (19) 16 (14) 1.2 (0.7 to 1.6)
> 40.9 20 (17) 19 (16) 1.1 (0.7 to 1.5)
Change WOMAC pain 1 year
< - 3.3 10 (9) 16 (14) 1 NA
- 3.3-10.1 15 (13) 11 (9) 1.6 (0.8 to 2.2)
> 10.1 17 (15) 9 (8) 1.9 (1.2 to 2.3)
Change WOMAC function 1 year
< - 1.4 9 (8) 17 (15) 1 1
- 1.4-6.7 13 (11) 14 (12) 1.5 (0.9 to 2.7) 1.9 (0.9 to 2.6)
> 6.7 20 (17) 5 (4) 2.4 (1.7 to 2.7) 2.3 (1.2 to 2.8)
Pain physical examination 44 (38) 13 (11) 1.2 (1.0 to 1.5) 1.2 (0.8 to 1.2)
Total range of motion (°)
> 554 14 (12) 25 (21) 1 1
522-554 25 (21) 14 (12) 1.4 (1.01 to 1.7) 1.2 (0.9 to 1.2)
< 522 23 (20) 16 (14) 1.4 (1.1 to 1.6) 1.2 (1.03 to 1.3)
Osteophyte score
1 19 (16) 28 (24) 1 NA
2-4 19 (16) 10 (9) 1.4 (1.0 to 3.8)
> 4 11 (9) 8 (7) 1.5 (1.0 to 1.8)
JSN score
 1 19 (16) 32 (27) 1 1
2-4 16 (14) 12 (10) 1.5 (0.9 to 2.1) 1.6 (0.7 to 2.4)
> 4 14 (12) 2 (2) 2.3 (1.5 to 2.6) 2.4 (1.9 to 2.7)
*Adjusted for age, sex and BMI.
**Multivariable model .




Table 4. Determinants of good prognosis of lower limb osteoarthritis over 6 years. 
Determinant







Age > 60 years 28 (24) 3 (3) 1.0 (0.7 to 1.0) NA
Female sex 29 (25) 68 (58) 2.8 (0.8 to 6.3) NA
Body mass index
< 25.5 14 (12) 25 (21) 1 NA
25.5-29.1 12 (10) 25 (21) 0.9 (0.4 to 1.6)
> 29.1 5 (4) 35 (30) 0.3 (0.1 to 0.9)
WOMAC pain 
< 18.0 4 (4) 34 (29) 1 NA
18.0-45.9 14 (12) 24 (20) 2.7 (0.7 to 3.6)
> 45.9 13 (11) 27 (23) 2.2 (0.7 to 3.8)
WOMAC function
< 18.0 6 (5) 34 (29) 1 NA
18.0-40.9 13 (11) 24 (20) 2.5 (0.1 to 4.5)
> 40.9 12 (10) 27 (23) 1.9 (0.7 to 3.8)
Change WOMAC pain 1 year
< - 3.3 14 (12) 12 (10) 1 1
- 3.3-10.1 5 (4) 21 (18) 0.3 (0.1 to 0.6) 0.6 (0.1 to 1.3)
> 10.1 3 (3) 23 (20) 0.1 (0.1 to 0.8) 0.5 (0.1 to 1.1)
Change WOMAC function 1 year
< - 1.4 15 (13) 11 (9) 1 1
- 1.4-6.7 5 (4) 22 (19) 0.3 (0.1 to 0.7) 0.3 (0.1 to 0.8)
> 6.7 2 (2) 23 (18) 0.1 (0.1 to 0.7) 0.2 (0.1 to 0.8)
Pain physical examination 20 (17) 11 (9) 0.9 (0.6 to 1.1) NA
Total range of motion (°)
> 554 12 (10) 27 (23) 1 NA
522-554 10 (9) 28 (24) 0.8 (0.3 to 1.7)
< 522 9 (8) 30 (26) 0.9 (0.4 to 1.8)
Osteophyte score
1 17 (15) 30 (26) 1 NA
2-4 6 (5) 23 (20) 0.6 (0.2 to 1.2)
> 4 4 (3) 15 (13) 0.5 (0.2 to 1.3)
JSN score
 1 18 (15) 33 (28) 1 NA
2-4 7 (6) 21 (18) 0.7 (0.3 to 1.4)
> 4 2 (2) 14 (12) 0.4 (0.1 to 1.4)
*Adjusted for age, sex and BMI.
**Multivariable model.
Abbreviations see table 3.
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combination of womac function changes in 1 year, limited trom and JsN scores 
provided the best explanation of variation in clinical progression of lower limb oa. 
worsening womac pain and function in 1 year were negatively associated with good 
prognosis. Patients in the highest tertile of worsening in womac pain and womac 
function in 1 year had 90% less chance to have good prognosis of their lower limb oa 
compared to patients with pain and function change in the lowest tertile. 
The proportion of the study sample showing clinical progression in our study is 
comparable to results from the bristol ‘oa 500 study’. in that descriptive study, where 
the majority of the study population was also female, clinical change was reported 
by the patients as: better, same or worse. They found that 63% and 54% of the 
patients reported worsening in overall condition for the knee and hip respectively, after 
8 years follow-up.9 in the present study, self-reported pain and function for the whole 
group did not change in 6 years. This can be explained by the variation in progression 
between individuals as depicted in the cumulative probability plots (figure 1a 
and 1b). although some patients remained stable and even reported improvement, 
a considerable proportion of patients reported more pain and worse function. as a 
result the mean change is small. as expected in the subgroup of patients receiving 
Figure 1. cumulative probability plot of western ontario and mcmaster universities (womac) 
scores change of patients without prosthesis during follow-up (n=81) for womac pain scores 
change (above) and womac function scores change (below).The horizontal line above is the line 
set at minimal perceptible clinical improvement (mPci) score which is used as the cut-off to define 
progression and the horizontal line below is the line set to define good prognosis.
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joint prosthesis during follow-up, self-reported pain improved over 6 years, however, 
self-reported function did not. These results are consistent with the notion that joint 
replacement is an effective treatment for pain in lower limb OA. However, it seems that 
joint replacement cannot replace the function of the natural joint. Our results showed 
some parallels with a recent study by Nilsdotter et al.20 They showed that patients had 
high preoperative expectations concerning reduction of pain and function but one year 
after knee replacement only the expectation regarding reduction of pain was fulfilled. 
While self-reported pain at baseline was not associated with clinical progression, 
rapid deterioration in self-reported pain and function in the first year (even after 
correction for WOMAC scores at baseline that could confound the association) was 
associated with higher risk of progression over 6 years. This has not been studied before 
in OA, but it is in accordance with studies in rheumatoid arthritis (RA): worsening 
in self-reported disability measured with the health assessment questionnaire was 
a predictor for severe RA outcomes on the long term.21 Interestingly, worsening in 
WOMAC pain and function score in 1 year were negatively associated with good 
prognosis. The consequence of these findings is that by following lower limb OA 
patients for 1 year, doctors can inform the patients about the progression of the OA in 
the long term. Therefore, it might be advisable that doctors see their patients again 1 
year after the first visit. It will be also interesting to investigate in a clinical trial whether 
modification of self-reported pain or function 1 year after the presentation by means 
of physical therapy or better pain medication could stop the clinical progression of OA. 
Pain on physical examination at baseline was associated with clinical progression. 
It was also the only pain variable that deteriorated over time. This observation reflects 
that pain as reported by the patient differs from pain on passive movement as found 
during physical examination as shown previously.22 
Limited tROM and presence of pain on physical examination at baseline probably 
reflected the structural damage and might be used as a surrogate for osteophyte and 
JSN scores. In a recent EULAR recommendation for the diagnosis of knee OA, limited 
movement was indeed proposed as one of the clinical signs needed to make the 
diagnosis, probably because it was associated with radiological OA.23 
Osteophyte and JSN scores were also identified as determinants of lower limb OA 
progression. Our findings support the findings of Lane and colleague, that osteophytes and 
JSN together with subchondral bone sclerosis were associated with hip OA progression.4 
We showed that the WOMAC function changes in 1 year, limited tROM and 
higher JSN scores were independent determinants of clinical progression of lower 
limb OA. Although the main aim of this paper was to identify the determinants that 
were associated with clinical progression and not to build a prognostic model, we 
tried to get an impression on how good these determinants are in predicting clinical 
progression when they are present together. We also tested the discriminative ability 
of this model to get an indication on how good the presence of these determinants 
predicts the clinical progression of lower OA. Their cumulative presence provided a 
very good explanation of variation in clinical progression, as shown with R2 of 48.6%. 
The AUCs of the ROC curves also indicate a reasonable discriminative ability. This 
means that performing assessment on these three determinants in clinical practice 
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will help clinician much in predicting the progression of lower limb OA and therefore 
give better patient information.
Roos et al. showed that female sex was associated with worsening in self-reported 
pain and function and that older age and higher BMI were associated with worsening 
in function assessed on physical examination. We found no associations between 
demographic determinants and clinical progression.5 Determinants for incidence are 
often failed to be identified as determinant of progression. The failure in finding 
determinants for progression is a common phenomenon that might be caused by 
methodological problem in studies restricted to subjects with existing disease.24 
Unfortunately, no method is yet available to overcome this problem. Another possible 
explanation in the difference between our results and Roos et al. is the difference in 
patient population. The population in the study of Roos et al. was a mix of knee OA 
patients and participants who underwent menisectomy in the past. 
Our study sample that consists of selected sibling pairs with OA at multiple sites has 
strengths and limitations. Since a generalised OA (GOA) population is associated with 
rapid OA progression25, our study population is suitable to investigate OA progression 
within a relatively short period. However, the generalisability of our results in other 
population settings, especially to general practice is arguably limited and we could 
not investigate GOA as determinant for progression. Yet, if we compare the ‘severity 
of OA’ by taking the incidence of joint prosthesis, we did not see much difference 
in the incidence of joint prosthesis in our study sample and in a hospital based OA 
population which was not selected for GOA, for a comparable follow-up time.9 It 
supports the observations in other patient populations that GOA is also common and 
it is important to bear in mind that OA is often present at multiple sites while only the 
most symptomatic sites draw attention.9,25 To leave out the familial effect, we have 
performed a correction for familial factors in the analysis. 
The choice of the composite outcome combining two outcomes, joint prosthesis and 
increase in WOMAC pain or function scores above MPCI, rewards comments. The two 
outcomes might be different; increase in WOMAC scores above MPCI might not always 
results in joint prosthesis. Also, the use of MPCI in defining progression is arbitrary. It 
was originally created to indicate clinical improvement in trials.8 However, since no clinical 
outcome regarding clinical progression of knee or hip or lower limb OA is available at this 
moment, our choice of outcome could be considered to be used in observational studies. 
It should be noted that our study population consists mainly of women. OA is 
known to be more common in women. The phenomenon that women tend to be 
overrepresented in OA studies is well known, such as in the large Bristol ‘OA 500 
study’ mentioned above.9 In the present study, effort has been taken to adjust for 
this possible confounder.
In summary, over a period of 6 years, more than half of the patients showed 
progression of lower limb OA, based on total joint replacement or change in self-
reported pain or function above the MPCI. Performing a combination of clinical and 
radiological assessment in clinical practice could evaluate the subgroup of patients 
with progression of lower limb OA. These findings would help doctors in patient 
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Objective. Investigate patterns of osteoarthritis (OA) progression within hand joints 
and the relationship between hand OA progression and progression of OA at the 
knee. 
Methods. Osteophytes and joint space narrowing (JSN) were scored at baseline and 
after 6 years on hand and knee radiographs of 236 hand OA patients (mean age 59 
years, 83% women) participating in the Genetics ARthrosis and Progression (GARP) 
sibling pair study. Radiographic progression was defined as change in osteophytes 
or JSN above the smallest detectable change. Clustering of radiographic progression 
between hand joint groups was assessed using a chi-squared test. Symmetry, clustering 
by row and ray, and familial aggregation in sibling pairs were also evaluated. The 
association between hand OA progression and progression of OA at the knee was 
assessed using generalised estimating equations analysis. 
Results. There was clustering of OA progression between hand joint groups. Other 
patterns were symmetry (OR (95%CI) 4.7 (3.3 to 6.5)) and clustering by row (OR 
(95%CI) 2.9 (1.9 to 4.6)), but not by ray (OR (95%CI) 1.3 (0.7 to 2.4)). There was 
familial aggregation of hand OA progression. Patients with progression of hand OA 
had a higher risk for radiographic change at the knee than those without hand OA 
progression (OR (95%CI) 2.3 (1.3 to 4.0)), which was also found in separate analyse 
in those with and without knee OA at baseline.
Conclusion. Progression of hand OA clusters between hand joint groups, within 






Hand osteoarthritis (OA) is a common musculoskeletal disorder characterised by 
degradation of cartilage and abnormalities in subchondral bone leading to pain and 
disability.1 It is a heterogeneous disease depicted by, for example, the involvement of 
multiple hand joints, the presence of several subsets and the variable course over time 
with some patients experiencing rapid progression and others remaining relatively 
stable over time as we showed previously.2
Hand OA often affects multiple hand joints with symmetry as the strongest 
pattern of joint involvement, followed by clustering by row and clustering by ray.3-5 
This has been found for radiographic as well as symptomatic hand OA. These patterns 
of joint involvement teach us about the aetiology of hand OA. Symmetry was the 
strongest pattern suggesting that systemic factors may play a more important role 
than mechanical factors. All data on this topic are cross-sectional and it is unclear if 
these patterns are also involved in the course of OA in hand joints over time. 
Apart from clustering of OA within the hand, hand OA occurs with OA at other 
joint sites.6-9 The strongest and most consistent association has been found between 
hand OA and the presence and future occurrence of knee OA. Only one study, 
conducted in the general population, assessed the relationship between progression 
at the two joint sites.10
Knowledge on the patterns of OA progression within hand joints and progression 
of hand OA in relation to progression of OA at other joint sites gives insight in the 
complex aetiology of hand OA, particularly the role of systemic factors. From a clinical 
point of view this has implications for hand OA treatment. Therefore, we investigated 
the patterns of OA progression within hand joints as well as the relationship between 
hand OA progression and progression of OA at the knee in a cohort of hand OA 
patients followed for 6 years. Because the population comprises sibling pairs, it was 
possible to assess the role of familial factors in hand OA progression.
Patients and metHods
Study design and patient population
The Genetics ARthrosis and Progression (GARP) study is a cohort study aimed at 
identifying determinants of OA susceptibility and progression. The study population 
comprises 192 Caucasian sibling pairs with symptomatic OA at multiple sites in the 
hand or in at least two of the following sites: hand, knee, hip or spine. Details about 
the recruitment and inclusion have been published elsewhere.11 In brief, probands 
were recruited from rheumatologists, orthopaedic surgeons and general practitioners. 
Subsequently, affected siblings were recruited via the probands. Both proband and 
sibling were required to have OA at multiple sites. The GARP study was approved by 
the medical ethics committee. 
Patients were included for baseline assessment between August 2000 and 
March 2003. From April 2007 to June 2008 participants who consented for a follow-
up evaluation were assessed. All consenters completed questionnaires and some of 
them visited the outpatient clinic for physical examination and radiographic evaluation. 
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Patients were eligible for the present study if they had hand OA defined according 
to the American College of Rheumatology criteria for clinical hand OA12 or if structural 
abnormalities were present. Structural abnormalities were defined as the presence 
of radiographic hand OA based on a Kellgren-Lawrence score of ≥2 in at least one 
interphalangeal (IP) or first carpometacarpal (CMC-1) joint, or the presence of at least 
two joints with Heberden’s or Bouchard’s nodes. Knee OA was defined as a Kellgren-
Lawrence score of ≥2.
Radiographic assessment
Standardised radiographs of the hands (dorsal-volar) and knees (posterior-anterior 
weight bearing, non-fluoroscopic fixed-flexion protocol) were obtained at baseline 
and follow-up by a single radiographer, employing a standard protocol with fixed 
film focus distance. 
Radiographs were scored paired in chronological order blinded for patient 
characteristics by consensus opinion of two experienced readers (JB, IW). To avoid 
bias radiographs for hand and knee were scored on separate occasions. Osteophytes 
and joint space narrowing (JSN) were graded 0-3 using the Osteoarthritis Research 
Society International (OARSI) atlas in the distal interphalangeal (DIP), proximal 
interphalangeal (PIP), first interphalangeal (IP-1), CMC-1, metacarpophalangeal (MCP) 
and scaphotrapezotrapezoidal (STT) joints and medial and lateral compartments of 
the tibiofemoral joints.13 Reproducibility based on 25 randomly selected pairs of 
radiographs was good with intraclass correlation coefficients (ICC) for osteophytes 
and JSN of 0.94 and 0.87 in the hands and 0.99 and 0.98 in the knees, respectively.
Definition of radiographic progression
For osteophytes and JSN the smallest detectable change (SDC) was used to assess 
change above measurement error.14 Progression was assessed in all hand joints 
together, separate hand joint groups (DIP, PIP, IP-1 and CMC-1 joints) and the knees. 
Radiographic progression for each of these joint sites was defined as a change in total 
score for osteophytes or JSN above the SDC. Patients without radiographic end-stage 
disease at baseline who received knee prosthesis during follow-up were considered 
to have radiographic progression in that joint. 
Statistical analysis
Data were analysed using SPSS, version 17.0 (SPSS, Chicago, Illinois, USA). The 
number of patients with radiographic progression of hand OA was assessed as well 
as the number of patients with radiographic progression at hand joint groups and the 
number of joints with radiographic progression within each hand joint group. 
To test whether progression of hand OA is likely to cluster in multiple hand joint 
groups of the same patient, we used the prevalence of progression for each hand joint 
group to calculate the numbers of patients expected to have progression in 0, 1, 2 or 
at least 3 joint groups, assuming that the occurrence of progression in different joints 
is independent. Observed frequencies were compared to the expected distribution 
using the chi-squared test. We assessed the relationship between the specific hand 




variance estimators to account for family effects within sibling pairs with adjustment 
for age, sex and body mass index (BMI). Other patterns of progression we assessed 
using GEE models were symmetry and clustering by row and ray. Adjustments were 
made for age, sex and BMI.
In addition, we assessed whether familial factors play a role in hand OA 
progression by comparing siblings of probands with and without progression of hand 
OA. This analysis requires availability of follow-up data for both proband and sibling. 
Odds ratios (ORs) were estimated for hand OA progression in siblings given hand OA 
progression in probands using logistic regression analyses with adjustment for age, 
sex and BMI.
The risk of radiographic progression at the knee given progression of OA in the 
hand was assessed using GEE analysis with corrections for age, sex and BMI. We 
assessed change in osteophytes and JSN at the knee in the total hand OA population 
as well as in hand OA patients with and without knee OA at baseline, separately. 




Of the 357 patients fulfilling the hand OA criteria at baseline, 300 (84%) consented 
for the follow-up study of which 242 visited the outpatient clinic and 58 completed 
questionnaires only. Consent was not given by 43 (12%) patients, 12 (3.3%) were 
deceased and 2 (0.6%) were lost to follow-up. Reasons for non-consent are listed 
elsewhere.2 Of the 242 eligible patients 236 had complete radiographic data and 
were included in the present study. The mean follow-up time was 6.1 years (range 
5.0-7.8 years). There were 87 sibling pairs with follow-up data for both proband and 
sibling for the analysis on familial aggregation.
Baseline characteristics are shown in table 1. The 87 sibling pairs did not differ 
from the whole patient group and there were no differences between probands and 
siblings (data not shown). Patients not included in the present study were somewhat 
older. Other clinical and radiographic baseline parameters did not differ between 
consenters and non-consenters (data not shown).
Table 1. Baseline characteristics of 236 patients with hand osteoarthritis (OA). 
Age, mean (SD), years 58.9 (7.1)
Women, no (%) 196 (83)
Postmenopausal women, no (%) 176 (90)
Body mass index, mean (SD), kg/m2 27.1 (5.0)
ACR criteria hand OA, no (%) 183 (78)
Knee OA* 76 (32)
*Defined as Kellgren-Lawrence score ≥2
ACR: American College of Rheumatology
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Patterns of radiographic progression of hand OA 
Over 6 years radiographic progression in the hand, defined as a change in osteophytes 
or JSN above the SDC, was present in 124 (52.5%) patients. progression of osteophytes 
and JSN was present in 106 (44.9%) and 61 (25.8%) patients, respectively. table 2 
shows that at the patient level progression was most frequent in DIp joints followed 
by the CMC-1 and pIp joints. however, at joint level progression was most frequent 
in CMC-1 and Ip-1 joints. this difference may be due to the higher number of DIp 
and pIp joints compared to the CMC-1 and Ip-1 joints. the distribution of changes at 
joint level is shown in table 3.
Table 2. Distribution of progression of hand osteoarthritis (Oa) in hand joint groups over 6 years in 





Joint space narrowing 
progression, n (%)
Patient level
DIp joints 98 (41.5) 73 (30.9) 53 (22.5)
pIp joints 69 (29.2) 67 (28.4) 24 (10.2)
Ip-1 joints 66 (28.0) 49 (20.9) 29 (12.3)
CMC-1 joints 84 (35.6) 66 (28.0) 42 (17.8)
Joint level
DIp joints (n=1886) 184 (9.8) 128 (6.8) 86 (4.6)
pIp joints (n=1881) 120 (6.4) 102 (5.4) 41 (2.2)
Ip-1 joints (n=471) 77 (16.3) 52 (11.0) 36 (7.6)
CMC-1 joints (n=466) 103 (22.1) 77 (16.5) 49 (10.5)
abbreviations: DIp: distal interphalangeal, pIp: proximal interphalangeal, Ip-1: first interphalangeal, 
CMC-1: first carpometacarpal.
Table 3. Distribution of changes in osteophytes and joint space narrowing of the hand over 6 years 
in 236 patients with hand osteoarthritis. the numbers represent the number of joints (%) with 
corresponding change for each hand joint group.
≥ -1 0 1 2 3
Osteophytes
DIp joints 3 (0.2) 1755 (93.1) 112 (5.9) 16 (0.8)
pIp joints 2 (0.1) 1777 (94.5) 85 (4.5) 16 (0.8) 1 (0.1)
Ip-1 joints 1 (0.2) 418 (88.7) 50 (10.6) 2 (0.4)
CMC-1 joints 389 (83.5) 69 (14.8) 8 (1.7)
Joint space narrowing
DIp joints 29 (1.5) 1771 (93.9) 68 (3.6) 17 (0.9) 1 (0.1)
pIp joints 12 (0.7) 1828 (97.2) 27 (1.4) 14 (0.7)
Ip-1 joints 3 (0.6) 432 (91.7) 32 (6.8) 4 (0.8)
CMC-1 joints 11 (2.3) 406 (87.1) 46 (9.9) 3 (0.6)




There was clear evidence for clustering of progression between hand joint groups 
(table 4). There were 42 patients with progression in at least three hand joint groups, 
compared with 11 patients expected in this category. The relationship between 
specific hand joint groups shows that all joint groups contributed to this clustering 
(table 5). The strongest relationship was between the interphalangeal joint groups. 
Another pattern for progression of hand OA was symmetry with an overall OR 
(95%CI) of 4.7 (3.3 to 6.5). There was also clustering by row with an OR (95%CI) of 
2.9 (1.9 to 4.6), but not by ray (OR (95%CI) 1.3 (0.7 to 2.4)).
The adjusted OR (95%CI) for a sibling having hand OA progression if the proband 
had progression of hand OA was 3.0 (1.2 to 7.5).
Radiographic progression of hand OA in relation to knee OA
In total 109 (46.2%) patients had a change in osteophytes or JSN of the knee 
above the SDC. Of these patients 90 had knee OA at baseline of whom 67 (74.4%) 
had radiographic progression. Of the 146 patients without knee OA at baseline 
radiographic change was present in 42 (28.8%) patients. 
Table 4. Observed and expected number of patients with radiographic 
progression in hand joint groups over 6 years in 236 patients with 
hand osteoarthritis.
Number of hand 







*Hand joint groups: DIP, PIP, IP-1 and CMC-1 joints.
Abbreviations see table 2.
Table 5. Association between radiographic progression at specific hand joint groups over 6 years 






Joint space narrowing 
progression*
DIP – PIP 5.4 (2.9 to 10.3) 4.5 (2.4 to 8.3) 4.4 (1.5 to13.0)
DIP – IP1 5.1 (2.6 to 9.9) 2.6 (1.2 to 5.4) 7.1 (2.8 to 17.7)
DIP – CMC-1 4.4 (2.4 to 8.0) 4.2 (2.1 to 8.3) 6.3 (2.4 to 16.5)
PIP – IP-1 5.5 (2.8 to 10.7) 6.3 (3.2 to 12.8) 4.5 (1.5 to 13.6)
PIP – CMC-1 4.6 (2.5 to 8.6) 3.0 (1.5 to 6.0) 12.8 (4.2 to 38.6)
IP-1 – CMC-1 3.9 (2.0 to 7.7) 3.1 (1.4 to 6.6) 3.8 (1.4 to 10.8)
*Adjusted for age, sex, BMI and family effects within sibling pairs.
Abbreviations see table 2.
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The relationship between hand OA progression and progression of OA in the knee 
is shown in table 6. Overall, patients with progression of hand OA had a higher risk 
for radiographic change at the knee than patients without hand OA progression (OR 
(95%CI) 2.3 (1.3 to 4.0)). For the patients with knee OA at baseline, a similar effect 
size was found. In the patients without knee OA at baseline, those with progression 
of hand OA had a higher risk for the development of radiographic OA in the knee 
than those without hand OA progression (OR (95%CI) 2.7 (1.3 to 5.9)). 
The presence of knee OA at baseline was not associated with progression of hand 
OA (OR (95%CI) 1.1 (0.6 to 1.9)).
discussion
This study is the first to show that progression of hand OA clusters between hand 
joint groups as well as in a symmetrical pattern and in rows but not in rays. Also, there 
was clustering of hand OA progression within sibling pairs. Patients with progression 
of hand OA over 6 years had a higher risk for radiographic change at the knee 
compared to those without hand OA progression. Separate analysis in those with and 
without knee OA at baseline showed similar results. These findings give insight in the 
complex aetiology of hand OA, suggesting that systemic factors play a role. 
Radiographic progression of hand OA was present in half of the patients. At the 
patient level progression was most frequent in the DIP joints followed by the PIP and 
CMC-1 joints. However, at the joint level progression was by far the most prevalent 
in the CMC-1 followed by the IP-1 joints. This difference is explained by the higher 
number of joints and thus higher chance of progression in the DIP and PIP joint 
groups. This may imply that progression at joint level is a better reflection of the true 
progression. Our findings are in line with the Framingham OA Study on progression 
of hand OA over a period of 9 years, showing that most radiographic progression 
was present at the CMC-1 joint.15 The findings at the joint level suggest that thumb 





All hand OA patients (n=236)
Absent (n=127) 1 1
Present (n=109) 2.0 (1.2 to 3.3) 2.3 (1.3 to 4.0)
Hand OA patients with knee OA at baseline (n=90)
Absent (n=23) 1 1
Present (n=67) 2.0 (0.8 to 5.3) 2.5 (0.9 to 6.9)
Hand OA patients without knee OA at baseline (n=146)
Absent (n=104) 1 1
Present (n=42) 2.4 (1.1 to 5.0) 2.7 (1.3 to 5.9)




base OA is more progressive than interphalangeal OA and may represent a subset of 
hand OA with worse outcome. This contributes to the emerging evidence proposing 
hand OA subsets based on differences in risk factors, associations and outcomes.16,17 
A number of cross-sectional studies assessed the clustering of hand OA in both 
radiographic and symptomatic hand OA.3-5 They all showed that symmetry was the 
strongest pattern of joint involvement, followed by clustering by row and clustering by 
ray. This is in line with our findings on clustering of hand OA change over time. In the 
Framingham OA study mentioned above, it was found that that incidence of hand OA 
occurred in a symmetrical way.15 These findings suggest that systemic factors are involved 
in the progression of hand OA. If mechanical factors would be more important, we would 
expect clustering by ray to have more influence than symmetry and clustering by row. 
It is known that systemic factors play a role in the development of hand OA.18,19 
However, risk factors for the progression of hand OA are less clear and they may 
differ from those associated with OA susceptibility.20 Evidence for the involvement of 
systemic factors in hand OA progression is growing. In the GARP study we showed that 
over 2 years accelerated localised bone mineral density loss was related to progression 
of hand OA.21 Since localised bone mineral density loss in rheumatoid arthritis is 
associated with progression of joint damage, indicating inflammatory activity, this 
indicates a role for inflammation in active, progressive hand OA.22,23 Adipokines are 
thought to contribute to inflammatory and metabolic processes, although the precise 
nature of their actions remains unclear.24 The adipokine adiponectin was associated 
with progression of hand OA over 6 years in the GARP study.25 In a systematic review 
Yusuf et al. found that obesity was associated with the development of hand OA.26 
We also found that familial factors play a role in hand OA progression, although 
we did not specifically assess familial factors in relation to the patterns of hand OA 
progression. This familial aggregation suggests involvement of genetic factors. It is well 
known that genetic factors influence OA susceptibility.27,28 However, their role in the 
disease course is still unclear. We made a first step in assessing this question concerning 
hand OA by providing evidence for transmission of the progression trait in families. A 
next step would be to assess specific genetic loci in the progression of hand OA.
We showed that patients with progression of hand OA over 6 years had a higher 
risk for radiographic change at the knee than those without hand OA progression 
independent of BMI. This again indicates that systemic factors may play a role in hand 
OA, since in active disease there is not only progression of OA signs at the hand but 
also at another joint site. To our knowledge there is only one other study that assessed 
the relationship between progression of OA at the hand and knee.10 This study by 
Hassett et al. over a period of 10 years showed that progression of knee osteophytes 
or JSN was not related to progression of osteophytes or JSN at the hand. The effect 
sizes found for progression of osteophytes were similar to our results. A general 
population study by Dahaghin et al. showed that the presence of hand OA at baseline 
was a risk factor for the future occurrence of knee OA.9 A number of cross-sectional 
studies found an association between the presence of hand and knee OA, with the 
strongest relationship in women.6-8 Since we had a study population selected on the 
presence of hand OA it was not possible to evaluate this cross-sectional relationship. 
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For clinical practice these findings imply that hand OA patients with progression 
are at risk for OA changes at the knee and maybe other joints as well. Thus, not 
only hand joints but also other joint sites, in particular the knee, should be evaluated 
at baseline and follow-up visits. Furthermore, the contribution of our study to the 
emerging evidence of the role for systemic and metabolic factors in the pathogenesis 
of hand OA may contribute to the development of new treatment strategies. 
There are a number of potential limitations to this study. First, the possibility 
of bias due to differences between consenters and non-consenters. However, only 
age was different between these groups and the baseline radiographic scores did 
not differ so we expect no effect on study outcome. Radiographic follow-up data 
were not available in all patients since a proportion only completed questionnaires. 
Baseline radiographic scores did not differ between those with and without complete 
data indicating that selection bias is probably absent. Secondly, we investigated 
patients with familial OA at multiple sites. Whether the results can be generalised to 
patients with other hand OA phenotypes has to be investigated. Although the hand 
OA patients had other sites involved we only assessed the relationship with knee OA. 
Hip OA was present in around 20% of the patients and therefore patient numbers 
were too small to draw meaningful conclusions. Finally, apart from genetic factors 
shared environmental influences may also explain the familial aggregation we found. 
By including only one sibling per proband we minimised this effect.
In conclusion, this study gives insight in the complex aetiology of hand OA by 
showing that its progression clusters between hand joint groups as well as with 
change of OA at the knee and that familial factors are involved, suggesting a role 
for systemic or metabolic factors. Further research on the progression of hand OA 
in relation to OA changes at other joint sites is needed to confirm and extend our 
findings. These findings contribute to unraveling the pathogenesis of hand OA which 
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Objective. Although a few consistent osteoarthritis (OA) susceptibility genes have 
been identified, little is known on OA progression. Since OA progression is clinically 
the most relevant phenotype, we investigated the association between ASPN, BMP5 
and GDF5 polymorphisms and progression of hand OA.
Methods. Single-nucleotide polymorphisms (SNPs) ASPN rs13301537, BMP5 
rs373444 and GDF5 rs143383 were genotyped in 251 hand OA patients from the 
Genetics ARthrosis and Progression (GARP) study and 725 controls. In a case-control 
comparison we assessed the association between these SNPs and radiographic 
progression of hand OA over 6 years, which was based on change in osteophytes 
or joint space narrowing (JSN), above the smallest detectable change. SNPs with 
suggestive evidence for association were further analysed for their effect on 
progression over 2 years and for the mean change in osteophytes and JSN. 
Results. The minor allele of ASPN SNP rs13301537 was associated with hand OA 
progression over 6 years (OR (95%CI) 1.49 (1.06 to 2.07); p=0.020). The mean 
change in osteophytes and JSN was higher in carriers of the minor allele compared to 
homozygous carriers of the common allele with mean difference of 0.73 (95%CI -0.07 
to 1.56; p=0.073) and 0.82 (95%CI 0.12 to 1.52; p=0.022), respectively. An 
association with similar effect size was found between ASPN SNP rs13301537 and 
2-year progression, and the mean change in osteophytes and JSN was significantly 
higher in homozygotes. 
Conclusion. ASPN is associated with hand OA progression. This gives insight in the 




GENES FOR HAND OA PROGRESSION
introduction
Osteoarthritis (OA) is a common joint disorder characterised by degradation of cartilage 
and changes in subchondral bone and a leading cause of disability.1 It is therefore a burden 
not only for the individual but also for society. OA is a multifactorial disease involving both 
genetic and environmental factors. The hand is the most frequently involved joint site.2
The role of genetic factors in influencing OA susceptibility is well documented.3,4 
However, very few studies assessed the role of OA susceptibility genes in the disease 
course. One of the difficulties in studying OA progression is its gradual and slow pace. 
Identification of genes associated with OA progression will expand our knowledge on 
the pathophysiological pathways involved in this process. This can contribute to the 
development of much desired new treatments and to the identification of patients at 
high risk for progression. Earlier we reported the presence of familial aggregation in 
OA progression in a relatively small number of sibling pairs over a period of 2 years 
indicating a role for genetics in OA progression.5
It is generally accepted that the genetic architecture of OA onset is complex and 
is expected to be modulated by many genes with small effects. Genetic studies have 
provided a few consistent signals with relevant functional follow-up. Among these 
genes are growth differentiation factor 5 (GDF5)6,7, bone morphogenic protein 5 
(BMP5)8,9 and asporin (ASPN)10,11, all involved in transforming growth factor β (TGF-β) 
signalling. GDF5 and BMP5 have been shown to be essential in the maintenance and 
repair of synovial joints as well as chondrogenesis and chondrocyte proliferation. 
The T allele of SNP rs143383 in the 5’ untranslated region of GDF5 is consistently 
associated with various subtypes of OA and with reduced activity in chondrogenic 
cells. SNP rs3734444 was shown to mark allelic imbalanced expression of BMP5. 
ASPN belongs to a family of small leucine-rich proteoglycans (SLRPs), which compose 
a major non-collagen component of the extra cellular matrix. The aspartic acid repeat 
(D) 14 allele was associated with an increased risk of knee OA, whereas the D13 
allele may be protective. Interestingly, functional studies showed that ASPN binds 
to TGF-β and thereby inhibits its function10,12. Because these genes are involved in 
chondrogenesis and chondrocyte proliferation, we expect them not only be involved 
in the onset of OA but also in the further evolution of the disease.
Therefore we investigated the association between single-nucleotide 
polymorphisms (SNPs) within GDF5, BMP5 and ASPN and radiographic hand OA 
progression in patients from the Genetics ARthrosis and Progression (GARP) study 
that were followed for 6 years. SNPs with suggestive evidence for association were 
further investigated for association with hand OA progression over 2 years, reflecting 
fast progression. We assessed hand OA since it has by far the highest prevalence in 
our study population.
Patients and metHods
Study design and selection of patients
The GARP study is a cohort study aimed at identifying determinants of OA susceptibility 
and progression, comprising 192 Caucasian sibling pairs with symptomatic OA at 
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multiple sites in the hands or in at least two of the following joint sites: hand, knee, 
hip or spine. Patients were assessed at baseline and after 6 years. Additionally, sibling 
pairs with at least one subject with symptomatic hip or knee OA were evaluated after 2 
years. This group only partly comprises the same patients evaluated after 6 years. Details 
on the recruitment and selection and on both follow-up periods have been published 
elsewhere.13-15 The GARP study was approved by the medical ethics committee.
Patients were eligible for the present study if they had radiographic hand OA 
at baseline defined as the presence of a Kellgren-Lawrence score16 of ≥2 in at least 
2 interphalangeal joints or first carpometacarpal (CMC-1) joints. To allow for case-
control comparison we included partners of the offspring in the Leiden longevity 
study as random control population (n=739).17
Radiographic outcome
Standardised radiographs of the hands (dorsal-volar) were obtained at baseline and 
after both follow-up periods by a single radiographer. Radiographs were scored in 
pairs (baseline-2 year, baseline-6 year) blinded for patient characteristics by consensus 
opinion of 2 experienced readers using the Osteoarthritis Research Society International 
(OARSI) atlas.18 Osteophytes and joint space narrowing (JSN) were graded 0-3 in the 
distal interphalangeal (DIP), proximal interphalangeal (PIP), first interphalangeal (IP-1), 
CMC-1, metacarpophalangeal (MCP) and scaphotrapezotrapezoidal (STT) joints, total 
scores ranging from 0 to 96. Intrareader reproducibility based on repeated reading 
of a 10% random selection of radiographs was high with intraclass correlation 
coefficients (ICC) for the 2-year and 6-year period, respectively, of 0.98 and 0.92 
for osteophytes and 0.94 and 0.87 for JSN. Radiographic progression was defined 
as a change in osteophytes or JSN above the smallest detectable change (SDC), 
reflecting change above measurement error.19 Over 2 years the SDC was 0.9 and 0.8 
for osteophytes and JSN, respectively. The SDC over the 6-year period was 1.3 for 
osteophytes and 1.5 for JSN.
SNP selection and genotyping
Because of our relatively small sample of hand OA patients we could only investigate a 
limited number of SNPs. The selection was based on SNPs that have shown consistent 
association with OA susceptibility within one pathway, the TGF-β superfamily, as 
explained in the introduction. The three SNPs are: GDF5 rs143383, BMP5 rs3734444 
and ASPN rs13301537. 
These genetic variants were genotyped using genomic DNA extracted from 
peripheral venous blood samples according to standard procedures. In total, 380 
subjects from the GARP study and 725 controls were genotyped by mass spectrometry 
(homogeneous MassARRAY system; Sequenom, San Diego, CA) using standard 
conditions. PCR reactions were carried out in a final volume of 5 µl and contained 2.5 
ng of genomic DNA. Genotypes were assigned using Genotyper version 3.0 software 
(Sequenom, San Diego, CA). All SNPs were in Hardy-Weinberg equilibrium. 
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Analysis strategy 
Because hand OA is by far the most prevalent OA phenotype in the GARP study, we 
choose to study hand OA. Radiographic progression of hand OA was assessed after 2 and 
after 6 years, with only partly overlap. These groups may reflect subjects with different 
disease progression phenotypes, fast and more gradual progression. Since the 6-year 
cohort has the largest number of patients and due to the longer follow-up period also the 
largest number of progressors, we used this group for the initial analysis. This implicates 
that if there is any association the chance of finding it in this group is higher compared to 
the 2-year cohort. In this analysis we compared subjects with OA progression over 6 years 
(cases) to the controls in a cross-sectional approach to establish the association between 
the SNPs with OA progression. To further explore SNPs showing evidence for association 
in this initial analysis, we repeated the case-control analysis in the 2-year cohort for these 
SNPs. In addition, we used a quantitative approach within the hand OA patients in both 
cohorts comparing mean change in osteophytes and JSN scores across the SNP genotypes 
showing evidence for association in the initial analysis. 
Statistical analysis
In our 6-year cohort the statistical power given a minor allele frequency (MAF) of 
0.37 using a log additive model with α=0.05 was 81% to detect an odds ratio (OR) 
of 1.55 or higher (Quanto software version 1.2.4 (University of Southern California, 
USA; http://hydra.usc.edu/gxe)). 
Associations were analysed using SPSS, version 16.0 (SPSS, Chicago, Illinois, USA). 
In the initial analysis (6-year cohort) we assessed the association between the three 
SNPs and the presence of radiographic progression as well as hand OA susceptibility 
in a case-control comparison. Allelic ORs were estimated by comparing the number 
of alleles among cases and controls using generalised estimating equations (GEE) 
models with robust variance estimators to account for familial dependency among 
sibling pair and sex was added as covariate. 
The SNPs showing evidence for association were subsequently assessed in the 
2-year cohort using the same case-control comparison. For these SNPs we also used 
a quantitative approach within the hand OA patients comparing the mean change 
in osteophytes and JSN scores across SNP genotypes using linear mixed models. 
Adjustment was made for age, sex, BMI and a random intercept was included to 
adjust for family effects within sibling pairs. 
results
Study population
Of the 384 patients in the GARP study, 251 fulfilled the definition of radiographic 
hand OA. Radiographic follow-up data over 6 years were available in 161 patients 
(64%). In addition, 128 patients (51%) had radiographic follow-up data over 2 years. 
Data over both periods was present in 86 patients. 
Baseline characteristics are shown in table 1. Since patients in the 2-year follow-
up study were selected based on the presence of knee or hip OA, the prevalence of 
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these OA phenotypes was higher in this population. In controls the mean age (SD) 
was 58.8 years (7.4) and 58% were female.
In the 6-year cohort 97 (60%) patients had radiographic progression of hand OA. 
Progression of osteophytes and JSN was present in 85 (53%) and 52 (32%) patients, 
respectively. Over 2 years radiographic progression was present in 50 (39%) hand OA 
patients. Osteophyte and JSN progression was present in 31 (24%) and 37 (29%) 
patients, respectively. 
Genetic association with hand OA progression over 6 years
In table 2 results of the initial analysis comprising the case-control comparison in the 
6 year cohort are shown. MAF and genotype distributions are provided for the ASPN, 
BMP5 and GDF5 variants in controls, all patients with radiographic hand OA (n=251) 
at baseline and patients with progression of hand OA over 6 years (n= 97). MAF were 
similar between controls and patients with radiographic hand OA. The minor allele 
of the SNP rs13301537 in ASPN was associated with hand OA progression with an 
OR (95%CI) of 1.49 (1.06 to 2.07) and a nominal p-value of 0.020. After adjustment 
for multiple testing (n=3) this association had suggestive evidence for association 
with radiographic progression (p=0.06). To further investigate this effect we stratified 
the analysis for progression of osteophytes and progression of JSN. This showed 
consistent allelic association with the ASPN SNP rs13301537 with an OR (95%CI) of 
1.53 (1.07 to 2.11) for osteophytes (p=0.019) and an OR (95%CI) of 1.70 (1.14 to 
2.55) for JSN (p=0.010). 
The mean change in osteophytes and JSN scores across ASPN SNP rs13301537 
genotypes was higher in homozygous and heterozygous carriers of the minor allele 
compared to homozygous carriers of the common allele (table 3), with a mean difference 
in change score of 0.73 (95%CI -0.07 to 1.56; p=0.073) for osteophytes and 0.82 
(95%CI 0.12 to 1.52; p=0.022) for JSN. There was no dose response effect of the allele. 
Table 1. Baseline characteristics of patients with radiographic hand osteoarthritis (OA) in the 6-year 
cohort and the 2-year cohort.
6-year cohort (n=161) 2-year cohort (n=128)
Age, mean (SD), years 60.0 (7.2) 61.0 (6.7)
Women, no (%) 131 (81) 105 (82)
Postmenopausal women, no (%) 124 (95) 100 (95)
Body mass index, mean (SD), kg/m2 27.2 (5.0) 26.2 (3.3)
Symptomatic hand OA, no (%) 131 (81) 103 (80)
Additional ROA sites, no (%)
Knee 72 (45) 67 (52)
Hip 43 (27) 49 (38)
Facet 107 (66) 90 (70)
Spine degenerative disc 112 (69) 101 (79)
Abbreviations: ROA: radiographic osteoarthritis.
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Association of ASPN SNP rs13301537 with hand OA progression over 2 years
Subsequently ASPN SNP rs13301537 was assessed in the 2-year cohort showing a 
similar effect size for the association with hand OA progression over that period 
compared to the 6-year cohort (table 4). However, only the association for progression 
of osteophytes reached nominal statistical significance. 
The mean change in osteophytes and JSN score was considerably higher in 
homozygous carriers of the minor allele of the ASPN SNP rs13301537 compared to the 
other genotypes (table 5), with a mean difference in change score of 1.10 (95%CI 0.24 
to 1.96; p=0.012) for osteophytes and 0.91 (95%CI 0.10 to 1.72; p=0.028) for JSN. 
Because the ASPN SNP rs13301537 has shown to be in linkage disequilibrium with 
the frequently described D14 and D13 allele in the ASPN D-repeat polymorphism we 
performed haplotype analysis involving a second ASPN SNP rs331377, to assess whether 
the effect is attributable to these D-repeat polymorphisms. We found that the D14 and 
D13 allele were not associated with progression of hand OA over both periods, suggesting 
that the effect of the ASPN SNP rs13301537 is independent of D14 and D13.
Table 2. Association between three single nucleotide polymorphisms (SNPs) and the presence of 
hand osteoarthritis as well as the progression of hand osteoarthritis over 6 years.
ASPN rs13301537
TT CT CC MAF n Allelic OR (95%CI)* p-value
Controls 366 297 62 0.29 1418
Presence hand ROA 119 104 26 0.32 489 1.15 (0.88 to 1.49) 0.309
Radiographic progression 37 47 12 0.37 189 1.49 (1.06 to 2.07) 0.020
BMP5 rs373444
TT CT CC MAF n Allelic OR (95%CI)* p-value
Controls 271 334 104 0.38 1388
Presence hand ROA 82 113 44 0.42 469 1.12 (0.87 to 1.43) 0.375
Radiographic progression 33 45 14 0.40 181 0.99 (0.72 to 1.37) 0.954
GDF5 rs143383
CC CT TT MAF n Allelic OR (95%CI)* p-value
Controls 105 330 290 0.37 1418
Presence hand ROA 31 131 86 0.39 487 0.98 (0.78 to 1.23) 0.859
Radiographic progression 14 44 38 0.37 189 1.04 (0.72 to 1.51) 0.833
*Adjusted for family effects within sibling pairs and sex.
Abbreviations: MAF: minor allele frequency, ROA: radiographic osteoarthritis.
Table 3. Mean change in osteophytes and joint space narrowing (JSN) in the hand over 
6 years for ASPN SNP rs13301537 genotypes. 
TT (N=67) CT (N=73) CC (N=19)
Change osteophytes, mean (SD) 1.8 (2.2) 2.5 (2.8) 2.7 (3.0)




In this study we investigated whether SNPs within ASPN, BMP5 and GDF5 are related 
to the progression of hand OA over 6 years in participants of the GARP study. 
Subsequently, SNPs with suggestive evidence for association were investigated for 
association with hand OA progression over 2 years, reflecting fast progression. We 
found that the SNP rs13301537 in ASPN was associated with radiographic progression 
of hand OA over 6 years (p=0.020). The minor allele of this variant was more common 
in patients with progression of hand OA compared to healthy controls. In addition, 
the mean change in osteophytes and JSN was higher in C-allele carriers compared to 
the TT genotype. In the 2-year cohort similar effect sizes were found, with the mean 
change in osteophytes and JSN being significantly higher in homozygous C-allele 
carriers. In patients with progression over both time periods (n=25), effect sizes for 
ASPN were similar to the risk in the whole 6-year and 2-year cohort implying that the 
effects over the long term and short term are independent.
This study is the first to assess specific genes associated with hand OA progression. 
To our knowledge there is only one other study investigating the association between 
specific SNPs and OA progression, which concerned knee OA.20 One of the reasons 
for the lack of genetic association studies on OA progression is the lack of follow-up 
data in combination with genotype data, especially when the hand is concerned. It is 
of interest to assess OA progression because this phenotype is clinically most relevant 
with respect to development of new interventions and patient management. 
The ASPN SNP we found to be associated with hand OA progression was 
originally identified by Kizawa et al. as susceptibility gene for both knee and hip OA 
in two independent Asian populations.10 Apart from the genetic association they 
demonstrated that ASPN is abundantly expressed in articular cartilage and inhibits 
expression of genes encoding aggrecan and type II collagen. Our association for ASPN 
Table 4. Association between ASPN SNP rs13301537 and progression of hand osteoarthritis over 2 years.
TT CT CC MAF n Allelic OR (95%CI)* p-value
Controls 366 297 62 0.29 1418
Radiographic progression 19 25 6 0.37 99 1.48 (0.95 to 2.32) 0.087
Progression osteophytes 10 16 5 0.43 61 1.85 (1.08 to 3.18) 0.025
Progression JSN 14 18 5 0.38 73 1.55 (0.92 to 2.60) 0.102
*Adjusted for family effects within sibling pairs and sex.
Abbreviations: JSN: joint space narrowing; MAF: minor allele frequency.
Table 5. Mean change in osteophytes and joint space narrowing (JSN) over 2 years for 
ASPN SNP rs13301537 genotypes. 
TT (N=59) CT (N=58) CC (N=10)
Change osteophytes, mean (SD) 0.4 (1.0) 0.6 (1.1) 1.5 (3.0)
Change JSN, mean (SD) 0.4 (1.2) 0.4 (1.1) 1.3 (2.0)
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SNP rs13301537 with OA progression was independent from the D14 and D13 alleles 
in the D-repeat polymorphisms, although these SNPs are in linkage disequilibrium. 
In the studies of Kizawa et al., D14 allele in the ASPN D-repeat polymorphism was 
found to increase OA risk, the D13 allele was protective. In a Greek population the 
association between the D-repeat polymorphisms was confirmed for knee OA.21 In 
Spanish and British populations no relationship with knee or hip OA was observed.22,23 
A study on the relationship between various ASPN polymorphisms and hand OA 
susceptibility showed no association.24 
ASPN inhibits both early- and late-stage chondrogenesis trough suppression of 
TGF-β, a central player among growth factors in articular cartilage.10,12 Excessive ASPN 
activity reduces TGF-β function to less optimal levels, leading to cartilage degeneration. 
Our findings suggest that this imbalance between ASPN and TGF-β is an ongoing 
process leading not only to the development, as shown in earlier research, but also to 
progression of OA. This was evident for long-term progression and probably also for 
progression on the short-term. This interaction between ASPN and TGF-β, leading to 
suboptimal TGF-β levels is a potential target for therapeutic approaches. 
We did not find an association between hand OA presence at baseline and 
the ASPN SNP. An explanation is that the SNP is associated with a subset of more 
progressive hand OA. The whole group comprises a wide variety of hand OA types, 
both slow and faster progressive types. Therefore analysis in the whole group does 
not show a relationship with the SNP. 
There are a number of potential limitations to be addressed. Although it is 
generally known that small studies are subject to spurious results and need replication 
to assess robust effects, we did not replicate our results. This is mainly due to a lack of 
populations with both radiographic follow-up data on hand OA and genotype data, 
implying that replication of our data was not possible at this time. Therefore, this study 
should be appreciated as an initial result for further research on the role of specific 
polymorphisms in OA progression. Despite this limitation we found an association 
between hand OA progression and ASPN over both follow-up periods. As discussed 
above, these effects seem independent, increasing the credibility of the association. 
In conclusion, we found that ASPN SNP rs13301537 was associated with 
progression of hand OA over both 6 years and 2 years. This finding gives insight in 
the pathogenesis of hand OA progression and identified a potential target for the 
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Objective. To investigate change in illness perceptions in patients with osteoarthritis 
(OA) and the association of those changes with disability, and to determine the 
predictive value of illness perceptions in disability. 
Methods. Illness perceptions and disability were measured at baseline and after 
6 years in 241 patients with OA at multiple sites (mean age 59.0 years, 82.2% 
women) using the Illness Perception Questionnaire (IPQ-R) and Health Assessment 
Questionnaire (HAQ), respectively. Mean changes for each IPQ-R dimension were 
reported and related to progression of disability, defined as the highest quartile of 
HAQ score change. The predictive value of baseline illness perceptions in disability at 
6 years (high disability defined as the highest quartile of HAQ score) was assessed 
using logistic regression. 
Results. Illness perceptions changed over time and these changes were related to 
progression of disability. Patients with progression of disability had an increase in 
symptoms attributed to OA, perceived consequences, perceived disease chronicity, 
negative emotions associated with OA and beliefs about immunity as causal factor, 
and a decrease in perceived control and understanding of OA compared to patients 
without progression of disability. Moreover, a higher number of symptoms attributed 
to OA, less perceived control and more perceived consequences of OA at baseline 
were predictive of high disability after 6 years. 
Conclusion. Illness perceptions in patients with OA change over time and these 
changes were related to outcome. Moreover, illness perceptions were predictive of 
disability. This may imply that interventions aiming at changing illness perceptions 
can contribute to better functional outcome. 
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introduction
Osteoarthritis (OA) is the most common musculoskeletal disorder and a major cause 
of disability. It is therefore a burden not only for the individual but also for society, 
increasing in relevance with an aging population.1,2 Hence, reducing disability is an 
important treatment goal in patients with OA.3
It is well recognised that disability in OA is not only associated with the disease 
process itself, but also with other factors. This multifactorial character of the disease 
is illustrated by the International Classification of Functioning, Disability and Health 
(ICF) developed by the World Health Organization.4 This classification describes the 
impact of a disease on a patient as a dynamic interaction between disease, personal 
and environmental factors. Functioning is classified in the activity and participation 
component. The health related component consists of the dimensions body structures 
and body functions. Personal and environmental factors are recognised as modifying 
factors for the association between these two components. 
An aspect of the personal factors that modify the association are the perceptions 
patients have regarding their disease. Research on these illness perceptions is guided 
by the Common-Sense Model, which hypothesises that patients create mental 
representations of their disease in order to make sense of and manage the health 
problem.5 These illness perceptions influence health behavior and outcome. Support 
for this theory was found in studies on the relationship between illness perceptions 
and clinical outcome, including disability, in various diseases including OA.6-14 
Because of the modifying effects of illness perceptions on the relationship between 
disease processes and disability, interventions aiming at these illness perceptions may 
reduce disability. One of the few intervention studies on illness perceptions suggests 
that actively changing illness perceptions can improve outcome.15 In order to establish 
a causal relationship between illness perceptions and outcome, longitudinal data are 
needed. Most of the studies on illness perceptions are cross-sectional and the few 
longitudinal studies that have been performed, had short term follow-up periods 
varying from 6 months to 2 years. To our knowledge, there have been no longitudinal 
studies on illness perceptions performed in OA.
For the present study, longitudinal data concerning illness perceptions over the 
relatively long period of 6 years were available in a well-characterised cohort of 
patients with OA at multiple sites. This made it possible to investigate whether illness 
perceptions changed over time and if these changes were associated with progression 
of disability. Furthermore, we determined if illness perceptions at baseline were 
predictive of disability after 6 years, which could be of importance with a view to illness 
perceptions as potential targets for therapy aiming at better functional outcome.
Patients and metHods
Study design and patient population
The present study is part of the Genetics ARthrosis and Progression (GARP) study, 
aimed at identifying determinants of OA susceptibility and progression. The population 
comprises 192 Caucasian sibships with symptomatic OA at multiple sites, recruited 
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from rheumatologists, orthopaedic surgeons and general practitioners. Details about 
the recruitment and selection have been published elsewhere.16 The GARP study was 
approved by the medical ethics committee of the Leiden University Medical Center. 
Patients were included for baseline assessment between August 2000 and 
March 2003. From April 2007 to June 2008 participants that consented to a follow-up 
visit were examined. Patients were eligible for the present study if baseline and 
follow-up measures of illness perceptions and disability were available.
OA diagnosis 
Patients were included in the GARP study with symptomatic OA in at least two joint 
sites in the hands or in two or more of the following joint sites: hand, knee, hip or spine. 
Patients with one joint site involved, were required to have structural abnormalities in 
at least one of the other joint sites defined by the presence of radiographic OA or the 
presence of two or more Heberden’s nodes, Bouchard’s nodes or squaring of at least 
one first carpometacarpal (CMC-1) joint on physical examination.
Symptomatic OA in the knee and hip was defined following the American College 
of Rheumatology (ACR) criteria.17,18 Knee OA was defined as pain or stiffness on most 
days of the prior month and osteophytes at joint margins of the tibiofemoral joints. 
Hip OA was defined as pain or stiffness in the groin and hip region on most days of the 
prior month in addition to femoral or acetabular osteophytes or joint space narrowing. 
Prostheses in the hip or knee for end-stage OA were included as OA in that joint.
Symptomatic hand OA was defined according to the ACR criteria as pain or 
stiffness on most days of the prior month in addition to three of the following criteria: 
bony swelling of ≥2 of the 10 selected joints (bilateral distal interphalangeal (DIP) 
joints II and III, bilateral proximal interphalangeal (PIP) joints II and III, and bilateral 
CMC-1 joints), bony swelling of ≥2 distal joints, <3 swollen metacarpophalangeal 
(MCP) joints and deformity of ≥1 of the 10 selected joints.19 
Symptomatic OA of the spine was defined as pain or stiffness on most days of 
the prior month in the spine in addition to a Kellgren-Lawrence score ≥2 in ≥1 disc 
or apophyseal joint.
Clinical assessment
Demographic characteristics, data on symptoms and signs of OA and medical history 
were collected at baseline and follow-up using standardised questionnaires. 
During physical examination pain upon lateral pressure or passive movement 
of the joint was graded 0-3 (0=no pain, 1=complaining of pain, 2=complaining 
of pain and wincing, 3=complaining of pain and joint withdrawal) in the hands, 
knees, hips and spine. It was graded on a dichotomous scale (0=no pain, 1=pain) 
in the acromioclavicular joints, sternoclavicular joints, shoulders, elbows, ankles and 
metatarsalphalangeal joints. This pain intensity score (range 0 to 145) is a modification 
of the articular index for the assessment of OA described by Doyle et al.20
Radiographs
Conventional radiographs of the hands (dorso-volar), knees (posterior-anterior (PA) 
weight bearing/semi-flexed), hips (PA), lumbar spine (PA and lateral) and cervical spine 
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(anterior-posterior, lateral and transbuccal) were obtained by a single radiographer, 
employing a standard protocol with a fixed film focus distance. Radiographic OA was 
scored by a single experienced musculoskeletal radiologist using the Kellgren-Lawrence 
grading scale21 in the hands (DIP, PIP, CMC-1 joints), tibiofemoral joints of the knee, 
hips and discs and apophyseal joints of the spine. Intrareader reproducibility was high.16
Disability
Functional status was assessed with the Dutch version of the Health Assessment 
Questionnaire (HAQ), which consists of 24 items in 8 categories concerning activities 
of daily living and mobility.22 Responses are scaled from 0 (without any difficulty) to 
3 (unable to do). If patients use aids they automatically score 2 on that item. The 
highest score in each of the 8 categories is summed and divided by 8 to produce a 
disability score (range 0 to 3).
Illness perceptions
Illness perceptions were assessed using the revised version of the Illness Perception 
Questionnaire (IPQ-R).23,24 The questionnaire consists of 3 sections, with 9 subscales 
that provide information about the components that underlie both cognitive and 
emotional representation of illness. 
The first section, the identity component, is concerned with symptoms patients 
associate with OA. Patients were asked whether or not they experienced 14 commonly 
occurring symptoms since the onset of their illness and if they believe these symptoms 
are related to OA. The sum of the yes-rated items on the second question forms the 
identity subscale.
The second section of the IPQ-R consists of 38 items arranged in seven subscales. The 
consequences subscale represents the individual’s perceptions about the impact of OA 
on physical, social and psychological functioning. The acute/chronic timeline represents 
the perceptions of likely chronic duration of the health problems. The cyclical timeline 
represents the perceptions of likely variability of the disease. Illness coherence reflects the 
patients’ understanding of OA. Personal control represents the perceptions of personal 
control and treatment control represents the beliefs in cure through treatment. The 
emotional representations dimension reflects the negative emotions experienced due to 
OA. Each item is rated on a five-point Likert scale, ranging from strongly disagree to 
strongly agree. High scores represent strong beliefs on that particular dimension.
The third section comprises of 18 possible causes that patients attribute OA to, 
grouped in four dimensions: psychological attributions (n=6), risk factors (n=7), 
immunity (n=3) and chance (n=2).
Statistical analysis
Data were analysed using SPSS, version 14.0 (SPSS, Chicago, Illinois, USA). For each 
IPQ-R dimension means and standard deviations (SD) were calculated. The mean 
change for each dimension with 95% confidence interval (95%CI) was calculated by 
subtracting the baseline scores from follow-up scores. In order to relate these changes to 
progression of disability, patients were classified as progressed or not progressed based 
on the minimal clinical important difference (MCID) of 0.22 on the HAQ.25 Patients with 
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change in HAQ score >0.22 were classified as progressed and those with a change in 
HAQ score <0.22 were classified as not progressed. Mean differences of change on 
each IPQ-R dimension between patients with and without progression were calculated 
with linear mixed models correcting for age, gender, body mass index (BMI), Kellgren-
Lawrence score, pain intensity score, baseline HAQ score, baseline IPQ-R score and 
with a random intercept to adjust for family effects within sibling pairs. The adjustment 
for family effects is based on the hypothesis from the CSM that illness perceptions are 
influenced by a patient’s social environment. This implies that illness perceptions within 
a sibling pair could be more alike then illness perceptions between sibling pairs. The 
estimates represent the difference in change of illness perceptions between patients 
with and without progression of disability and are reported with 95%CI. 
At baseline the association between illness perceptions and disability was assessed 
using linear mixed models adjusting for age, gender, BMI, Kellgren-Lawrence score, 
pain intensity score, family effects and mutual IPQ-R dimensions.
In order to investigate the predictive value of illness perceptions at baseline for 
disability at follow-up, IPQ-R baseline scores were categorised in tertiles and HAQ 
scores at follow-up were categorised in quartiles, both based on the distribution in 
this population. The highest quartile of HAQ follow-up scores was regarded as high 
disability and the other quartiles as low disability. Logistic regression analyses were 
used to estimate crude and adjusted odds ratios (OR) with 95%CI. Adjustments were 
made for age category (40-49 yrs, 50-59 yrs, 60-69 yrs, 70-79 yrs), gender, BMI 
category (<20, 20-25, 25-30, >30), Kellgren-Lawrence score (binary using median as 
cut-off), pain intensity score (binary using median as cut-off) and baseline HAQ score 
quartile. To take into account intrafamily effect, robust standard errors were computed 
using Stata, version 8.0 (Stata, College Station, TX). The crude and adjusted ORs 
were subsequently transformed to risk ratios (RRs) using the approximation formula 
described by Zhang, et al.26, because ORs for common outcomes in a cohort are not 
good approximations of RRs. 
results
Patient demographics and disease characteristics
Of the 384 patients included at baseline 317 (82.6%) consented to participate in 
the follow-up study of whom 260 patients completed questionnaires and visited the 
outpatient clinic, and 57 patients completed questionnaires only. Consent was not 
given by 50 (13.0%) patients, 15 (3.9%) were deceased and 2 (0.5%) were lost to 
follow-up. Of the 317 eligible patients 241 completed the IPQ-R at baseline and 
follow-up at time of the present study and were included. The mean follow-up time 
was 6.0 years (range 5.0-7.4 years). 
Baseline characteristics are shown in table 1. The mean age was 59.0 years and 82.2% 
were women. Symptomatic OA of the spine and hand were most prevalent with 80% 
and 71%, respectively. The knee was involved in 34% of the patients and the hip in 25%. 
The median (IQR) HAQ score was 0.50 (0.13-0.94) at baseline and 0.75 (0.38-1.13) 
at follow-up. The mean change was 0.17 (95%CI 0.12 to 0.23). Patients with 
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progression on the HAQ (n=110) had a mean change (SD) in HAQ score of 0.53 (0.29). 
Patients without progression (n=131) on the HAQ had a mean change of -0.13 (0.25).
Perceptions about OA at baseline and after 6 years
Mean baseline scores on all IPQ-R dimensions and the mean change with 95%CI 
after 6 years are shown in table 2. Although changes were small, ranging from -1.0 
to 0.8, significant differences over 6 years were found for the dimensions timeline 
acute/chronic, personal control, illness coherence and emotional representations. 
This means patients perceived their OA as more chronic and less controllable, that 
they believed to have better understanding of their disease and that they experienced 
less negative emotions due to OA after 6 years.
The most commonly reported symptoms on the identity dimension at baseline 
were stiff joints (98%), pain (97%), fatigue (86%), loss of strength (77%) and 
sleeping difficulties (75%), which were perceived as related to OA in 97%, 97%, 
72%, 77% and 61% of patients, respectively. 
Relationship at baseline between perceptions about OA and disability 
At baseline positive associations between the IPQ-R dimensions identity and 
consequences and HAQ were found, with β-coefficients (95%CI) derived from linear 
mixed model analysis of 0.03 (0.01 to 0.06) and 0.04 (0.02 to 0.06), respectively. 
This means that at baseline higher disability was associated with more symptoms 
attributed to OA and perceiving more consequences due to OA. For the other IPQ-R 
dimensions no association was found (data not shown). 
Table 1. Baseline demographic characteristics, Health Assessment Questionnaire 
(HAQ), Kellgren-Lawrence and pain intensity scores of 241 patients with 
osteoarthritis (OA) at multiple sites.
Age, mean (SD), years 59.0 (7.5)
Women, no (%) 198 (82.2)
Postmenopausal, no (%) 175 (88.4)
Body mass index, kg/m2 25.8 (23.6-29.1)









HAQ (range 0-3) 0.50 (0.13-0.94)
Kellgren-Lawrence score (range 0-180) 41.0 (29.0-55.0)
Pain intensity score (range 0-145) 5.0 (2.0-10.0)
Values are medians (IQR) unless stated otherwise
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Change of perceptions about OA in relation to progression of disability 
To investigate the relationship between changes of illness perceptions over 6 years 
and progression of disability, change on the IPQ-R dimensions was compared between 
patients with (n=110) and without progression (n=131) of disability (table 3). 
Baseline IPQ-R scores did not differ between the groups. Patients with progression 
of disability increased more on the dimension timeline acute/chronic, increased less 
on the dimensions illness coherence and decreased less on the dimension emotional 
representations than patients without progression. Scores on identity, consequences 
and the immune function attribution increased in patients with progression of 
disability but decreased in patients without progression. The opposite was found 
for treatment control, in which patients with progression of disability decreased and 
patients without progression increased. This means that patients with progression 
of disability had an increase in the number of symptoms they associated with OA, 
increasingly stronger perceptions about consequences of OA, the chronicity of 
the disease and immunity as a causal factor, and an increase in negative emotions 
experienced due to OA compared to patients without progression of disability. 
Patients with progression of disability showed a decrease in perceived control and 
understanding of OA compared to patients without progression of disability. 
Prediction of disability
The association between high disability after 6 years and tertiles of the IPQ-R 
dimensions at baseline is shown in table 4. The lowest tertiles represent the most 
helpful perceptions. Significant relationships between high disability after 6 years and 
the IPQ-R dimensions identity, consequences, personal control and treatment control 
were found, meaning that high disability after 6 years was associated with a higher 
number of symptoms attributed to OA at baseline, less perceived control at baseline 
and perceptions of stronger consequences due to OA at baseline. There was a trend 
Table 2. Mean (SD) baseline scores on IPQ-R and mean change (SD) with 95%CI after 6 years in 241 
patients with osteoarthritis at multiple sites. 
IPQ-R dimension Range Baseline
Mean 
change 95%CI
Identity 0-14  5.3 (2.5) -0.2 (2.4) (-0.5 to 0.1)
Consequences 6-30 16.8 (4.6) -0.4 (4.6) (-0.9 to 0.2)
Timeline acute/chronic 6-30 25.4 (3.7)  0.8 (3.9) ( 0.3 to 1.3)
Timeline cyclical 4-20 14.3 (3.1) -0.5 (3.4) (-0.9 to 0.0)
Personal control 6-30 18.8 (3.5) -0.8 (3.9) (-1.3 to -0.3)
Treatment control 5-25 13.9 (2.8) -0.3 (3.2) (-0.7 to 0.1)
Illness coherence 5-25 17.9 (4.1)  0.7 (3.4) ( 0.3 to 1.2)
Emotional representations 6-30 14.3 (5.2) -1.0 (4.7)  (-1.6 to -0.4)
Cause - psychological 6-30 12.6 (4.3) -0.2 (4.0) (-0.7 to 0.3)
Cause - risk factor 7-35 17.8 (3.3)  0.2 (3.7) (-0.2 to 0.7)
Cause - immunity 3-15  6.7 (2.0) -0.2 (2.1) (-0.5 to 0.0)
Cause - chance 2-10  4.9 (1.6) -0.0 (1.8) (-0.3 to 0.2)
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towards an association between high disability after 6 years and more perceived 
chronicity and more negative emotions experienced due to OA at baseline. 
discussion
This study in patients with OA at multiple sites shows that illness perceptions change 
over time and that these changes are related to disability. Moreover, illness perceptions 
regarding the number of symptoms attributed to OA, the level of perceived control and 
perceived consequences are predictive of disability. Over a period of 6 years patients in 
general perceived their OA as more chronic and less controllable, their understanding 
of OA increased and emotions associated with OA were less negative. Patients with 
progression of disability had an increase in the number of symptoms attributed to OA, 
stronger beliefs about the negative impact of OA, chronicity of the disease, immunity 
as causal factor and an increase in negative emotions experienced due to OA compared 
to patients without progression of disability. They also showed a decrease in perceived 
control of OA and understanding of OA compared to patients without progression of 
disability. A higher number of symptoms attributed to OA, lower perceived control, and 
stronger perceived consequences at baseline were predictive of high disability after 6 
years. These findings imply that illness perceptions do change over time, that they are 
related to and, most importantly, predictive of disability. Therefore, interventions aimed 
at changing illness perceptions may influence clinical outcome. 
To our knowledge, few studies investigated illness perceptions in OA and all of 
them were cross-sectional. In our study it was found that at baseline more disability 
Table 3. Mean change (SD) in IPQ-R scores and adjusted mean difference in change of IPQ-R scores 
after 6 years for patients with progression (n=110) versus patients without progression (n=131) on 
the Health Assessment Questionnaire (HAQ)*.
IPQ-R dimension Progression No progression
Mean difference 
(95%CI)** 
Identity 0.1 (2.4) -0.4 (2.4) 0.87 ( 0.40 to 1.34)
Consequences 0.2 (4.6) -0.9 (4.6) 1.38 ( 0.37 to 2.39)
Timeline acute/chronic 1.4 (4.0) 0.2 (3.8) 1.33 ( 0.51 to 2.14)
Timeline cyclical -0.5 (3.5) -0.4 (3.3) -0.02 (-0.79 to 0.74)
Personal control -1.0 (3.8) -0.6 (3.9) -0.44 (-1.34 to 0.46)
Treatment control -0.8 (3.8) 0.1 (3.1) -1.00 (-1.70 to -0.29)
Illness coherence 0.4 (3.7) 1.0 (3.1) -0.86 (-1.66 to -0.06)
Emotional representations -0.1 (4.3) -1.8 (4.8) 2.04 ( 0.93 to 3.15)
Cause - psychological 0.0 (4.3) -0.4 (3.6) 0.69 (-0.25 to 1.63)
Cause - risk factor 0.3 (3.9) 0.1 (3.5) 0.60 (-0.26 to 1.47)
Cause - immunity 0.0 (2.2) -0.4 (2.0) 0.56 ( 0.07 to 1.06)
Cause - chance 0.0 (1.8) 0.0 (1.7) 0.00 (-0.40 to 0.40)
*Progression on the HAQ was defined as the highest quartile of the HAQ change after 6 years. The 
lower quartiles of HAQ change after 6 years were regarded as no progression.
**Adjusted for age, sex, BMI, Kellgren-Lawrence score, pain intensity score, baseline HAQ score, 
baseline IPQ-R score and family effects.
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Table 4. Association between high disability after 6 years, defined as the highest quartile of Health 
Assessment Questionnaire (HAQ) score after 6 years, and tertiles of IPQ-R dimensions at baseline. 
IPQ-R dimension tertiles* Crude risk ratio (95%CI) Adjusted risk ratio (95%CI)**
Identity  
<4 1 1
4-6 12.8 (2.1 to 39.7) 11.5 (1.6 to 39.7)
>6 17.7 (3.2 to 44.6) 12.6 (2.1 to 39.4)
Consequences 
<15 1 1
15-18 3.0 (0.8 to 9.2) 2.5 (0.5 to 9.8)
>18 9.4 (3.7 to 17.0) 6.2 (1.7 to 15.2)
Timeline acute/chronic
<24 1 1
24-28 2.6 (1.2 to 4.9) 3.1 (1.1 to 6.5)
>28 2.5 (1.1 to 4.8) 2.5 (0.8 to 5.6)
Timeline cyclical 
<13 1
13-16 0.9 (0.4 to 1.7) 1.2 (0.3 to 2.6)
>16 1.3 (0.7 to 2.2) 1.4 (0.6 to 2.7)
Personal control 
>21 1 1
17-21 1.7 (0.9 to 3.1) 2.9 (1.3 to 5.0)
<17 2.5 (1.3 to 4.1) 2.8 (1.1 to 5.3)
Treatment control 
>15 1 1
13-15 2.1 (1.1 to 3.6) 3.7 (1.4 to 6.5)
<13 2.7 (1.5 to 4.2) 3.2 (1.3 to 5.8)
Illness coherence 
>20 1 1
16-20 1.0 (0.5 to 1.9) 1.5 (0.5 to 3.1)
<16 1.6 (0.9 to 2.6) 1.5 (0.6 to 2.8)
Emotional representations 
<12 1 1
12-16 2.3 (0.9 to 4.7) 2.8 (1.2 to 5.5)
>16 3.1 (1.4 to 5.9) 2.1 (0.7 to 4.9)
*The lowest tertile represents the most helpful illness representation and is regarded as reference 
category.
**Risk ratios (RR) are adjusted for age, sex, BMI, Kellgren-Lawrence score, pain intensity score, 
baseline HAQ score quartiles and family effects. 
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was associated with more symptoms attributed to OA and stronger perceived 
consequences. These results are in line with earlier studies in OA patients.6,10,11 
Earlier cross-sectional results from the GARP study showed that patients with high 
scores on identity, consequences and chronic timeline had an increased risk of 
reporting more activity limitation of the lower extremities than expected based on 
disease characteristics.6 Hill et al. found that in patients with self-reported hand OA, 
worse hand function was related to reporting more symptoms and more serious 
consequences.11 Hampson et al. found an association between reporting more 
symptoms and perceiving OA as more serious and a greater use of health services 
and poorer quality of life.10 
Few longitudinal studies reporting on changes of illness perceptions have been 
conducted, none of which included patients with OA. Our study is the only one with a 
long-term follow-up period (6 years) during which some illness perceptions changed, 
although the changes were small. Patients with progression of disability had increasingly 
negative illness perceptions compared to patients without progression of disability. 
These results are in line with a study by Foster et al. in primary care patients with low 
back pain, where illness perceptions showed the same small range of change over a 
period of 6 months.7 After stratification of the population in their study according 
to clinical outcome, patients with poor outcome were found also to attribute more 
symptoms to their disease, experience more serious consequences, perceive less control 
of their disease and more negative emotions due to their disease compared to patients 
with good outcome. This shows that over both short- and long-term follow-up periods 
illness perceptions change and that this change is related to change of clinical outcome. 
The predictive value of illness perceptions in disability in OA has not been previously 
investigated. It was found that a higher number of symptoms attributed to OA, low 
perceived control and more serious perceived consequences at baseline were predictive 
of high disability after 6 years. The number of symptoms attributed to the disease 
was the strongest predictor. In other chronic conditions the number of symptoms 
attributed to disease has shown also to be a strong predictor of clinical outcome. In 
rheumatoid arthritis (RA) it was found that more perceived symptoms was associated 
with higher levels of pain after 1 year.13 Better outcome on physical functioning, social 
functioning and mental health after 1 year in patients with psoriasis was associated 
with fewer perceived symptoms.14 In a 2-year follow-up study by Frostholm et al. in 
primary care patients, the number of reported symptoms was the strongest predictor 
of future mental health.8 A possible explanation for the strong predictive value of the 
number of disease attributed symptoms for clinical outcome is the direct influence of 
perceived symptoms on the level of disability that patients experience. It might be that 
other illness perceptions influence the experience of disability less directly. 
In accordance with two other studies we found that in addition to the number 
of associated symptoms, strong perceived consequences and weak beliefs in the 
controllability of the disease were predictive of outcome. Foster et al. found that in 
low back pain patients strong perceived consequences and low perceived control were 
related to poor outcome at 6 months.7 In RA patients perceiving strong consequences 
was associated with more hospital visits and more tiredness after 1 year.13 
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In predicting high disability after 6 years a dose-response relationship was seen 
for the number of symptoms attributed to OA and perceived consequences, but 
not for beliefs concerning the controllability of OA. This may reflect that for certain 
illness perceptions maximum scores may not be the optimal situation. For instance, 
very strong beliefs in the controllability of OA, meaning cure, are not clinically 
realistic or desirable. This should be kept in mind when interventions influencing 
illness perceptions are considered. Therefore perceptions should be optimised, not 
necessarily meaning they should be maximised. 
There are a number of potential limitations of this study. The possibility of bias 
exists due to differences between those who did and those who did not participate in 
the follow-up study. However, demographic and disease characteristics were similar 
between consenter and non-consenters, except for a lower age of the consenters. We 
expect that this age difference will have no effect on the study outcome. Moreover, 
adjustment for age was made in all analyses. As noted earlier only small changes 
in illness perceptions were found. It is unclear whether these changes are clinically 
significant because no cut-off points for illness perceptions have been determined 
as of yet. By relating the changes to outcome, an alternative way of giving a clinical 
meaning to the result was created. As outcome for disability after 6 years the HAQ 
was used, since it reflects functioning of the whole body. A limitation could be that 
the HAQ, which is self-reported, does not reflect actual performance of subjects.27,28 
Ideally, a combined score of self-reported and performance-based measures should 
be used to assess disability. However, no such score exists. Potential bias which may 
exist with the use of a self-reported measure is also present if a performance-based 
measure is used, since performance is related to self-efficacy.29,30 The MCID for RA was 
used as the cut-off for HAQ progression, because no MCID on the HAQ is established 
for OA. It may be that the MCID for OA differs from that for RA. Finally, limited 
information is available about interventions during the follow-up period. In the future, 
intervention studies should be carried out to assess the effect on illness perceptions. 
This study showed that illness perceptions in patients with OA change over time 
and that they are related to and predictive of disability. This implies that interventions 
aimed at changing illness perceptions might contribute to improving clinical outcome. 
Evidence to support this hypothesis is scarce, but promising.15,31 For clinical practice 
it is important to bear in mind that illness perceptions influence clinical outcome and 
it might be useful to explore and discuss a patient’s illness perceptions as part of 
patient evaluation. Further research on the influence of illness perceptions on clinical 
outcome in OA and other chronic disorders is needed to support this premise, as well 
as research on the role of possible interventions aimed at altering illness perceptions. 
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Objective. To examine the association between changes in common sense models 
and changes in functional status over a 6-year follow-up period in patients with 
osteoarthritis (OA). 
Design. At baseline and follow-up, OA outpatients (N=241) recruited from a 
university medical center completed the Illness Perception Questionnaire-Revised 
(IPQ-R), the Australian/Canadian Osteoarthritis Hand Index and the Western Ontario 
and McMasters Universities Osteoarthritis Index. Also, their physician-assessed pain 
intensity, biomedical and clinical measures of medical severity of OA were recorded. 
Main outcome measures. Functional disability, pain intensity. 
Results. Over 6 years, functional disability and pain intensity increased. The IPQ-R 
dimensions of timeline, personal control and illness coherence became more 
negative, and emotional representations became less negative (i.e., more accepting). 
Patients identified as sharing a similar profile of negative changes on the IPQ-R had 
significantly worse functioning on 2 of 3 outcomes, independent of objectively 
measured OA severity. 
Conclusions. Changes in illness perceptions were associated with changes 
in outcomes. Interventions to prevent increasingly negative patterns of illness 
perceptions over time, with an emphasis on strengthening control cognitions, may 
benefit functional status outcomes in patients with OA.
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introduction
The outcome of medical care for patients with chronic physical illness is determined 
to a considerable extent by nonmedical factors.1 According to the Common Sense 
Model (CSM), illness perceptions (both cognitive and emotional) and coping 
responses are determinants of medical outcomes.2 There is considerable evidence 
in support of various aspects of the CSM, although studies of processes by which 
illness perceptions change and the health consequences of these changes remain 
relatively rare.3 The present study examined the association between changes in 
illness perceptions and changes in functional status over a 6-year follow-up period 
for patients with osteoarthritis (OA). 
Longitudinal studies of illness perceptions for a chronic illness create the opportunity 
to examine whether illness perceptions change over time. We are aware of only three 
previous longitudinal studies in which changes in illness perceptions were examined 
together with change in health status. Foster et al.4 found that the changes seen 
in several dimensions of the Illness Perception Questionnaire-Revised (IPQ-R)5 were 
different in patients with low back pain who had a good clinical outcome compared 
with those who had a poor outcome at 6-month follow-up. Furze et al. found that 
change in beliefs about angina was the most significant predictor for physical status 
at 1-year follow-up.6 In a large sample of recently diagnosed patients with type 2 
diabetes, self-management and a patient education program led to changes in illness 
perceptions with consequent changes in quality of life and metabolic control at 
3-months follow-up.7 
Our study also enabled the exploration of a new theoretical issue regarding illness 
perceptions, namely the examination of clusters of persons characterised by similar 
change profiles across dimensions of illness perception and the relation of these clusters 
to changes on various outcomes. The developers of the CSM have emphasised the 
potential value of examining interrelations between combinations of illness perceptions 
as predictors of outcomes in patients with chronic physical illness.2 Clatworthy et al. 
took up this challenge and maintained that “people do not hold illness representations 
in isolation, they are part of a schema …when it comes to the analysis, it may be 
more appropriate to use a method that takes into account all aspects of a patient’s 
illness schema…cluster analysis enables the identification of groups of people who 
share similar illness perceptions, and the utility of the CSM in predicting coping and 
outcome from these beliefs can still be tested”.8 An objective of our study, therefore, 
was to determine whether there would be differences on outcomes between groups of 
patients identified as sharing similar patterns of change in illness perceptions.
OA is one of the most common chronic conditions in elderly persons in developed 
societies, with a significant impact on their quality of life.9 Current treatment for OA 
includes pharmacological therapy to alleviate the impact of inflammation and pain, 
physiotherapy to facilitate activities of daily living and psychosocial interventions 
to reduce the negative psychosocial effects and to encourage social participation 
in society.10-12 We are aware of 13 previous empirical studies in which illness 
perceptions of OA patients were addressed.13-25 These studies corroborate the CSM 
by demonstrating that OA patients’ illness perceptions are associated with limitations 
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in daily activities, well-being, health status and quality of life. A pattern emerged 
across these various studies to indicate that more negative perceptions of OA 
were associated with more functional disability. However, these studies shared the 
limitation of being cross-sectional, precluding inferences about causes and effects. 
In the present Genetics ARthrosis and Progression (GARP) study illness perceptions 
were assessed at entry and 6 years later. The aim of the GARP cohort study is to identify 
determinants of OA susceptibility and progression.26 Given the longitudinal design of 
the GARP study and the detailed and objective assessments of biomedical and clinical 
characteristics, this study allowed examination of the association between changes 
in illness perceptions and changes in functional status over an extended follow-up 
period, controlling for various indicators of health status. Although OA is a chronic 
condition, treatment and self-management activities can prevent further decline in or 
even improve functional status. Over a 6-year follow-up, there is ample opportunity 
for illness perceptions to change in response to changes in health status and for health 
status to change in response to coping activities prompted by illness perceptions. 
In furtherance to Leventhal et al.2 and Clatworthy et al.8, we hypothesised that a 
group of patients sharing similar positive changes in illness perceptions would have 
reductions in functional impairments, whereas the patients with negative changes in 
illness perceptions would have a greater degree of functional impairment. 
metHods
Participants and recruitment
The GARP study population comprises Caucasian sibling pairs of Dutch ancestry 
with familial OA at multiple sites. Details on the recruitment, selection and inclusion 
have been published elsewhere.26 Patients were included in the study through 
rheumatology and orthopaedic outpatient clinics or through practices of general 
practitioners (family physicians). Patients with secondary OA, familial syndromes with 
a clear Mendelian inheritance pattern or a shortened life expectancy were excluded. 
The GARP study was approved by the medical ethics committee of the Leiden 
University Medical Center. 
OA diagnosis
All patients had familial OA. The OA had to have a polyarticular or generalised nature, 
defined as OA at multiple sites. Patients were eligible for inclusion if they had symptomatic 
OA at multiple joint sites in the hand or with OA in two or more of the following joint 
sites: hand, spine, knee or hip. Patients with just one symptomatic joint site with OA 
were required to have structural abnormalities (radiographic OA or bony swelling) in 
at least one other joint site. This phenotype is in accordance with the definition by 
Kellgren and Lawrence of generalised OA.27,28,29 The generalised nature of the disease 
was not the same in all patients; for example, a combination of hand and spine or of 
knee and hand. The frequency of all combinations was described by Riyazi et al.26 More 
patients had involvement of hands (about 70%) than knee (approximately 30%) and 
hip (approximately 25%), but all patients had generalised OA. 
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Symptomatic OA in the knee and hip was defined with the American College 
of Rheumatology (ACR) criteria for knee and hip OA.30 Knee OA was defined as 
pain or stiffness on most days of the prior month and osteophytes at joint margins 
of the tibiofemoral joints. Hip OA was defined as pain or stiffness in the groin and 
hip region on most days of the prior month in addition to femoral or acetabular 
osteophytes of joint space narrowing on radiograph. Symptomatic hand OA was 
defined according to the ACR criteria31 as pain or stiffness on most days of the prior 
month in addition to three of the following criteria: bony swelling of ≥2 of the 10 
selected joints (bilateral distal interphalangeal (DIP) joints II and III, bilateral proximal 
interphalangeal (PIP) joints II and III, and bilateral carpometacarpal (CMC-1) joints), 
bony swelling of ≥2 distal joints, <3 swollen metacarpophalangeal (MCP) joints and 
deformity of ≥1 of the 10 selected joints. Symptomatic OA of the spine was defined 
as pain or stiffness on most days of the prior month in the spine in addition to a 
Kellgren-Lawrence score ≥2 in ≥1 disc or one apophyseal joint.
Of the 384 patients evaluated at baseline (August 2000 – March 2003), 317 
(82.6%) gave informed consent to participate. Of the eligible patients, 241 completed 
the IPQ-R at baseline and follow-up (April 2007 – May 2008). The mean follow-up 
time was 6.0 years (SD 0.4 years).
Measures
Sociodemographic characteristics (e.g., age, sex, marital status, body mass index 
(BMI), education) were collected at baseline. Three biomedical measures were used to 
assess severity of OA: the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) 
assesses hand pain, stiffness and function by self-report32; the Kellgren-Lawrence scale 
is a measure of radiographically assessed degree of OA28; and the Western Ontario 
and McMaster Universities Osteoarthritis Index (WOMAC)) assesses lower extremity 
pain, stiffness and function in OA of the knee or hip by self-report.33 Pain intensity 
was assessed during a physical examination in response to lateral pressure or passive 
movement of the joint, (0=no pain, 1=complaining of pain, 2=complaining of pain and 
wincing, 3=complaining of pain and withdrawal of the joint) in the hands, knees, hips 
and spine, and on a dichotomous scale (0=no pain, 1=pain) in the acromioclavicular 
joints, sternoclavicular joints, elbows, ankles and metatarsalphalangeal joints. This 
pain intensity score (range 0 to 145) is a modification of the articular index for the 
assessment of OA described by Doyle et al.34
We assessed CSMs of OA using the Illness Perception Questionnaire-
Revised (IPQ-R).5 In the instructions, patients were asked to answer the questions 
with regard to their OA, as suggested by the designers of the IPQ-R. The IPQ-R 
measures illness perceptions, emotional representations, and perceived causes, and 
assesses patients’ beliefs about 1) the identity of the disease (labels and symptoms 
describing the illness (14 items); in the instruction, “illness” was substituted with 
“osteoarthritis”), 2) whether the timeline is acute or chronic (6 items), 3) the 
consequences of the disease (the severity of the illness and the impact of the disease 
on life in general, self-image, finance and family members (6 items)), 4) the degree 
of personal control over OA (6 items), 5) the extent to which treatment controls 
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or cures the disease (5 items), 6) illness coherence (the degree to which patients 
believe they understand their illness (5 items)), 7) the cyclical nature of the disease 
(the likely variability of the disease and/or symptoms (4 items)), and 8) the emotional 
representation of the disease (negative emotions experienced due to OA (6 items)). 
The causes subscale assesses the degree to which the patient attributes the cause of 
the disease to psychological factors, risk, immune function and accident or chance. 
As in the Identity scale, in the fragment “Causes of my illness”, “osteoarthritis” 
replaced “illness”. All items were rated on five-point Likert scales ranging from 
strongly disagree to strongly agree. Items were coded so that high scores represent 
strong beliefs on these particular dimensions. Higher scores indicate a stronger belief 
that the experienced symptoms are part of the patient’s illness, in the chronicity of 
OA, in serious negative consequences of OA, in the patient’s own ability to control 
symptoms, in the effectiveness of treatment for controlling OA, in the coherence of 
OA, in the cyclical nature of OA and a stronger negative emotional response to OA.
Statistical analysis
Two repeated measures multivariate analysis of variance (MANOVA) were conducted 
to compare IPQ-R scores and disease progression at baseline with scores at follow-up. 
Cluster analysis was used to classify patients into subgroups according to their change 
in illness perceptions from baseline to 6-year follow-up. Simple change scores (follow-
up score minus baseline score) of the illness perceptions dimensions identity, timeline 
chronic, timeline cyclical, consequences, personal control, treatment control and 
emotional representations were used to perform the two-stage clustering method 
as researched and advised for research in illness perceptions by Clatworthy et al.8 
All change scores were standardised to z-scores prior to clustering. Ward’s clustering 
method was conducted to determine the centroids and number of groups, followed 
by K-means analysis. Squared Euclidian distance was selected as the similarity measure 
and the cluster centroids and numbers of clusters determined by Ward’s method were 
used for the K-means analysis. The dendrogram and agglomeration schedule of the 
initial Ward’s clustering method suggested that it would be appropriate to set the 
K-means clustering solution to produce two clusters.
Independent t-tests were used to investigate differences in IPQ-R change scores 
between both cluster groups.
We performed three repeated measures analyses of covariance (ANCOVAs) to test 
the effects of cluster group on changes in pain intensity, AUSCAN and WOMAC. The 
factors in these analyses were cluster group (cluster 1: patients identified as having 
more negative illness perceptions over time; cluster 2: patients identified as having 
more positive illness perceptions over time), time (baseline and 6-year follow-up) 
and potentially confounding variables entered as covariates: age, sex, BMI, Kellgren-
Lawrence score at baseline, and additionally, pain intensity (at baseline and at 6 
years) for the dependent variables AUSCAN and WOMAC. The reported values for 
the strength of the associations between independent and dependent variables in the 
MANOVAs and ANCOVAs are partial etas squared (η2)
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results
Sample
At the time of the present study, 241 patients completed the IPQ-R, AUSCAN and 
WOMAC at baseline and follow-up. Patient baseline characteristics are shown in 
table 1. The majority of participants were older women, with a BMI at the lower end 
of overweight, representing a range of educational achievement. 
Mean scores on the IPQ-R dimensions, AUSCAN, WOMAC and physician-reported 
pain intensity at baseline and at follow-up are presented in table 2. 
Change on IPQ-R dimensions and disease progression
We conducted a repeated measures MANOVA to investigate differences over time 
in scores on the IPQ-R dimensions. All dimensions and the perceived causes were 
entered as dependent variables. There was a statistically significant difference over 
time on the combined dependent variables with F(12.224)=3.66, p<0.01, Wilks’ 
Lambda=0.84, multivariate η2=0.16. When the results for the dependent variables 
were considered separately, five IPQ-R dimensions differed significantly between 
baseline and follow-up. For the entire sample, beliefs changed to a significantly 
more chronic timeline (F(1.235)=8.28, p=0.004, η2=0.03), less personal control 
over the illness (F(1.235)=8.69, p=0.004, η2=0.04), increased sense of coherence 
(F(1.235)=10.72, p=0.001, η2=0.04), a reduction in the belief in OA as cyclical 
(F(1.235)=4.91, p=0.028, η2=0.02) and a less strong negative emotional response to 
OA (i.e., more positive) (F(1.235)=11.58, p=0.001, η2=0.05). No significant differences 
between baseline and follow-up were found on the other IPQ-R dimensions or on the 
IPQ-R questions that explore perceived causes of OA. 
A repeated measures MANOVA was also conducted to investigate differences over 
time in disease progression. AUSCAN, WOMAC and pain intensity scores were entered 
as dependent variables. There was a statically significant difference over time on the 
combined dependent variables with F(3.206)=11.41, p<0.001, Wilks’ Lambda=0.86, 
multivariate η2=0.14. When the results for the dependent variables were considered 
Table 1. Baseline characteristics in 241 patients with osteoarthritis.





















*Kellgren-Lawrence is a measure of radiographic defined osteoarthritis severity 
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separately, sores on aUSCaN (F(1.208)=10.31, p=0.002, η2=0.05) and pain intensity 
(F(1.208)=31.85, p< 0.001, η2=0.13) indicated an increased (negative) impact on 
daily functioning and pain. No significant differences were observed for the sample 
as a whole on WOMaC scores.
table 3 shows the mean IpQ-r change scores for the two subgroups of patients 
classified according to their profile of change in illness perceptions. Increases in identity, 
chronic timeline and consequences and decreases in personal control, treatment 
control and emotional representations (cluster group 1) describe an illness model 
that becomes more negative over time.2,3,8 Decreases in identity, chronic timeline, 
consequences and emotional representations and increases in personal control and 
treatment control (cluster group 2), represent an illness model that can be defined 
as positive. Both clusters had negative change scores on emotional representations, 
indicating a tendency for both to get less negative over time. however, the positive 
cluster became significantly less negative than the negative cluster, which is consistent 
with the theoretical model.2,3,8 
Differences between cluster groups on functional status
Pain intensity. a 2 (time) x 2 (cluster group) mixed-model aNCOVa revealed 
that the main effects for cluster group (F(1.203)=1.39, p>0.05, η2=0.01) and time 
(F(1.203)=2.80, p>0.05, η2=0.01) were not significant (figure 1). thus, there were 
no overall differences in the mean pain intensity scores of the negative cluster 





mean (SD) F* p
Illness Perception Dimension
Identity 0-14 5.3 (2.5) 5.2 (2.2) 0.60 .438
timeline acute/chronic 6-30 25.4 (3.7) 26.2 (3.4) 8.28 .004
Consequences 6-30 16.8 (4.6) 16.5 (4.6) 0.87 .351
personal control 6-30 18.8 (3.5) 18.0 (3.8) 8.69 .004
treatment control 5-25 13.9 (2.8) 13.6 (3.0) 2.50 .115
Illness coherence 5-25 17.9 (4.1) 18.6 (4.0) 10.72 .001
timeline cyclical 4-20 14.3 (3.1) 13.8 (3.2) 4.91 .028
emotional representations 6-30 14.3 (5.2) 13.3 (5.4) 11.58 .001
psychological attribution 6-30 12.7 (4.3) 12.4 (4.4) 0.69 .407
risk attribution 7-35 17.7 (3.3) 18.0 (3.6) 1.40 .237
Immune function attribution 3-15 6.7 (2.0) 6.4 (2.2) 2.69 .102
accident/chance attribution 2-10 4.9 (1.6) 4.9 (1.6) 0.05 .823
AUSCAN total score 0-60 19.5 (14.2) 22.2 (14.1) 10.31 .002
WOMAC total score 0-100 27.2 (22.9) 28.9 (23.1) 0.28 .598
Pain intensity 0-145 7.9 (8.3) 10.8 (9.5) 31.85 .000
*a repeated measures MaNOVa was conducted to investigate differences over time
abbreviations: aUSCaN: australian/Canadian Osteoarthritis hand Index; WOMaC: Western Ontario 
and McMaster Universities Osteoarthritis Index.
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group (8.54) compared to the positive cluster group (10.01). Mean pain intensity 
scores at follow-up (10.76) were not significantly higher than at baseline (7.80). Of 
the potentially confounding variables (age, sex, BMI, K-L score), only the time x sex 
interaction was significant (F(1.203 =3.90, p<0.05, η2=0.02) suggesting a sharper 
rise in pain intensity for females across both groups. 
AUSCAN. A significant time x cluster group effect was obtained with F(1.201)=9.96, 
p<0.01, η2=0.05. Examination of the cell means indicated that, although there was an 
increase in mean AUSCAN scores for the negative cluster group from baseline (17.65) 
to follow-up (22.86), the positive cluster group did not change in mean AUSCAN 
scores from baseline (21.26) to follow-up (21.60). At baseline, the negative cluster 
group had significantly better AUSCAN scores than did the positive cluster group 
(t(238)=-1.99, p<0.05). Other significant effects emerged for Kellgren-Lawrence 
scores (F(1.201)=8.74, p<0.01, η2=0.04), baseline pain scores (F(1.201)=19.17, 
p<0.001, η2=0.09) and for follow-up pain scores (F(1.201)=41.16, p<0.001, η2=0.17) 
showing more negative AUSCAN scores across both time points for patients with 
higher Kellgren-Lawrence scores and higher pain intensity scores.
WOMAC. A significant time x cluster group effect was obtained with F(1.200)=9.43, 
p<0.01, η2=0.05. Examination of the cell means indicated that, although there was 
an increase in mean WOMAC scores for the negative cluster group from baseline 
(25.51) to follow-up (31.42), the positive cluster group did slightly improve in mean 
WOMAC scores from baseline (28.97) to follow-up (26.85). At baseline the negative 
cluster group had slightly (non-significant) better WOMAC scores than did the 
positive cluster group. 
Other significant effects emerged for BMI (F(1.200)=32.89, p<0.001, η2=0.14), 
baseline pain scores (F(1.200)=8.22, p<0.01, η2=0.04) and follow-up pain scores 
(F(1.200) = 37.44, p<0.001, η2=0.16), showing more negative WOMAC scores across 
both time points for patients with higher BMI scores and higher pain intensity scores.
Although the two patient clusters were not significantly associated with changes 
over time in physician-reported pain intensity, they were associated with modest but 
Table 3. Mean differences (SD) in IPQ-R change scores* between cluster groups.
Cluster 1: Illness 
model more negative 
over time (n=114)
Cluster 2: illness 
model more positive 
over time (n=126) F p-value
Identity 0.45 (2.35) -0.71 (2.39) 3.793 .000
Timeline acute/chronic 3.01 (3.42) -1.24 (3.24) 9.882 .000
Consequences 1.81 (4.28) -2.31 (4.06) 7.648 .000
Personal control -2.76 (3.30) 0.99 (3.46) -8.582 .000
Treatment control -2.19 (2.70) 1.38 (2.59) -10.436 .000
Illness coherence 0.48 (3.17) 0.95 (3.60) -1.077 .283
Timeline cyclical -0.52 (3.69) -0.42 (3.12) -0.214 .831
Emotional representations -0.06 (4.14) -1.91 (4.96) 3.113 .002
*Change scores: follow-up score minus baseline score.
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Figure 1. Change in pain intensity from baseline to 6 years follow-up for the two cluster groups.
Figure 2. Change in AUSCAN score from baseline to 6 years follow-up for the two cluster groups. 
Figure 3. Change in WOMAC score from baseline to 6 years follow-up for the two cluster groups. 
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meaningful changes at follow-up in AUSCAN and WOMAC scores. As hypothesised, 
the cluster with a more positive illness model was associated with better outcomes, and 
the cluster with a more negative illness was associated with poorer outcomes on the 
two functional impairment scales, AUSCAN and WOMAC. These results corroborate 
the validity of the two-cluster solution for the IPQ-R dimensions presented here and 
suggest that these clusters may be associated with clinically meaningful changes in 
functional impairment. 
discussion
The results of this prospective study with a 6-year follow-up add to the limited number 
of empirical studies in which longitudinal changes in IPQ-R dimensions were examined. 
They advanced our knowledge of changes in CSMs of OA over time, suggesting which 
IPQ-R dimensions remain stable and which ones change. For OA, it appears that 
attributions of causality remain relatively unaffected by the passage of time. However, 
over time, OA is increasingly perceived as a relatively chronic condition, as less cyclical 
and as less amenable to personal control, independent of objectively assessed illness 
severity. Moreover, the identification of two patient clusters, each with similar change 
profiles across the dimensions of illness perceptions as recommended by Clatworthy et 
al.8, yielded additional meaningful associations between change in illness perceptions 
and change in functional status. Consistent with the conclusions from Hagger and 
Orbell’s meta-analysis of illness perceptions, a deterioration in functional abilities 
over time was associated with a pattern of change on illness perceptions associated 
with poor outcomes: more passive and chronic views, perceiving less control and 
experiencing a higher emotional load regarding the illness.3
Demonstrating that change to a more negative illness representation is associated 
with deterioration of functional status across long-term follow-up is indicative of a 
reciprocal process between illness representations and illness outcomes as proposed 
by the CSM.2 The present findings for OA are comparable to previous studies of low 
back pain4, angina6, venous thrombosis35 and diabetes7. Together, these results have 
important clinical implications. They suggest that identifying illness dimensions on 
which patients hold beliefs indicative of poor outcomes and intervening to change 
these beliefs may have beneficial effects on the course of a chronic disease.3,8,12 As 
noted by Clatworthy et al.8 “as the focus of illness perception research moves towards 
intervention development, there is a further practical advantage to grouping people 
in this way. Groups of people with schemata associated with poor coping or outcome 
would be ideal targets for interventions. The cluster analysis would not only identify 
these groups but would also provide information on the types of beliefs held by the 
groups that may need to be addressed in an intervention”. 
Strengths of the present study include the comparatively large sample size 
compared to previous research on OA illness perceptions, the unusually long follow-
up period and the relatively low level of subject attrition. The present sample was 
comparable to the samples of OA patients in the studies mentioned in the introduction 
with regard to sociodemographic and other medical characteristics. The measure of 
137
CHAPTER 10
the illness perceptions used here reflected the same theoretical base (the CSM of 
Leventhal et al.2) as many of these studies. Such comparability increases the external 
validity and hence the generalisibility of our findings. 
Limitations include the absence of a measure of functional status that was not 
based on self-report. However, the AUSCAN and WOMAC are widely used to assess 
the impact of OA in daily life and are considered the gold standard in research on 
OA patients. Moreover, unlike many previous studies, pain intensity was measured 
objectively and controlled for in all analyses. Assessment of change on both illness 
perceptions and functional status at one or more times during the follow-up period 
could have yielded even more interesting results, enabling the examination of 
correlated change across time and investigated cross-lagged correlations. Multiple 
assessments are recommended for future studies. 
The potential of interventions to change illness perceptions and examine effects 
thereof on disease outcomes is only just beginning to be recognised.36 Only a few 
intervention studies have been published up to now.4,6,37-42 Theoretical and conceptual 
issues in designing interventions in the context of the CSM are discussed by Deary and 
Wearden et al.43,44 The present study suggests that interventions that increase patients’ 
pattern of positive beliefs, especially the control components in illness perceptions – that 
is increase perceived ability to control their OA and the effectiveness of their medical 
treatment; reduce perceived symptoms and the perceived physical, social and emotional 
consequences of the disease – could result in less self-reported functional disability. 
Future research on patients with OA should focus on identifying more precisely which 
patterns of illness perceptions are associated with more specific outcome measures and 
developing interventions designed to change these patterns of beliefs. 
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aBstract
Objective. To study the association between metacarpal bone mineral density (BMD) 
loss and progressive hand osteoarthritis (OA) over 2 years. 
Methods. Using the Kellgren-Lawrence (KL) grading scale and the Osteoarthritis 
Research Society International (OARSI) atlas, standardised hand radiographs of 181 
patients with primary OA at multiple sites (mean age 60 years, 80% females, mean body 
mass index 27 kg/m2) were assessed for hand OA at baseline (KL ≥2 in ≥2 hand joints) 
and progressive hand OA over 2 years (≥1 point increase in total osteophyte and joint 
space narrowing score in patients with hand OA at baseline). Changes in BMD were 
measured over 2 years in metacarpals 2-4 by digital X-ray radiogrammetry. Accelerated 
BMD loss was defined as loss of >3 mg/cm2/year. Logistic regression analyses were 
performed to assess the associations between BMD loss and progressive hand OA.
Results. The baseline prevalence of hand OA was 68% and, after 2 years, 32% 
of these patients had progressive hand OA. Accelerated BMD loss was present in 
79% of the patients with progressive hand OA compared to 60% and 57% of the 
patients with non-progressive hand OA and no hand OA, respectively. BMD loss was 
independently associated with progressive hand OA compared to non-progressive 
hand OA with a RR (95%CI) of 2.1 (1.1 to 4.3). 
Conclusion. Accelerated metacarpal BMD loss is associated with progressive hand 
OA over a period of 2 years, knowledge of common mechanisms may lead to 
development of therapeutic interventions for hand OA.
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introduction
Osteoarthritis (OA) is a heterogeneous disease characterised by degradation of 
articular cartilage, changes in subchondral bone and osteophyte formation at the 
joint margins leading to joint failure. The disease has a major impact on the patient 
by increased morbidity and mortality and on society by high health care costs.1
The pathogenesis of OA is incompletely understood, but thought to be 
multifactorial involving degenerative, biomechanical, metabolic, hormonal and 
genetic factors.2 Within OA, hand OA seems to be a separate subset of the disease 
compared to knee and hip OA with differences in genetic factors, pathogenesis and 
disease course.3 Increasing evidence supports the involvement of local and low-grade 
systemic inflammation in the pathogenesis of OA, especially in the hands. With 
sensitive imaging modalities, inflammatory signs such as synovitis in interphalangeal 
joints in the hand is frequently seen in patients with OA.4-6 In patients with OA, 
increased levels of pro-inflammatory cytokines in synovial fluid7,8 and of high sensitive 
C-reactive protein (hsCRP) in peripheral blood are found.9,10
Experimental animal studies have provided substantial evidence suggesting that 
inflammatory activity plays an important role in the pathogenesis of osteoporosis or 
bone mineral density (BMD) loss.11 In health subjects, levels of inflammatory markers, 
such as interleukin 1β and interleukin 6, tumour necrosis factor α and hsCRP, are 
associated with, and predictive for, changes in BMD over time.12-14 In patients with 
rheumatoid arthritis, measurement of localised BMD loss over time has been shown to 
be associated with radiographic progression over time and to be sensitive to indicate 
inflammatory bone involvement.15,16 In patients with OA, the level of BMD loss and 
the relation to the development or progression of OA is less clear. In contrast to data 
of cross-sectional studies17-21, longitudinal data on the relation between BMD and 
OA are limited. Two studies investigating changes in BMD in OA showed generalised 
BMD loss over time in hand, hip and knee OA.22,23 Only one study investigated both 
BMD and OA parameters longitudinally, showing that generalised BMD loss was 
associated with progressive knee OA.24 To our knowledge, no data exists on the 
association between localised BMD loss and progressive OA in the hands.
We hypothesised that accelerated localised BMD loss might be present in hand OA 
and associated with disease progression, as a marker for an inflammatory pathway of 
the disease. Therefore, we investigated the relationship between changes in BMD at 
the metacarpals and radiographic progression of hand OA over a period of 2 years.
Patients and metHods
Study design and patient selection
Patients were selected from the Genetics ARthrosis and Progression (GARP) cohort.25 
The cohort comprises 192 Caucasian sibling pairs with symptomatic primary OA, 
defined according to the American College of Rheumatology criteria, at multiple sites 
in the hands or in at least two of the following joint sites: hand, knee, hip or spine 
(cervical and lumbar).26-28 Patients with secondary OA (congenital or developmental 
diseases, bone dysplasia, local factors such as severe scoliosis and hypermobility, 
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metabolic diseases, intra-articular fractures, inflammatory joint diseases and other 
bone disease such as Paget disease and osteochondritis), patients with familial 
syndromes with a Mendelian inheritance pattern and patients with a shortened life 
expectancy were excluded. The medical ethics committee of the Leiden University 
Medical Center approved the study protocol and all patients gave written informed 
consent prior to participation in the study.
Of the original 192 sibling pairs, 105 pairs with at least one subject with 
symptomatic hip or knee OA were included in the 2-year follow-up study.29 These 
210 patients were eligible for the present study. 
Radiographic assessment of hand OA
Standardised analogue radiographs of both hands (dorsal-volar) were obtained in a 
single center by the same experienced radiographer at baseline and after 2 years. 
To assess the presence of hand OA, baseline hand radiographs (distal 
interphalangeal joints, proximal interphalangeal joints, first interphalangeal joints 
and first carpometacarpal joints) were scored by a single experienced reader using the 
Kellgren-Lawrence (KL) grading scale (0-4 for each joint).30 This is a five-point scoring 
system with ascending severity based on the presence of osteophytes, joint space 
narrowing (JSN), sclerosis and degenerative cyst formation. Hand OA was defined as 
KL score of ≥2 in at least 2 hand joints. 
To assess OA progression, baseline and 2-year hand radiographs were scored in 
pairs for osteophytes and JSN by consensus opinion of two experienced readers, 
blinded for patient characteristics and time sequence, using the Osteoarthritis 
Research Society International (OARSI) atlas (0-3 per joint for each feature).31 In case 
of disagreement the lower, more conservative score, was recorded. Progressive hand 
OA was defined as an increase in the total osteophyte and JSN score of at least 1 
point over 2 years in patients with hand OA at baseline. 
Intrareader reliability for the assessment of the prevalence and progression of 
hand OA, both dichotomous variables, expressed by kappa coefficients based on a 
random selection of 10% of the radiographs, was 1.0 for both assessments. 
Metacarpal BMD measurements
Analogue radiographs of both hands were digitised by a high-resolution 300 DPI 
scanner (Canon Vidar VXR-12 plus, Canon Inc., Tokyo, Japan) and analysed under 
blinded conditions using the digital X-ray radiogrammetry (DXR) online from the 
Pronosco X-posure system (Sectra, Linköping, Sweden). 
DXR is a computerised version of the traditional technique of radiogrammetry 
originally proposed by Barnett and Nordin to estimate bone strength with radiological 
assessed cortical bone thickness.32 The digitised hand radiograph was subjected 
to a number of image processing algorithms where the three regions of interests 
around the narrowest part of the second, third and fourth metacarpal joints were 
automatically identified and, subsequently, the outer and the inner cortical edges 
of the included cortical bone parts were found.32 The BMD estimate is defined as: 
BMD = c x VPA x (1-p), where c is a constant, VPA is volume per area and p is 
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porosity. DXr can measure changes in BMD with high precision and has a smallest 
detectable differences ranging from 1.2 to 2.8 mg/cm2.33 DXr measurements are 
highly correlated with dual energy x-ray absorptiometry (DeXa) measurements at the 
hip and forearm, with correlation coefficients of 0.7 and 0.9, respectively.33
Both hands were measured using the DXr method and the mean was used for the 
analyses to avoid bias regarding dominant and non-dominant hands and to achieve 
better precision. accelerated metacarpal BMD loss was defined as BMD loss of >3 
mg/cm2/year, equal to standard error of the DXr technique.34 
Demographic variables
Demographic variables, including age, sex, weight, length, smoking status and the 
use of hormone replacement therapy (hrT), bisphosphonates, and calcium and 
vitamin D supplements were collected by standardised questionnaires. 
hsCRP measurement
hsCrp was measured in serum using an ultrasensitive immunonephelometry method on a 
Bna Behring nephlelometer (n laterx Crp mono; Behringwerke ag, Marburg, germany).
Statistical analysis
analyses were performed using spss, version 17 (spss, Chicago, illinois, Usa) and 
stata, version 8.0 (stata, College station, Texas, Usa). The association between BMD 
loss and progressive hand oa were tested by Mann-Whitney and chi-squared tests. 
The p-values derived by multiple comparison tests were corrected by the step-down 
Bonferroni-holmes adjustment. To determine the independent associations between 
BMD loss and progressive hand oa, multivariable logistic regression analyses were 
performed adjusted for age, sex, postmenopausal status, body mass index (BMi), 
family effect, smoking status, use of hrT, bisphosphonates, calcium and vitamin D 
supplements and BMD scores at baseline. 
odds ratios (ors) and corresponding 95% confidence intervals (95%Ci) were 
transformed to relative risks (rr) with 95%Ci using the approximation formula 
described by Zhang and Yu, since ors for common outcomes in a fixed cohort are 
not good approximations of rrs.35
RESULTS
Patient characteristics
in 17 of the 210 patients eligible for the present study, 2-year hand radiographs were 
missing. in addition, of 12 patients baseline or 2-year BMD could not be analysed due 
to improper positioning of the hands and artifacts in regions of interest. hence, 181 
patients were included in the present study. There were no significant differences in 
baseline characteristics between the 181 patients included in the current study and 
the 29 patients who were not included (data not shown).
Baseline demographic, oa and osteoporosis related characteristics are shown in 
table 1. The mean age was 60 years and 80% were women, of which the majority were 
postmenopausal. at baseline, 123 patients (68%) had hand oa, defined as at least two 
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hand joints with KL ≥2. The mean (SD) metacarpal BMD was 0.57 (0.07) g/cm2. Patients 
with non-progressive hand OA during the 2-year study period were significantly older 
and more often postmenopausal at baseline than patients with no hand OA and 
progressive hand OA (table 1). Patients with no hand OA during the study period had 
significantly higher metacarpal BMD at baseline than patients with hand OA. There 
were no other significant differences in baseline characteristics between patients with 
no hand OA and non-progressive hand OA and progressive hand OA (table 1).
Changes in hand OA and BMD after 2 years
Of the 123 patients with hand OA at baseline, 39 patients (32%) had progressive 
hand OA, defined as at least 1 point increase in total osteophyte and JSN score over 
2 years, while 84 patients (68%) had non-progressive hand OA. Of the women, 
31 (31%) had progressive hand OA compared to 8 men (35%) (p=0.918). 
In the total population, the median (IQR) metacarpal BMD change after 2 years 
was -9.9 (-17.6 to -3.1) mg/cm2 which was -1.7% (-3.2% to -0.6%) of baseline BMD. 
On the individual level, 114 (63%) of the 181 patients had accelerated BMD loss, that 
is more than -6 mg/cm2 over 2 years. Women had more BMD loss than men (table 2). 
Progressive versus non-progressive versus no hand OA and BMD loss
Cumulative probability plots are shown in figure 1 categorised for no hand OA and non-
progressive hand OA and progressive hand OA over 2 years. Patients with progressive 
Table 1. Demographic, osteoarthritis (OA) and osteoporosis related baseline characteristics of the 
total study population and patients with no, non-progressive and progressive hand OA during the 















Demographic and OA related
Age, years, mean (SD) 60 (7) 59 (7) 62 (7) 58 (6) 0.001
Women, no. (%) 145 (80) 45 (78) 69 (82) 31 (79) 0.8
Postmenopausal, no. (%) 133 (92) 38 (84) 69 (100) 26 (84) 0.003
BMI, kg/m2, mean (SD) 27 (4) 27 (4) 26 (3) 26 (3) 0.2
Current smokers, no. (%) 33 (18) 14 (24) 15 (18) 4 (10) 0.2
hsCRP, mg/l, median (IQR) 1.8 (1.1-4.4) 2.0 (1.1-5.0) 1.7 (1.0-3.9) 1.8 (1.0-4.0) 0.4
Hand OA, no. (%) 123 (68)
Osteoporosis related 
Metacarpal BMD, mean (SD) 0.57 (0.07) 0.60 (0.06) 0.58 (0.08) 0.57 (0.06) 0.027
HRT use, no. (%) 25 (14) 9 (20) 11 (16) 5 (16) 0.8
Bisphosphonates, no. (%) 6 (3) 2 (4) 3 (4) 1 (3) 1.0
Calcium supplements, no. (%) 5 (3) 2 (4) 3 (4) 0 0.5
Vitamin D supplements, no. (%) 3 (2) 0 2 (2) 1 (3) 0.5
Abbreviations: BMI: body mass index; BMD: bone mineral density; hsCRP: high sensitive C-reactive 
protein; HRT: hormone replacement therapy. 
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hand OA had higher BMD loss over 2 years than patients with non-progressive hand 
OA and patients without hand OA (table 3). There were no significant differences in 
BMD loss over 2 years between patients with non-progressive hand OA and no hand 
OA (table 3). Accelerated BMD loss occurred in 31/39 patients (79%) with progressive 
hand OA compared to 50/84 patients (60%) with non-progressive hand OA and 
33/58 patients (57%) with no hand OA (table 4). In multivariable analysis, accelerated 
BMD loss was independently associated with progressive hand OA compared to non-
progressive hand OA over 2 years with a RR (95%CI) of 2.1 (1.1 to 4.3) (table 4). This 
association with BMD loss concerned both osteophyte and JSN progression equally 
over 2 years (data not shown). Accelerated BMD loss was also independently associated 
Table 2. Median (IQR) changes in metacarpal bone mineral density (BMD) and number (%) of patients 







BMD change, mg/cm2 -9.9 (-17.6 to -3.1) -10.0 (-18.4 to -3.9) -6.9 (-11.9 to -0.4) 0.029
BMD change, % 
baseline BMD -1.7 (-3.2 to -0.6) -3.4 (-1.9 to -0.7) -1.1 (-2.0 to -0.1) 0.009
Accelerated BMD loss 114 (63) 94 (65) 20 (56) 0.302
Accelerated BMD loss is defined as more than -6 mg/cm2
Figure 1. Cumulative probability for no hand osteoarthritis (OA) and non-progressive and progressive 
hand OA over 2 years with changes in bone mineral density (BMD), in mg/cm2, on the y-axis.
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Table 3. Median (IQR) changes in metacarpal bone mineral density (BMD) in patients with progressive 
hand osteoarthritis (OA), non-progressive hand OA and no hand OA over 2 years.
Progressive hand 
OA group 1 (n=39)
Non-progressive hand 
OA group 2 (n=84)
No hand OA
group 3 (n=58)
BMD change, mg/cm2 -12.6 (-23.3 to -6.5) -8.5 (-15.1 to -3.2) -9.2 (-17.4 to -2.2)
p-value overall 0.025
p-value 1 vs 2* 0.033
p-value 1 vs 3* 0.040
p-value 2 vs 3* 0.858
BMD change, % baseline BMD -2.2 (-4.1 to -1.4) -1.4 (-2.9 to -0.6) -1.4 (-3.1 to -0.4)
p-value overall 0.032
p-value 1 vs 2* 0.045
p-value 1 vs 3* 0.042
p-value 2 vs 3* 0.604
*p-values are corrected for multiple testing by the step-down Bonferroni-Holmes adjustment.
Table 4. Associations between progressive hand osteoarthritis (OA), non-progressive hand OA and 










BMD loss 31 50 0.030 2.0 (1.1 to 4.0) 2.1 (1.1 to 4.3)
Non-accelerated 
BMD loss 8 34 1 1
Non-progressive 
hand OA No hand OA p-value





BMD loss 50 33 0.755 1.1 (0.8 to 1.3) 0.9 (0.6 to 1.2)
Non-accelerated 
BMD loss 34 25 1 1
*Adjusted for age, sex, postmenopausal status, BMI, family effect, smoking status, the use of 
hormone replacement therapy, bisphosphonates, calcium and vitamin D supplements and BMD 
scores at baseline.
with progressive hand OA over 2 years in comparison with no hand OA (data not 
shown). There was no association between accelerated BMD and non-progressive hand 
OA (table 4).
Association between hsCRP at baseline and BMD loss after 2 years
There was no correlation between hsCRP at baseline and metacarpal BMD loss after 2 
years (data not shown). Furthermore, at an individual level, patients with high hsCRP 
at baseline did not have more BMD loss than patients with low hsCRP at baseline 
(data not shown). 
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discussion
As far as we know, this is the first study evaluating localised BMD loss in relation to 
radiographic progression of hand OA. We have shown that accelerated metacarpal BMD 
loss is associated with radiographic progression of hand OA over a period of 2 years. 
Our results are in line with the data of Sowers et al., who showed that cortical 
bone loss over 23 years, estimated by a semiobjective method on plain radiographs, 
was associated with progressive hand OA in female patients.36 
There are several explanations for the association between accelerated BMD loss 
and progressive hand osteoarthritic joint damage in the hands. First, inflammatory 
activity may drive both processes. Previous studies have suggested that BMD loss 
is partially a result of circulating inflammatory factors in healthy subjects.11-14 In 
rheumatoid arthritis, localised hand BMD loss has even been proposed as an outcome 
measure owing to the predictive value of inflammatory activity.37 The finding that 
there were no differences in BMD changes over 2 years in patients with non-
progressive hand OA compared to patients with no hand OA supports the role of 
inflammation in active, progressive OA only. However, it is also possible that there are 
two disease entities, namely, inflammatory and non-inflammatory subtypes of OA. 
Inflammatory OA might be defined as OA in the presence of subchondral erosions. A 
small proportion of our population hand erosive hand OA (12%).38 Sensitivity analysis 
showed the same effects in those with and without erosive OA. However, this may 
be owing to the small number of patients with erosive OA. Subanalyses did not show 
any association or correlation between hsCRP at baseline and metacarpal BMD loss 
over 2 years. Unfortunately, we had no data on changes in hsCRP during the study 
period. In order to unravel the possible inflammatory pathways of OA more research 
is needed on inflammatory activity in OA. 
Second, other pathways driving both bone processes, such as estrogen 
deficiency, low BMI and familial factors, might explain accelerated BMD loss in 
patients with progressive hand OA. However, sensitivity analysis adjusted for age, 
sex, postmenopausal status, BMI, family effects and use of HRT showed unchanged 
associations and risk estimates. 
Third, physical activity or immobility of hands with more severe OA might result in 
lower localized BMD in these hands. Subanalyses in which we additionally adjusted 
for functional limitations and pain, measured by the Health Assessment Questionnaire 
(HAQ) or Australian/Canadian OA Hand Index (AUSCAN), as surrogate for immobility, 
revealed no changes in associations. 
Fourth, data on calcium intake and serum vitamin D levels were missing and 
therefore their effect on BMD loss and OA progression are unknown. On the 
other hand, the use of antiresorptive agents (calcium and vitamin D supplement 
and bisphosphonate use) was very low in the total population and there were no 
significant differences between the subgroups. 
Our study has some limitations. First, since hand OA is a heterogeneous disease 
with entities varying from mild disease to erosive, destructive hand OA, our conclusions 
might not be relevant for all entities of hand OA. Second, BMD was measured by DXR. 
Generally DEXA is considered the gold standard for measuring BMD. However, DXR 
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and DEXA BMD measurements are highly correlated. Furthermore, DXR can detect 
changes in BMD with high precision and seems to identify patients with OA with 
low BMD better than quantitative ultrasound.33,34,39 DXR measures bone loss in the 
metacarpals, enabling assessment of local effects in the hands such as inflammation, 
without measuring the extra bone formation by osteophytes which can lead to ‘false’ 
high BMD measurements. Third, although there was a clear association between 
hand OA progression and BMD loss, 60% of patients with non-progressive hand OA 
had accelerated bone loss. This may be owing to the high proportion of females or 
advanced age of our population or because mild progressive hand OA is not traceable 
on radiographs with the methods used during the relatively short follow-up period 
of 2 years. Fourth, the rate of incident hand OA in this study is unknown. Therefore 
associations between accelerated metacarpal BMD loss and the development of 
new hand OA during the study period could not be investigated. Fifth, the degree 
of osteoporosis might have influenced the readers scoring the radiographs for OA. 
However, at the time of the radiographic assessment the readers were unaware of 
the objective of this study. And finally, data on physical activity or immobility of the 
hands were unavailable in our study.
In summary, we showed that accelerated metacarpal BMD loss is associated 
with progressive hand OA, suggesting that localised BMD loss and radiographic 
progression of hand OA share common pathophysiological pathways. Further 
research is needed to understand these mechanisms in order to develop possible 
therapeutic interventions for OA. 
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doyle index is a valuable 
additional pain measure  
in osteoarthritis
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Objective. To determine reliability, feasibility and validity of the Doyle Index (DI), a 
pain score proposed for osteoarthritis (OA). 
Methods. The DI was performed in 260 patients with OA at multiple sites (mean 
age 64.9 years, 84% women) by grading pain (0-3) in 48 joints and joint groups 
by palpation or passive movement. Reliability and feasibility were determined in a 
random sample of 18 patients, by examining them twice using four raters. Intraclass 
correlation coefficients (ICCs) for intra- and interrater reliability were calculated, as 
well as the mean time to perform the DI. Validity was assessed in 260 patients, by 
correlating DI total scores and DI scores for the hand and knee/hip joints separately, 
to the pain and function subscales of the Australian/Canadian Osteoarthritis Hand 
Index (AUSCAN) and Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC), using Spearman’s rank coefficient (r).
Results. In the total population the median (interquartile range) DI score was 11.0 
(5.0-19.0). Intrarater ICCs (95%CI) ranged from 0.94 (0.84 to 0.98) to 0.97 (0.93 to 
0.99). Interrater ICC was 0.88 (0.77 to 0.94). The mean time to perform the total DI 
was 5.1 minutes (range 2.4-7.8). DI total scores as well as scores for the hand and 
knee/hip joints separately were related to AUSCAN (r range 0.61-0.65) and WOMAC 
(r range 0.43-0.51), although the level of correlation was moderate.
Conclusion. The DI is a reliable, easy to perform and valid measure for OA pain 
during physical examination and therefore a promising additional outcome measure 
not only for OA research but also for clinical practice.
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introduction
Osteoarthritis (OA) is a common heterogeneous joint disorder which may affect any 
joint, but mostly the hand joints, knees, hips and spine. Often multiple joints are 
affected in a patient. Joint pain is the primary symptom of OA, accompanied by 
stiffness and gradual loss of function. To date only treatment of symptoms is available. 
Pain is one of the core outcome measures in the evaluation of OA.1,2 It can be 
assessed using subscales of standardised questionnaires or a single item global 
pain Visual Analog Scale, both reflecting self-reported pain.2 In addition, pain can 
be assessed during physical examination, which may reflect a different aspect of 
disease. Self-reported pain may incorporate more psychosocial aspects, whereas pain 
on physical examination may be less subjective.
A standardised method to assess pain during physical examination is lacking. In 
1981 an articular index for the assessment of joint pain in OA was proposed, the 
Doyle Index (DI).3 This articular index is a modification of the Ritchie index which 
is widely used in rheumatoid arthritis.4 The DI includes 48 joints or joint groups for 
assessment, based on the pattern of joint involvement in OA. Since it may evaluate 
other aspects of pain than questionnaires, it can be a valuable additional outcome 
measure in OA. However, its clinimetric properties have not been investigated yet. 
Therefore we determined the reliability, feasibility and validity of the DI in patients 
with OA at multiple sites. Besides its application in research, the DI can be used in 
patient care. 
metHods
Study design and patient population
The study population consisted of 260 patients participating in the Genetics ARthrosis 
and Progression (GARP) study, visiting for a follow-up evaluation after 6 years.5 Patients 
were included in the GARP study with familial OA at multiple sites in the hands or 
in at least two joint sites being hand, knee, hip or spine. They were required to have 
symptomatic OA in at least one joint site. In case of one symptomatic OA joint site, 
structural abnormalities in at least one other joint site were required. Symptomatic 
hand OA was defined according to the American College of Rheumatology (ACR) 
criteria.6. In the knee, hip and spine symptomatic OA was defined as a combination 
of symptoms and radiographic OA signs as described by the ACR criteria.7,8 Details 
on the recruitment and follow-up have been published elsewhere.5,9 The study was 
approved by the medical ethics committee. 
A random sample of 18 patients was used to determine reliability and feasibility 
during an additional visit. Using four raters the DI was performed twice in each 
patient by each rater, with a 90-minute time interval. The order in which patients were 
assessed differed between raters and between the first and second scoring. The time 
to perform the DI in each patient was measured using a stopwatch. All raters were 




Using the DI, pain is graded during physical examination in 48 joints or joint groups 
(table 1) by pressure on the lateral joint margin or by passive joint movement on a 
four-point scale: 0=no pain, 1=patient complains of pain, 2=patient complains of 
pain and winces, 3=patient complains of pain, winces, and withdraws joint. The total 
score ranges from 0 to 144. Joints with prosthesis are not graded and not included 
in the score.
Subscores for the hand were calculated by summing the scores for all hand joints 
(range 0 to 72). The same was done for the knee and hip (range 0 to 12). 
Questionnaires
Self-reported pain and functional limitations were assessed with the corresponding 
subscales of the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) and 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing 
hand and knee and hip, respectively.10,11 Using the AUSCAN, pain and functional 
limitations are graded on a Likert scale (0=none to 4=extreme), total scores ranging 
from 0 to 20 and 0 to 36, respectively. WOMAC scores range from 0 to 100 since the 
VAS format was used. 
Table 1. Using the Doyle Index pain is graded 0-3 in 48 joints or joint groups by palpation 
or passive movement.
Joint Method of testing Number of units
DIP 2-5 (individually) Pressure 8
PIP 2-5, IP-1 (individually) Pressure 10








Cervical spine Movement 1







MTP 2-5 Pressure 2
Total 48
Abbreviations: DIP: distal interphalangeal; PIP: proximal interphalangeal; IP-1: first 
interphalangeal; MCP: metacarpophalangeal; CMC-1: first carpometacarpal; MTP: metatarsal. 
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Statistical analysis
Data were analysed using SPSS 16.0 (SPSS, Chicago, Illinois, USA). To evaluate intra- 
and interrater reliability intraclass correlation coefficients (ICCs) with 95% confidence 
intervals (95%CI) were estimated using a one-way random ANOVA model and a 
two-way random ANOVA model for absolute agreement, respectively. Before estimating 
the final ICC it was assessed whether DI scores within one patient got worse as effect 
of repetitive assessment. In addition, the Bland and Altman method was used.12
Feasibility was determined by calculating the mean time to perform the DI for each 
rater separately and for all raters together. The relationship between the performance 
time (dependent variable) and DI scores (independent variable) was determined using 
linear regression analysis. 
Construct validity was assessed by testing three a priori defined hypotheses. The first 
was that the DI is positively related to self-reported pain and function. This was tested by 
correlating DI scores to the pain and function subscales of the AUSCAN and WOMAC 
using Spearman’s rank correlation coefficient, r, with 95%CI. Secondly, we determined 
whether DI hand and knee/hip scores correlated to pain and function measured with the 
AUSCAN and WOMAC, respectively. Finally, we tested whether DI scores increased with 
an increasing number of OA joint sites, using the Kruskal-Wallis test. 
results
Population description
Patient characteristics are shown in table 2. The median (interquartile range (IQR)) DI 
total score was 11.0 (5.0-19.0). Median (IQR) DI scores for the hand and the knee/hip 
joints separately were 4.0 (2.0-9.0) and 2.0 (0.0-3.0), respectively.
Table 2. Patient characteristics of 260 patients with osteoarthritis 
(OA) at multiple sites.
Age, mean (SD) years 64.9 (7.2)
Women, no (%) 217 (84)
Body mass index, mean (SD) kg/m2 28.3 (5.7)
Symptomatic OA sites, no (%)
Hand OA 206 (81)
Knee OA 98 (39)
Hip OA 80 (32)
Spine OA 193 (75)
AUSCAN pain (0-20), mean (SD) 7.2 (4.8)
AUSCAN function (0-36), mean (SD) 13.7 (8.8)
WOMAC pain (0-100), mean (SD) 28.6 (25.8)
WOMAC function (0-100), mean (SD) 28.2 (24.0)
Abbreviations: AUSCAN: Australian/Canadian Osteoarthritis Hand 





Intrarater reliability for the four raters separately was high (table 3). The average 
intrarater ICC (95%CI) was 0.95 (0.93 to 0.97). The ICC (95%CI) for interrater 
reliability was 0.88 (0.77 to 0.94). No effect of repetitive assessment was present, 
meaning that DI scores per patient did not increase with a second performance. 
Bland-Altman plots for intrarater reliability did not show any systematic differences 
(not shown). However, from plots for interrater reliability (figure 1) it seems that there 
are some systematic differences between raters. 
Feasibility
The mean time to perform the DI for the four raters is shown in table 3. For all 
raters together the mean time was 5.1 minutes (range 2.4-7.8 minutes). The time to 
perform the DI was positively related to the DI total score, meaning that it took more 
time to perform the DI in patients with more pain.
Construct validity
DI total scores and scores for the hand and the knee/hip joints separately were related 
to the pain and function subscales of the AUSCAN and WOMAC (table 4). However, 
the level of correlation was only moderate. With an increasing number of OA joint 
sites DI scores increased. Median (IQR) DI scores for patients with one, two, three and 
four symptomatic OA sites were 7.0 (3.5-13.5), 10.0 (5.0-16.0), 16.0 (9.0-25.0), and 
16.0 (7.0-24.0), respectively (p<0.01).
Table 3. Intrarater reliability for each rater and overall interrater reliability expressed as intraclass 
correlation coefficients (ICC) and time to perform the Doyle Index for four raters in 18 patients with 





Time, minutes  
mean (SD)
Rater 1 0.97 (0.93 to 0.99)
0.88 (0.77 to 0.94)
4.3 (0.8)
Rater 2 0.95 (0.88 to 0.98) 5.8 (1.4)
Rater 3 0.94 (0.84 to 0.98) 6.0 (0.7)
Rater 4 0.95 (0.86 to 0.98) 4.1 (0.3)
Table 4. Correlation of the Doyle Index (DI) with AUSCAN and WOMAC expressed as Spearman’s 
rank correlation coefficient (95%CI) in 260 patients with osteoarthritis at multiple sites.
DI total DI hand DI knee/hip 
AUSCAN pain 0.61 (0.53 to 0.68) 0.65 (0.57 to 0.72) -
AUSCAN function 0.62 (0.54 to 0.69) 0.61 (0.53 to 0.68) -
WOMAC pain 0.51 (0.42 to 0.59) - 0.46 (0.36 to 0.55)
WOMAC function 0.49 (0.39 to 0.58) - 0.43 (0.33 to 0.52)
For all values p<0.01
Abbreviations: see table 2.
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Sensitivity analysis in patients without prosthesis (n=203) showed similar 
correlations between WOMAC and DI scores. DI scores for the whole lower extremity 
showed the same level of correlation to WOMAC as DI total scores. 
discussion
This study in patients with OA at multiple sites showed that the DI is a reliable, 
feasible and valid measure for pain in OA. Intra- and interrater reliability were high 
and on average it took 5 minutes to perform the DI. The higher the DI score, the more 
time it takes to perform. Patients with more symptomatic joint sites involved had 
higher DI scores. The DI is obtained during physical examination and therefore may 
reflect a different aspect of disease than self-reported pain, which is supported by the 
modest strength of correlation between the DI and self-reported outcome measures. 
The favorable clinimetric properties in combination with the possibility to assess all 
joints together as well as specific joint groups separately, make the DI a valuable 
additional outcome measure for OA research and use in clinical practice.
The Outcome Measures in Rheumatology (OMERACT) filter identifies three 
concepts that should be evaluated for a potential outcome measure: truth (validity), 
feasibility and discrimination (reliability and sensitivity to change).13 In this study 
sensitivity to change was not assessed. However, follow-up data over 2 years from 
the GARP study on a modified DI and self-reported pain measured with the AUSCAN 
and WOMAC have been published.14,15 Using the modified DI the same joints were 
assessed, only grading was slightly different. The studies showed that the sensitivity 
to change of the modified DI concerning the hand joints and the knee/hip joints, 
expressed by the standardised response mean (SRM), was 0.67 and 0.41, respectively. 
The sensitivity to change of the AUSCAN and WOMAC pain subscale was lower with 
SRMs of 0.25 and 0.15, respectively. Because the modified DI is very similar to the DI, 
we feel that the sensitivity to change of the DI will be comparable, being better than 
established outcome measures for pain in OA.
The DI is hand-oriented since half of the assessed joints belong to the hand. 
We have shown that the DI subscores for separate joint groups have comparable 
correlations with self-reported outcome as the DI total score. The reliability for the 
subscores was good, but ICCs were slightly lower because of the lower possible 
range in DI subscores compared to the DI total score. This implies that the DI can be 
used to assess separate joint groups, which is valuable for clinical trials. 
Besides its use for research purposes, the DI can be used in clinical practice, 
especially the subscores for specific joint groups. We have shown that it takes 
approximately 5 minutes to perform the total DI. Performing only part of the DI 
takes less time and therefore implementation in daily clinical practice seems realistic. 
Because of its good clinimetric properties it can be a valuable measure since it is more 
quantitative in nature than taking a pain history only.
We found a moderate level of correlation between AUSCAN and WOMAC and 
the DI. This supports the idea that self-reported outcomes measure other aspects of 
disease than physician obtained outcomes. Our findings are in line with two studies 
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assessing the validity of the AUSCAN and WOMAC showing comparable or lower 
levels of correlation with a modified DI.10,16 In inflammatory arthritis similar levels of 
correlation between self-reported and clinically obtained outcome measures have 
been reported.17,18 
There are some limitations to the present study. First, the study was conducted 
in patients with familial OA at multiple sites. The behaviour of the DI in other 
OA phenotypes may be different, although pain is a shared symptom in all OA 
manifestations. Second, the mean level of self-reported symptoms in this population 
seems to be low considering the Patient Acceptable Symptom State (PASS).19 Assuming 
that self-reported symptoms are related to pain on physical examination, this will 
result in relatively low DI scores. We expect the influence on study outcome to be 
minimal since ICCs and correlation coefficients are more dependent on the variability 
in measures.20 We feel that the variability in AUSCAN, WOMAC as well as DI scores in 
this study population was sufficient. Moreover, a higher mean level of symptoms does 
not imply more variability in scores. Finally, it was not possible to assess responsiveness 
to treatment, since this is an observational study. Responsiveness is an important 
issue when use in clinical trials is concerned. In the original DI paper this feature was 
evaluated in a double-blind cross-over study.3 It was demonstrated that compared 
to treatment with a simple analgesic, treatment with an anti-inflammatory agent 
resulted in a significant reduction of the DI score. No effect on self-reported pain was 
observed, supporting that the DI has better features than self-reported outcomes.
In conclusion, this study demonstrated that the DI is a reliable, easy to perform 
and valid measure of pain in OA. Its sensitivity to change, evaluated previously in 
the GARP study, was higher than established OA pain outcome measures. Because 
of these favorable clinimetric properties and the idea that pain during physical 
examination may reflect a different aspect of the disease, the DI seems a valuable 
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Objective. To compare the reliability, sensitivity to change and feasibility of three 
radiographic scoring methods for hand osteoarthritis (OA). 
Methods. Baseline, 2-year and 6-year hand radiographs of 90 patients with hand 
OA were read in triplicate in chronological order by three readers from different 
European centres using the OARSI atlas (OARSI), Kellgren-Lawrence grading scale (KL) 
and Verbruggen-Veys anatomical phase score (VV). Reliability was determined using 
intraclass correlation coefficients and smallest detectable change (SDC). Sensitivity to 
change was assessed by the proportion of progression above the SDC. Feasibility was 
reflected by the mean performance time.
Results. Intra- and interreader reliability was similar across methods. Interreader 
SDCs (% maximum score) for KL, OARSI and VV were 2.9 (3.2), 4.1 (2.9) and 2.7 (1.8) 
over 2 years and 3.8 (4.1), 4.6 (3.3) and 4.0 (2.5) over 6 years. KL detected a slightly 
higher proportion of progression. There were differences between readers, despite 
methods to enhance consistency. The mean performance time (SD, minutes) for KL, 
OARSI and VV was 4.3 (2.5), 9.3 (6.0) and 2.8 (1.5), respectively.
Conclusion. Methods had comparable reliability and sensitivity to change. Global 
methods were fastest to perform. For multicentre trials using a central reading centre 
and multiple readers may minimise interreader variation.
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introduction
Despite the high prevalence and health impact of hand osteoarthritis (OA), no structure 
modifying treatments exist.1,2 The development of these treatments implies the 
need for reliable and sensitive outcome measures.3 Structural damage is considered 
a primary outcome, with serial radiographs as recommended outcome measure. 
Various radiographic scoring methods exist to assess severity and progression of 
structural damage.4-10 They differ with respect to the number of hand joints scored, 
the use of a global score as opposed to grading of individual radiographic features, 
the radiographic features scored and the grading of features. There is no consensus 
on the preferred method, but owing to these differences the choice for a method 
may depend on the study objective.
Only one previous study has compared scoring methods for hand OA, which 
was over a relatively short period of 1 year.11 In order to gain further insight in 
the clinimetric properties of available scoring methods, we assessed the reliability, 
sensitivity to change and feasibility of three radiographic scoring methods for the 
assessment of hand OA over a period of 2 and 6 years. 
Patients and metHods
Study design and patient population
Patients were participants of the Genetics ARthrosis and Progression (GARP) study 
comprising 192 Caucasian sibling pairs with symptomatic OA at multiple sites in 
the hand or in at least two of the following sites: hand, knee, hip or spine. Patients 
were evaluated at baseline and some of them after 2 and 6 years. Details on the 
recruitment and selection have been published elsewhere.12 The study was approved 
by the medical ethics committee.
Patients were eligible for the present study if they had hand OA defined by the 
American College of Rheumatology criteria for clinical hand OA13 or if structural 
abnormalities were present and if baseline, 2-year and 6-year radiographs were 
available. From this group a sample of 90 patients was included to ensure variability 
in baseline and progression scores based on a previous study.14 See appendix 1 for 
more information on inclusion and sampling.
Radiographs and scoring methods
Standardised hand radiographs (dorsal-volar) were obtained at baseline and follow-
up by a single radiographer. 
With the Kellgren-Lawrence grading scale (KL)6,10, a global score, the distal 
interphalangeal (DIP), proximal interphalangeal (PIP), interphalangeal thumb (IP-1), 
metacarpophalangeal (MCP) and first carpometacarpal (CMC-1) joints were graded 
0-4 as described in the atlas (0=no OA; 1=doubtful OA; 2=definite minimal OA; 
3=moderate OA; 4=severe OA). Total scores range from 0 to 120. 
Using the OARSI atlas (OARSI)4 individual radiographic features were graded. 
Osteophytes (0-3), joint space narrowing (JSN) (0-3), subchondral erosions (0-1), 
sclerosis (0-1) and malalignment (0-1) were assessed in the DIP, PIP, IP-1 and CMC-1 
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joints. Pseudowidening (0-1) was assessed in the DIP joints and cysts (0-1) were 
assessed in the PIP and CMC-1 joints. Total scores range from 0 to 198.
The Verbruggen-Veys anatomical phase score (VV)9 comprises five phases with a 
numerical value representing the evolution of hand OA: N=normal joint; S=stationary 
OA with osteophytes and JSN; J=complete loss of joint space in the whole or part of 
the joint; E=subchondral erosion; R=remodelling of subchondral plate. The DIP, PIP, 
IP-1 and MCP joints were assessed. This score ranges from 0 to 218.4.
Reading procedures
Radiographs of all time points were read simultaneously in chronological order 
blinded for patient characteristics by three readers (JB, IKH, CM) from three European 
centres independently. Readers attended a training session before starting the study. 
A standard set of radiographs with scores was available for individual practice. 
For assessment of intrareader reliability a random sample of 40 sets of radiographs 
was rescored with each method. 
To randomise patients as well as methods a random number was assigned to each 
possible patient-scoring method combination, resulting in 390 combinations ((90 sets 
+ 40 sets for intrareader reliability)x3 methods). To avoid mistakes and confusion 
because of frequent switching between methods, we grouped scoring methods per 
10 sets of radiographs.
Statistical analysis
To evaluate intra- and interreader reliability for status scores, intraclass correlation 
coefficients (ICCs) were estimated. For change scores measurement error due to 
intrareader and interreader variability was assessed by estimating the smallest detectable 
change (SDC).15 Sensitivity to change was assessed by the percentage of progression 
above the SDC. This analysis was done for all joints together and for separate joint 
groups (DIP/PIP, MCP and CMC-1 joints). Feasibility was determined by the mean 
scoring time of three time points for all readers together. The relationship between 
radiographic scores and performance time was assessed using linear regression analysis. 
results
At baseline the mean age was 60.2 years and 70 patients (78%) were female. The 
observed status and change scores are shown in appendix 2. There were differences 
between readers, especially for change scores. 
Intrareader and interreader ICCs for status scores were high with little difference 
between methods (table 1, appendix 2 for separate joint groups). For change scores 
the intrareader SDCs were good, with reader 3 showing higher SDCs than the other 
readers (table 2). Over both follow-up periods the method with the best reliability 
varied between readers. Interreader SDCs were lowest for VV, although differences 
from the other methods were small (table 2). Looking at separate reader pairs 
showed heterogeneity among readers with one reader scoring differently from the 
others (data not shown). Analysis in separate joint groups showed comparable results 
concerning comparison between methods (appendix 3). 
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Table 1. Reliability for status scores for the Kellgren-Lawrence grading scale (KL), OARSI atlas (OARSI) 









Baseline* 1 0.96 (0.92 to 0.98) 0.97 (0.95 to 0.99) 0.97 (0.95 to 0.99)
2 0.93 (0.87 to 0.96) 0.96 (0.92 to 0.97) 0.97 (0.94 to 0.98)
3 0.90 (0.81 to 0.95) 0.77 (0.61 to 0.87) 0.88 (0.78 to 0.93)
Interreader
Baseline* 1-2 0.91 (0.87 to 0.94) 0.95 (0.93 to 0.97) 0.95 (0.88 to 0.97)
1-3 0.85 (0.76 to 0.90) 0.81 (0.56 to 0.90) 0.84 (0.56 to 0.93)
2-3 0.84 (0.77 to 0.89) 0.80 (0.46 to 0.91) 0.81 (0.21 to 0.93)
All 0.87 (0.82 to 0.91) 0.85 (0.71 to 0.91) 0.86 (0.66 to 0.93)
*ICCs for status scores at year 2 and 6 are very similar to those at baseline.
Table 2. Reliability for change scores and sensitivity to change assessed by the smallest detectable 
change (SDC) and percentage of patients with progression above the SDC for the Kellgren-Lawrence 














Intrareader SDC and progression above this SDC
2-Year
Reader 1 2.1 (2.8) 17 (18.9) 1.2 (1.1) 20 (22.2) 1.4 (1.2) 17 (18.9)
Reader 2 2.5 (2.7) 22 (24.7) 3.0 (2.7) 16 (17.8) 3.4 (2.6) 9 (10.0)
Reader 3 7.1 (8.9) 11 (12.4) 10.2 (7.3) 11 (12.2) 7.8 (5.2) 14 (15.6)
6-Year
Reader 1 3.7 (4.7) 45 (50.6) 3.0 (2.5) 50 (55.6) 3.5 (2.6) 24 (26.7)
Reader 2 4.4 (4.7) 51 (57.3) 4.8 (3.7) 54 (60.0) 6.3 (4.6) 19 (21.1)
Reader 3 8.1 (9.3) 41 (46.1) 11.1 (8.0) 32 (35.6) 9.9 (6.1) 31 (34.4)
Interreader SDC and progression above this SDC
2-Year
Reader 1 2.9 (3.2) 17 (18.9) 4.1 (2.9) 6 (6.7) 2.7 (1.8) 12 (13.3)
Reader 2  22 (24.7) 11 (12.2) 12 (13.3)
Reader 3 50 (56.2) 34 (37.8) 47 (52.2)
6-Year
Reader 1 3.8 (4.1) 45 (50.6) 4.6 (3.3) 30 (33.3) 4.0 (2.5) 24 (26.7)
Reader 2 60 (67.4) 54 (60.0) 29 (32.2)
Reader 3 71 (79.8) 67 (74.4) 59 (65.6)
*SDC expressed as absolute value and as percentage of maximum observed score.
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Based on the interreader SDC KL detected most progression (table 2). This was 
found for all three readers, although the percentages of progression varied between 
them. The results in the separate joint groups were similar (appendix 4).
The global scoring methods KL and especially VV were fastest to perform and 
scoring individual features with OARSI took more time (table 3). Each method took 
more time to perform in patients with higher levels of structural abnormalities.
discussion
This study on the reliability, sensitivity to change and feasibility of three radiographic 
scoring methods for hand OA shows minor differences between the methods. 
Reliability was high and sensitivity to change was good over both time periods, with 
slightly higher values for KL. There were differences in change scores and proportions 
of progression between readers, despite use of methods to enhance consistency. VV 
was the quickest method to perform. 
To our knowledge, only one previous study has compared the clinimetric 
properties of radiographic scoring methods in hand OA, showing equal performance 
for reliability and sensitivity to change over 1 year.11 Reliability was high in that study. 
Sensitivity to change expressed by standardised response means (SRMs) was low, 
whereas we found it to be good based on the SDC. Because different methods were 
used, meaningful comparison is difficult. 
We used the SDC to assess reliability of change scores since it was more suitable 
than the ICC. The ICC is a measure of relative agreement reflecting signal-to-noise 
ratio. Therefore it is sensitive to relative subtle interreader discrepancies if the total 
range of scores is narrow, which was the case in this study. 
We found that the global scoring methods VV and KL were faster to perform 
than OARSI. Recently it was shown that scoring osteophytes, JSN, malalignment and 
erosions may be sufficient to differentiate subjects with regard to disease severity.16 
This may improve the ease of use of OARSI. 
There were differences between readers, despite a training session before starting 
the study, discussion sessions and use of atlases. The multicentre international 
study design might have contributed to this finding. The differences did not lead to 
Table 3. Performance time for each set of three hand radiographs and the association between 
performance time and radiographic score for the Kellgren-Lawrence grading scale (KL), OARSI atlas 
(OARSI) and Verbruggen-Veys anatomical phase score (VV).
KL OARSI VV
Performance time (minutes)
Mean (SD) 4.3 (2.5) 9.3 (6.0) 2.8 (1.5)
Range 0.9-13.1 1.1-35.0 0.9-9.1
5th-95th Percentile 1.2-9.0 3.4-20.6 1.1-5.7
Association with radiographic score, 
β-coefficient (95%CI)* 3.9 (1.0 to 6.8) 8.0 (5.3 to 10.7) 21.1 (12.9 to 29.2)
*Number of points in radiographic score associated with one minute increment in performance time.
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inconsistency in the comparison of methods. Clinical trials frequently involve multiple 
international centres, and the use of a central reading centre for radiographs therefore 
seems appropriate. The question remains: what is the true amount of structural 
abnormalities in OA? Experts in the field involved in this study scored a range of 
radiographic OA pathology together and concluded that it is very challenging to 
define a true score owing to variation in interpretation between readers. The use 
of quantitative measures, for instance measurement of joint space width, reduces 
interperson interpretation considerably. Using mean scores from multiple readers will 
on average be close to the “truth” and increase precision and generalisibility. 
This study has a number of potential limitations. First, the level of radiographic 
abnormalities at baseline was relatively low compared with other samples from 
patients with hand OA. Although this has no effect on the comparison between 
methods, they may perform differently in other hand OA phenotypes. Second, we 
scored in chronological order. This may lead to overestimation of progression, but 
also to higher sensitivity to change. 17 Since potential overestimation will occur for all 
scoring methods it has no influence on the conclusions. 
In conclusion, based on our findings it is not possible to recommend one of the 
scoring methods. Rather, based on the different character of the methods, the choice 
depends on the study objective. Further research on the validity of radiographic 
scoring methods as well as possibilities for their modification in order to enhance 
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 RADIOGRAPHIC SCORING METHODS FOR HAND OA
aPPendix 1.
Inclusion criteria and sampling
Structural abnormalities were defined as the presence of radiographic hand OA 
based on a Kellgren-Lawrence score grade ≥2 in at least one interphalangeal (IP) or 
first carpometacarpal (CMC-1) joint, or the presence of ≥2 Heberden’s or Bouchard’s 
nodes on physical examination.
From the group of 102 eligible patients a sample of 90 patients was included to 
ensure variability in baseline and progression scores based on previous results from 
the GARP study on progression of hand OA over 2 years. Since progression rates 
were low, we included all patients with progression over this period (n=33). From the 
remaining group we included patients to ascertain maximal variability in Kellgren-
Lawrence score at baseline; so both patients with low as well as high Kellgren-




Status and change scores for the Kellgren-Lawrence grading scale (KL), OARSI atlas (OARSI) 
and Verbruggen-Veys anatomical phase score (VV) in 90 hand osteoarthritis patients.
A. For the joints described in original method together
KL (0-120) OARSI (0-198) VV (0-218.4)
Mean (SD) Range Mean (SD) Range Mean (SD) Range
Reader 1
Baseline 19.2 (12.9) 2 to 75 31.4 (17.5) 6 to 106 27.7 (18.4) 10.4 to 116.6
Year 2 20.4 (13.5) 2 to 75 32.3 (18.5) 6 to 108 28.7 (19.9) 11.6 to 119.1
Year 6 23.8 (15.1) 2 to 79 35.8 (21.4) 6 to 120 32.1 (25.0) 11.6 to 135.5
Change year 2 1.2 (2.1) -2 to 9 1.0 (1.9) -2 to 10 1.0 (2.3) 0 to 14.8
Change year 6 4.6 (4.3) 0 to 21 4.5 (5.9) -4 to 35 4.5 (7.9) 0 to 32.9
Reader 2
Baseline 20.4 (14.8) 4 to 90 32.6 (18.3) 6 to 113 30.8 (20.1) 5.8 to 129.2
Year 2 22.0 (15.4) 5 to 91 35.0 (20.0) 6 to 113 32.0 (21.4) 7.0 to 130.3
Year 6 26.4 (17.1) 6 to 93 40.0 (22.9) 6 to 129 35.7 (26.0) 8.1 to 136.9
Change year 2 1.6 (2.0) -2 to 9 2.4 (3.5) -1 to 21 1.1 (2.4) 0 to 16.8
Change year 6 6.0 (4.8) -2 to 22 7.4 (6.7) 0 to 38 4.9 (8.2) -1.2 to 37.3
Reader 3
Baseline 21.7 (15.9) 2 to 77 24.2 (23.1) 0 to 125 20.4 (25.6) 0 to 138.6
Year 2 25.4 (17.1) 4 to 79 28.7 (25.4) 1 to 139 24.1 (25.9) 0 to 148.8
Year 6 30.8 (19.0) 6 to 87 35.1 (28.3) 1 to 139 29.4 (30.0) 1.2 to 162.6
Change year 2 3.6 (4.1) -5 to 24 4.4 (6.1) -5 to 40 3.7 (4.2) -4.4 to 16.7
Change year 6 9.1 (6.2) -1 to 28 10.9 (9.6) -3 to 51 9.0 (8.9) -2.3 to 39.2
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B. For separate joint groups: DIP/PIP joints (KL, OARSI, VV), MCP joints (KL, OARSI), CMC-1 joints (KL, 
OARSI). VV is not included for MCP and CMC-1 joints since it is most frequently used for assessment 
of interphalangeal joints.
DIP/PIP joints
KL (0-64) OARSI (0-160) VV (0-124.8)
Mean (SD) Range Mean (SD) Range Mean (SD) Range
Reader 1
Baseline 12.7 (10.4) 0 to 52 24.9 (15.2) 5 to 90 22.4 (15.6) 3.5 to 91.0
Year 2 13.5 (11.0) 0 to 55 25.6 (16.1) 5 to 91 23.3 (17.1) 3.5 to 102.7
Year 6 15.6 (12.5) 0 to 58 27.8 (18.8) 5 to 102 26.4 (22.2) 3.5 to 118.1
Change year 2 0.8 (1.7) -2 to 9 0.7 (1.7) -1 to 9 0.8 (2.3) 0 to 14.8
Change year 6 2.9 (3.4) 0 to 15 3.0 (5.2) -4 to 30 4.0 (7.7) 0 to 30.9
Reader 2
Baseline 12.7 (11.7) 0 to 57 25.6 (15.7) 3 to 95 23.6 (16.6) 3.5 to 97.5
Year 2 13.8 (12.4) 0 to 59 27.3 (17.0) 3 to 97 24.7 (18.1) 4.6 to 97.6
Year 6 16.8 (13.9) 0 to 62 31.3 (20.0) 3 to 107 27.9 (22.6) 4.6 to 108.9
Change year 2 1.0 (1.6) -2 to 9 1.7 (3.3) -6 to 20 1.0 (2.5) 0 to 16.8
Change year 6 4.1 (3.9) -2 to 19 5.7 (6.2) 0 to 31 4.2 (7.9) -1.2 to 37.3
Reader 3
Baseline 14.8 (12.6) 0 to 58 19.1 (19.3) 0 to 102 17.5 (20.4) 0 to 110.4
Year 2 17.2 (13.7) 1 to 60 22.7 (21.6) 0 to 112 20.4 (22.4) 0 to 116.6
Year 6 20.8 (15.1) 2 to 64 27.3 (24.2) 0 to 112 24.6 (26.1) 0 to 121.2
Change year 2 2.4 (3.3) -5 to 14 3.6 (5.4) -6 to 30 2.9 (3.7) -4.4 to 12.6




KL (0-40) OARSI (0-70)
Mean (SD) Range Mean (SD) Range 
Reader 1
Baseline 1.6 (2.5) 0 to 13 3.1 (4.3) 0 to 29
Year 2 1.7 (2.6) 0 to 13 3.2 (4.4) 0 to 29
Year 6 2.0 (2.8) 0 to 13 3.5 (4.7) 0 to 29
Change year 2 0.1 (0.3) 0 to 2 0.1 (0.3) -1 to 2
Change year 6 0.4 (0.9) -1 to 6 0.4 (1.0) -1 to 6
Reader 2
Baseline 2.2 (3.5) 0 to 23 4.8 (5.3) 0 to 33
Year 2 2.4 (3.6) 0 to 23 4.9 (5.3) 0 to 33
Year 6 2.8 (4.0) 0 to 23 5.5 (5.8) 0 to 33
Change year 2 0.3 (0.6) -1 to 3 0.1 (0.6) -2 to 2
Change year 6 0.6 (1.3) -2 to 6 0.7 (1.7) -2 to 7
Reader 3
Baseline 1.6 (2.5) 0 to 12 1.6 (3.9) 0 to 26
Year 2 1.8 (2.9) 0 to 16 2.0 (4.4) 0 to 26
Year 6 2.4 (3.4) 0 to 18 2.7 (5.1) 0 to 29
Change year 2 0.2 (1.1) -2 to 5 0.4 (1.4) -3 to 8
Change year 6 0.8 (1.7) -2 to 8 1.1 (2.1) -2 to 10
CMC-1 joints
KL (0-8) OARSI (0-20)
Mean (SD) Range Mean (SD) Range 
Reader 1
Baseline 2.7 (2.2) 0 to 8 4.0 (2.8) 0 to 14
Year 2 2.8 (2.2) 0 to 8 4.1 (2.9) 0 to 14
Year 6 3.3 (2.4) 0 to 8 4.8 (3.3) 0 to 14
Change year 2 0.1 (0.4) 0 to 2 0.1 (0.5) -2 to 2
Change year 6 0.6 (0.8) 0 to 2 0.8 (1.3) -1 to 6
Reader 2
Baseline 3.3 (1.9) 0 to 8 4.7 (3.1) 0 to 16
Year 2 3.4 (1.9) 0 to 8 5.0 (3.1) 0 to 16
Year 6 3.8 (2.0) 0 to 8 5.6 (3.4) 0 to 17
Change year 2 0.2 (0.6) -1 to 2 0.3 (0.6) -1 to 2
Change year 6 0.6 (0.7) -1 to 3 0.8 (1.3) -2 to 5
Reader 3
Baseline 3.4 (2.2) 0 to 8 3.2 (3.4) 0 to 16
Year 2 3.8 (2.3) 0 to 8 3.6 (3.8) 0 to 17
Year 6 4.3 (2.5) 0 to 8 4.6 (4.1) 0 to 16
Change year 2 0.4 (0.9) -2 to 3 0.5 (1.6) -3 to 9
Change year 6 0.8 (1.3) -2 to 4 1.5 (2.1) -2 to 9
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aPPendix 3.
Reliability for status scores for the Kellgren-Lawrence grading scale (KL), OARSI atlas 
(OARSI) and Verbruggen-Veys anatomical phase score (VV) expressed by intraclass 
correlation coefficient (ICC) for separate joint groups; DIP/PIP joints (KL, OARSI, VV), 
MCP joints (KL, OARSI), CMC-1 joints (KL, OARSI). VV is not included for MCP and 










Baseline* 1 0.95 (0.91 to 0.97) 0.97 (0.94 to 0.98) 0.98 (0.96 to 0.99)
2 0.92 (0.86 to 0.96) 0.96 (0.93 to 0.98) 0.97 (0.95 to 0.98)
3 0.89 (0.80 to 0.94) 0.77 (0.61 to 0.87) 0.90 (0.82 to 0.94)
Interreader
Baseline* 1-2 0.92 (0.89 to 0.95) 0.96 (0.94 to 0.97) 0.97 (0.95 to 0.98)
1-3 0.85 (0.76 to 0.90) 0.83 (0.59 to 0.92) 0.85 (0.69 to 0.91)
2-3 0.85 (0.77 to 0.91) 0.83 (0.52 to 0.92) 0.86 (0.59 to 0.93)
All 0.87 (0.82 to 0.91) 0.86 (0.74 to 0.92) 0.88 (0.79 to 0.93)








Baseline* 1 0.91 (0.84 to 0.95) 0.95 (0.90 to 0.97)
2 0.84 (0.72 to 0.91) 0.88 (0.78 to 0.93)
3 0.83 (0.69 to 0.90) 0.79 (0.64 to 0.88)
Interreader
Baseline* 1-2 0.81 (0.72 to 0.87) 0.71 (0.51 to 0.82)
1-3 0.71 (0.59 to 0.80) 0.70 (0.49 to 0.81)
2-3 0.57 (0.41 to 0.69) 0.52 (0.11 to 0.74)
All 0.70 (0.60 to 0.78) 0.63 (0.43 to 0.76)










Baseline* 1 0.88 (0.78 to 0.93) 0.89 (0.80 to 0.94)
2 0.85 (0.75 to 0.92) 0.86 (0.75 to 0.92)
3 0.80 (0.64 to 0.89) 0.75 (0.58 to 0.86)
Interreader
Baseline* 1-2 0.78 (0.63 to 0.87) 0.87 (0.75 to 0.92)
1-3 0.68 (0.49 to 0.80) 0.71 (0.56 to 0.81)
2-3 0.72 (0.61 to 0.81) 0.68 (0.36 to 0.83)
All 0.73 (0.62 to 0.81) 0.75 (0.61 to 0.83)
*ICCs for status scores at year 2 and 6 are very similar to those at baseline.
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aPPendix 4.
Reliability for change scores and sensitivity to change assessed by the smallest 
detectable change (SDC) and percentage of patients with progression above the SDC 
for the Kellgren-Lawrence grading scale (KL), OARSI atlas (OARSI) and Verbruggen-
Veys anatomical phase score (VV) for separate joint groups; DIP/PIP joints (KL, OARSI, 
VV), MCP joints (KL, OARSI), CMC-1 joints (KL, OARSI). VV is not included for MCP 
and CMC-1 joints since it is most frequently used for assessment of interphalangeal 
joints. Panel A. Intrareader SDC and progression above this SDC. Panel B. Interreader 






n (%) SDC (%)
Progression,  




Reader 1 1.7 (3.2) 17 (18.9) 1.0 (1.1) 25 (27.8) 1.3 (1.4) 13 (14.4)
Reader 2 1.8 (3.0) 25 (27.8) 1.9 (2.0) 32 (35.6) 2.4 (2.5) 14 (15.6)
Reader 3 5.2 (8.7) 15 (16.9) 7.8 (7.0) 14 (15.6) 6.7 (6.1) 15 (16.7)
6-Year
Reader 1 2.0 (3.5) 40 (44.4) 2.4 (2.3) 30 (33.3) 3.3 (2.8) 22 (24.4)
Reader 2 4.0 (6.4) 32 (35.6) 3.6 (3.3) 49 (54.4) 4.0 (3.6) 24 (26.7)
Reader 3 6.3 (9.9) 31 (34.8) 7.9 (7.1) 35 (38.9) 9.4 (7.7) 26 (28.9)





n (%) SDC (%)
Progression, 











Reader 2  12 (13.3) 14 (15.6) 14 (15.6)









Reader 2 55 (61.1) 49 (54.4) 24 (26.7)
Reader 3 67 (75.3) 59 (65.6) 48 (53.3)












Reader 1 0.2 (1.7) 5 (5.6) 0.6 (2.0) 6 (6.7)
Reader 2 1.3 (5.8) 5 (5.6) 0.9 (2.8) 3 (3.3)
Reader 3 2.7 (16.9) 4 (4.5) 2.8 (11.0) 6 (6.7)
6-Year
Reader 1 0.8 (6.1) 20 (22.2) 1.0 (3.6) 19 (21.1)
Reader 2 1.8 (7.7) 22 (12.2) 1.5 (4.6) 16 (17.8)
Reader 3 2.3 (12.8) 10 (11.2) 4.0 (13.9) 7 (7.8)
















Reader 2  19 (21.1) 16 (17.8)







Reader 2 11 (12.2) 16 (17.8)
Reader 3 18 (20.2) 22 (24.4)














Reader 1 0.8 (9.4) 6 (6.7) 0.6 (4.1) 11 (12.2)
Reader 2 0.8 (9.5) 18 (20.0) 1.2 (7.5) 4 (4.4)
Reader 3 1.5 (19.2) 12 (13.5) 3.1 (18.0) 4 (4.4)
6-Year
Reader 1 0.9 (11.7) 35 (38.9) 1.5 (10.5) 21 (23.3)
Reader 2 1.0 (12.9) 41 (45.6) 1.7 (10.1) 24 (26.7)
Reader 3 2.2 (28.0) 8 (9.0) 4.0 (25.1) 16 (17.8)















Reader 2  18 (20.0) 4 (4.4)







Reader 2 41 (45.6) 24 (26.7)
Reader 3 45 (50.6) 38 (42.2)
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Objective. To investigate the validity of joint space width (JSW) measurements in 
millimetres (mm) in hand osteoarthritis (OA) patients by comparison to controls, 
grading of joint space narrowing (JSN) and clinical features.
Methods. Hand radiographs of 235 hand OA patients (mean age 65 years, 83% 
women) and 471 controls were used. JSW was measured with semi-automated 
image analysis software in the distal interphalangeal, proximal interphalangeal and 
metacarpophalangeal joints (DIPJs, PIPJs and MCPJs). JSN (grade 0-3) was assessed 
using the Osteoarthritis Research Society International (OARSI) atlas. Associations 
between the two methods and clinical determinants (presence of pain, nodes and/or 
erosions, decreased mobility) were assessed using Generalised Estimating Equations 
with adjustment for age, sex, BMI and mean width of proximal phalanx.
Results. JSW was measured in 5631 joints with a mean JSW of 0.98 mm (SD 0.21), 
being the smallest for DIPJs (0.70 (SD 0.25)) and largest for MCPJs (1.40 (SD 0.25)). 
The JSN=0 group had a mean JSW of 1.28 mm (SD 0.34), the JSN=3 group 0.17 
mm (SD 0.23). Controls had larger JSW than hand OA patients (p-value < 0.001). In 
hand OA, females had smaller JSW than men (β -0.08, (95%CI -0.15 to -0.01)) and 
lower JSW was associated with the presence of pain, nodes, erosions and decreased 
mobility (adjusted β (95%CI) -0.21 (-0.27 to -0.16), -0.37 (-0.40 to -0.34), -0.61 
(-0.68 to -0.54) and -0.46 (-0.68 to -0.24) respectively). These associations were 
similar for JSN in grades. 
Conclusion. In hand OA the quantitative JSW measurement is a valid method to 
measure joint space and shows a good relation with clinical features. 
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introduction
Hand osteoarthritis (OA) is a prevalent musculoskeletal disease, which can lead to 
pain and functional limitations in daily life.1,2 Classical structural features of hand OA, 
such as osteophytes and joint space narrowing (JSN) can be visualised on conventional 
radiographs3, even if persons do not suffer from any complaints. These features are 
slowly progressive in time.4,5 JSN in OA is considered to reflect damage and loss of 
articular cartilage.6
Several standardised visual grading methods are being used to score osteophytes 
and JSN together or separately in patients with hand OA.3,7-9 However, these visual 
methods with graded scores have shortcomings. Visual grading methods are subjective 
and dependent on the scorer. Methods that measure these features in a more 
objective manner are preferable. Moreover, the visual grading methods are not able 
to discriminate small differences. A quantitative method would give opportunities to 
monitor small effects of these features. With visual grading methods it is not possible 
to score positive or negative changes of the joint space (e.g. widening, as present in 
early stages of osteoarthritis or in secondary OA, such as in acromegalic patients). 
For measurement of joint space widening or narrowing, a quantitative method to 
measure the joint space width (JSW) is desirable. 
Van‘t Klooster et al. developed a semi-automated quantitative measurement 
method that is able to measure JSW in hand OA in a reproducible and accurate way.10 
This method has a high accuracy and repeatability in acrylic phantom joints and 
human-derived cadaver interphalangeal joints.11 Until present, however, no data of 
studies are available which quantify JSW in a large population with hand OA patients 
and validate JSW against JSN in “in vivo” patients with hand OA.
The aim of this paper is to quantify the JSW in finger joints with a semi-automated 
quantitative method in hand OA patients and to validate it by comparing JSW with the 
JSW of normal controls and with the visual grading method of JSN. The association 
with clinical determinants on joint and patient level of JSW using the visual grading 
method of JSN as the standard method was also investigated. 
Patients and metHods
Study design and patient population
The Genetics ARthrosis and Progression (GARP)12 study is a cohort study aimed at 
identifying determinants of OA susceptibility and progression. The study population 
comprises 192 Caucasian sibling pairs with symptomatic OA at multiple sites in the 
hand or in at least two of the following sites: hand, knee, hip or spine. Patients were 
recruited from rheumatologists, orthopaedic surgeons and general practitioners. 
Further details about the recruitment and selection have been published elsewhere.12 
The study was approved by the medical ethics committee. 
Hand OA patients from this population that were evaluated after 6 years were 
eligible for the present study.5 Hand OA was defined according to the American College 
of Rheumatology (ACR) criteria for clinical hand OA13 or as the presence of structural 
abnormalities. Structural abnormalities were defined as the presence of bony swelling 
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in at least two of the ten selected joints from the ACR criteria and a Kellgren-Lawrence 
score ≥2 in any interphalangeal or first carpometacarpal (CMC-1) joint.
Hand OA was scored for JSN using Osteoarthritis Research Society International 
(OARSI) atlas, and JSW was measured. Data from OA patients were compared with 
two control cohorts.
Control population for JSW measurements
A control group was selected from databases of the Leiden Early Arthritis Clinic (EAC, 
n=167) and a prospective study in patients with knee complaints (n=304). None of 
these controls had symptoms of the hands. The EAC study is a prospective study started 
in 1993 and includes patients with early arthritis with symptoms ≤2 years.14 The aim is to 
detect inflammatory disorders early in the disease state and to treat these accordingly. 
In all patients, conventional radiographs of hands and feet were performed at baseline. 
For the purpose of the present study, a selection of patients without hand symptoms 
was made and hand radiographs of their inclusion visit were used. 
The second control population was derived from an epidemiological study 
which includes patients with traumatic or non-traumatic sub-acute knee complaints 
(also known as the KART-study).15 At a follow-up visit 10 years later, routine hand 
radiographs were performed in all patients. Since patients were not included in the 
study on the basis of hand joint pathology, we assumed that their hand joints are a 
valid sample of the general population for hand OA. Protocols of both studies were 
approved by the medical ethics committee. Written informed consent was given by 
all patients who participated in the studies. 
Radiographic assessment 
Digital hand radiographs (dorsal-volar) in both the GARP and KART study were 
obtained by a single radiographer using the same standard protocol with a fixed film 
focus distance (1.15 m) and tube voltage of 45 kVp, 250 mA and 3.2 mAs (type of 
film cassette Canon Detector CXDI-31, imaging geometry 2256 x 2878 mm, pixel 
spacing 100μm, gray scale resolution 12-bit). Of the EAC controls, 133 radiographs 
were analog and 39 were digital. For computerised analyses the analog radiographs 
were digitised first (VXR-12, VIDAR System Corporation, Herndon, VA). Radiographs 
of the EAC controls were made according to the standard usual care protocol, without 
a fixed film focus distance and 5.0 mAs.
Measurement of JSW
JSW was measured using a semi-automated method described extensively elsewhere.10 
In brief, JSW measurement was applied to the distal interphalangeal joints (DIPJs), 
proximal interphalangeal joints (PIPJs) and second to fifth metacarpophalangeal joints 
(MCPJs) of both hands. The joints of the thumb were omitted since they were not 
perpendicular to the image plane and could therefore not be assessed reliably. The 
image analysis software identifies all joints of interest and the corresponding joint 
margins and subsequently measures the JSW in millimetres (mm) within a measurement 
interval in each joint, which was determined by the width of the respective phalanx. 
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The automatic results of the image analysis from all study populations were reviewed 
by an expert (SHM) and corrected if needed. The intra-individual variation between 
repeat readings (n=24) was low, reflected by an intraclass correlation coefficient 
(ICC) of 0.99. The smallest detectable difference (SDD) is used to discriminate the 
JSW measurements above measurement error and was calculated as 1.96 x standard 
deviation (SD) of the difference between repeated JSW measurement divided by the 
square root of two.16 The mean difference (SD) of repeated JSW measurements was 
0.017 mm (0.04) and the SDD was 0.055. Regarding feasibility, the mean time to 
determine the JSW was 5 min and 7 s per patient (SD 2 min and 46 s).
Grading of JSN and other OA features
Using the visual grading method, JSN was graded 0-3 in the DIPJs, PIPJs and second to 
fifth MCPJs by consensus opinion of two experienced readers using the OARSI atlas in 
hand OA patients only.3 MCPJs were not included in the original OARSI atlas, but for 
scoring these were regarded as PIPJs. In addition, osteophytes were graded 0-3 using 
the OARSI atlas. Erosions were scored by the Verbruggen-Veys scoring method and 
were defined as having eroded (E-phase) or remodeled irregular sclerotic subchondral 
plates (R-phase) in DIPJs or PIPJs.9 Intrareader reproducibility of JSN based on 25 
randomly selected pairs of radiographs was good with an ICC of 0.92.
Hand pain and functioning
Self-reported pain on joint level was assessed using a standard diagram including all 
hand joints on which the patient was asked to mark painful joints. Pain upon lateral 
joint pressure was graded 0-3 for each hand joint by a single observer (JB) during 
physical examination (0=no pain, 1=complaining of pain, 2=complaining of pain and 
wincing, 3=complaining of pain and withdrawal of the joint). 
Self-reported hand pain and functional limitations on patient level were assessed 
with the pain (5 items) and function (9 items) subscales of the Australian/Canadian 
Osteoarthritis Hand Index (AUSCAN), on a five-point Likert scale (0=none to 
4=extreme).17 Higher scores indicate more pain and functional limitations. 
Hand performance was assessed by measuring grip strength with a hydraulic 
hand dynamometer (Saehan corporation, Masan, South-Korea). Hand mobility was 
assessed with the Hand Mobility in Scleroderma test (HAMIS).18 Using HAMIS, nine 
movements included in the range of motion of the hand were graded 0 (normal) to 3 
(unable to do) for each hand and summed. The total score is the mean of two hands. 
Statistical analysis
Data were analysed using SPSS, version 17.0 (SPSS Inc, Chicago, Illinois, USA). The JSW 
in relation with the JSN score was quantified and presented as mean scores with SDs. 
To validate the JSW method we hypothesised that the JSW would be smaller 
in hand OA patients than controls and decrease with the presence of clinical 
determinants as age, female sex, nodes, erosive lesions and joint pain. Generalised 
Estimating Equations (GEE) models were performed to investigate the association of 
JSW with age and female sex, with adjustments for the presence of osteophytes. The 
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GEE model is used to correct for effects within the same patient and family effects 
within sibling pairs in the patient population. In addition, the association of JSW 
with female sex was adjusted for the mean width of all phalanges of both hands. 
The width of the proximal phalanx was measured by detecting bone contours of the 
proximal phalanx with an edge detector and calculating the distance between the 
contours at the central part of the phalanx.10 GEE models were also used to estimate 
β-coefficients for associations between JSW and JSN scores on joint level with clinical 
determinants with robust variance estimators to account for effects within the same 
patient, family effects within sibling pairs and mean width of the proximal phalanx. 
Adjustments were also made for age, sex and body mass index (BMI). For JSW, a 
positive or negative β-coefficient means an increase or decrease of the mean JSW 
(larger or smaller joint space), respectively. For the JSN score, a positive or negative 
β-coefficient represents an increase (smaller joint space) or decrease (wider joint 
space) of the mean JSN score, respectively. 
To investigate the associations of JSW and JSN scores with clinical determinants 
on the patient level, the JSW and JSN score of both hands were summed up per 
patient. Associations between the summed JSW and summed JSN score with clinical 
determinants were estimated using a linear mixed model with adjustments for 
age, sex, BMI, family effects within sibling pairs and mean width of the proximal 
phalanx. The fixed effects were age, sex and BMI. A random intercept was used 
to adjust for family effects, meaning resemblance between siblings of one family, 
with an unspecified covariance matrix. An additional adjustment for osteophytes was 
made for the association between JSW and JSN score. The results are presented 
as unstandardised β-coefficients with 95% confidence interval (95%CI). Since the 
JSN score is not a continuous outcome measure, but a graded scoring method, the 
β-coefficients of the JSW and JSN score cannot be compared with each other. 
results
Study population
In one of the 236 eligible patients JSW measurement was not possible due to technical 
problems with the radiograph. Characteristics of 235 hand OA patients included in 
the analyses are shown in table 1. The mean age was 64.8 years and the majority was 
female. JSW was measured in 5631 joints. JSN score was not applicable in 9 joints 
due to technical problems and were therefore excluded.
In one of the 471 controls the JSW measurement was not available. The mean age 
of the controls was 46.1 years (SD 11.4) and 195 persons (42%) were female. JSW 
was measured in 11280 joints.
Quantification of JSW in OA patients and controls 
Most of the DIPJs (56%) and PIPJs (62%) in OA patients were classified in JSN=1. For 
the MCPJs, the majority of the joints (81%) in OA patients were normal (classified 
as JSN=0). The mean JSW for all joints in hand OA patients was 0.98 mm (SD 0.21), 
being the smallest for the DIPJs and largest for the MCPJs with 0.70 mm (SD 0.25) 
192
14
JOINT SPACE WIDTH MEASUREMENT IN HAND OA
and 1.40 mm (SD 0.25), respectively (table 2). The mean JSW for all joints in controls 
from the KART study was 1.18 mm (SD 0.41), for MCPJs 1.61 mm (SD 0.23), for 
PIPJs 0.96 mm (SD 0.20) and for DIPJs 0.90 mm (SD 0.26). The JSW of KART-controls 
was significantly larger than the JSW in hand OA patients (p-value <0.001). The 
significance remained the same if EAC-controls were included in the analyses.
JSW in relation with age, sex (in controls and OA patients) and JSN scores 
(in OA patients only)
The quantification of JSW in relation to the JSN score according to OARSI atlas is also 
shown in table 2. The largest JSW was seen in the JSN=0 group, the smallest JSW in 
the JSN=3 group. No estimation for the JSW in the MCPJs with JSN=3 is given, since 
only two MCP joints were present in this group. 
In hand OA patients, being female was associated with a smaller JSW of the 
finger joints only after adjustment for presence of osteophytes (adjusted β -0.08 
(95%CI -0.15 to -0.01)). In controls, being female was also associated with a smaller 
JSW, when adjusted for the mean width of phalanges of the hands only (adjusted 
β -0.08 (95%CI -0.12 to -0.05)), and not statistically significant for hand OA patients 
(adjusted β -0.04 (95%CI -0.12 to 0.05)). Age was not associated with a smaller 
JSW in hand OA patients (with or without adjustment for presence of osteophytes), 
but older age was associated with smaller JSW in controls (table 3). The associations 
of JSW (as dependent variable) and female sex, with additional adjustment for age, 
remained the same in both control and patient populations (data not shown).
Table 1. Characteristics of 235 patients with hand osteoarthritis (OA).
Age, years 64.8 (6.9)
Women, no (%) 194 (83)
Postmenopausal women, no (%) 184 (95)
Body mass index, kg/m2 28.3 (5.8)
ACR criteria hand OA, no (%) 205 (87)
Right handed, no (%) 186 (79)




AUSCAN pain 7.3 (4.8)
AUSCAN function 13.9 (8.7)
No. self-reported painful joints* 6.0 (6.3)
No. painful joints on pressure* 4.7 (5.3)
Grip strength, kg 21.4 (10.4)
HAMIS 4.0 (2.9)
Values are means (SD) unless stated otherwise.
*DIPJs 2-5, PIPJs 2-5, MCPJs 2-5 both hands.
Abbreviations: ACR: American College of Rheumatology; AUSCAN: 




Associations of JSW and JSN with clinical determinants at joint level
On the joint level, decreased JSW was associated with presence of osteophytes, 
self-reported pain, nodes, pain on palpation and erosions (table 4). The unstandardised 
β-coefficient can be interpreted as the mean difference in JSW between the presence 
and absence of the determinant in that joint. For example, if an erosive lesion was 
present in a joint, the mean JSW is -0.61 mm smaller in that joint. If a joint was scored 
as an osteophyte grade 1 or grade 3 according to the OARSI atlas, the mean JSW is 
-0.20 or -0.62 mm smaller than in a joint without an osteophyte, respectively.
For the JSN score, associations with clinical determinants showed that an increase in 
JSN score is related to the presence of each of the determinants named above (table 4). 
These associations were similar to those with JSW. For example, if an erosive lesion was 
present, the mean JSN score is 1.43 higher than for a joint without an erosion. Since 
the JSN score is not a continuous outcome measure, but a graded scoring method, the 
β-coefficient cannot be interpreted as an exact mean difference in this table. 
Table 2. A. Distribution of number of joints (%) in the visual grading method for joint space 
narrowing (JSN) graded 0-3 according to the OARSI scoring method. B. Mean joint space width in 
millimetres (SD) in relation to JSN according to the OARSI scoring method.
A.
JSN=0 JSN=1 JSN=2 JSN=3
All joints (n=5631) 2574 (46) 2529 (45 405 (7) 123 (2)
DIPs (n=1878) 454 (24) 1048 (56) 284 (15) 92 (5)
PIPs (n=1873) 588 (31) 1156 (62) 100 (5) 29 (2)
MCPs (n=1880) 1532 (81) 325 (17) 21 (1) 2 (0.1)
B.
Controls Hand OA JSN=0 JSN=1 JSN=2 JSN=3
All joints 1.15 (0.17) 0.98 (0.21) 1.28 (0.34) 0.80 (0.23) 0.42 (0.28) 0.17 (0.23)
DIPs 0.89 (0.23) 0.70 (0.25) 0.95 (0.23) 0.72 (0.20) 0.39 (0.27) 0.16 (0.23)
PIPs 0.95 (0.15) 0.84 (0.22) 1.05 (0.25) 0.79 (0.19) 0.47 (0.30) 0.18 (0.24)
MCPs 1.61 (0.23) 1.40 (0.27) 1.47 (0.27) 1.12 (0.23) 0.54 (0.34) *
All joints = DIP 2-5, PIP 2-5 and MCP 2-5 in both hands, DIPs = DIP 2-5 in both hands, PIPs = PIP 2-5 
in both hands, MCPs = MCP 2-5 in both hands. 
*No estimation since only 2 joints were present.
Table 3. Association of joint space width in millimetres with age and sex in the control group (11280 
joints) and in patients with hand osteoarthritis (5631 joints), expressed as β-coefficient with 95%CI 
and p-value.
Control group Hand OA
Crude Crude Adjusted*
Female -0.17 (-0.20 to -0.14), <0.01 -0.07 (-0.15 to 0.01), 0.08 -0.08 (-0.15 to -0.01), 0.02
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Associations of summed JSW and JSN with clinical determinants at patient level
Lower total JSW was associated with a higher osteophyte scores and a higher number of 
joints with self-reported pain, pain on palpation and nodes (table 5). The presence of more 
pain and functional limitations measured with the AUSCAN and worse hand mobility 
according to the HAMIS were also associated with lower total JSW. JSW was positively 
associated with grip strength, meaning that a higher JSW is related to more grip strength. 
Similar to JSW, a higher JSN score was associated with higher osteophyte scores 
and a higher number of joints with self-reported pain, pain on palpation and nodes 
(table 5). Again more JSN was related to the presence of more pain and functional 
limitations measured with the AUSCAN and worse hand mobility according to the 
HAMIS. JSN was not related to grip strength. The crude estimates for both JSW and 
JSN did not differ from the adjusted estimates.
discussion
This paper compares the JSW in millimeters of finger joints in a large population of patients 
with hand OA with visual grading score for JSN and JSW measurements of controls. We 
showed that quantitative JSW measurements and the visual grading method for JSN are 
both associated with self-reported pain and functional ability, pain on palpation and the 
Table 4. Association of joint space width (JSW) and joint space narrowing (JSN) with clinical 
determinants in hand osteoarthritis patients, at joint level, expressed as β-coefficient with 95%CI 
and p-value
JSW (5631 joints) JSN (5631 joints)
Osteophytes (OARSI)
Osteophyte=0 0
Osteophyte=1 -0.20 (-0.23 to -0.17), <0.001 0.36 (0.31 to 0.41), <0.001
Osteophyte=2 -0.54 (-0.61 to -0.48), <0.001 1.24 (1.11 to 1.38), <0.001
Osteophyte=3 -0.62 (-0.74 to -0.51), <0.001 1.31 (1.12 to 1.50), <0.001
Self-reported pain
No pain 0 0
Pain present -0.21 (-0.27 to -0.16), <0.001 0.39 (0.30 to 0.48), <0.001
Presence of nodes
No nodes 0 0
Nodes present -0.37 (-0.40 to -0.34), <0.001 0.48 (0.42 to 0.55), <0.001
Pain on palpation
No pain 0 0
Pain present -0.25 (-0.29 to -0.21), <0.001 0.37 (0.29 to 0.44), <0.001
Erosions*
No erosion 0 0
Erosion present -0.61 (-0.68 to -0.54), <0.001 1.43 (1.31 to 1.54), <0.001
β-coefficient adjusted for age, sex, BMI, family effect within sibling pairs and mean width of the 
phalanx.
*Erosion defined as an erosive joint or joint with a remodeled irregular sclerotic surface.
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presence of osteophytes, nodes and erosions. This implies that JSW measurement is a valid 
method to evaluate loss of joint space in finger joints of hand OA patients.
The expectation was that the mean JSW in patients with hand OA would be 
smaller than in controls without hand complaints. We confirmed this hypothesis. 
The radiographs and JSW measurements of these controls were judged by the same 
expert and measured in the same hospital with identical semi-automated method as 
in the present study minimising confounding factors. 
The present study showed that females had smaller JSW than men in hand OA 
patients after adjustment for the presence of osteophytes, since this is another feature 
of OA. Additional adjustment for age did not change these results. In controls, females 
also have smaller JSW than men after adjustment for the size of the hand (reflected 
by the mean width of phalanges of the hand), so partly this effect can be contributed 
to the fact of having smaller hands. These results that females have smaller JSW are 
in accordance to data from patients with rheumatoid arthritis and healthy controls, 
showing that JSW in females were smaller than in males (without adjustments).19-21 
The study in healthy controls showed an age-dependent decrease of the JSW in both 
males and females.20,21 In patients with rheumatoid arthritis (94 females, 34 males), 
only in females an association between age and JSW was seen.19 In the present study, 
older age was associated with a lower JSW in controls, but no association between age 
and JSW was seen in hand OA patients. This could be explained by the small age range 
between 50 and 85 years in hand OA patients which could lead to a biased (positive) 
association of age and JSW in this population. Alternatively, the positive association 
between age and JSW in hand OA patients could be explained by thickening of the 
cartilage in early stages of OA reflecting a larger JSW on radiographs.22
We show that JSW measurements are a valid method to measure the joint space, 
since it is related to clinical features. In the past it was shown that the quantitative 
method itself is accurate and reproducible.10,23-25 The visual grading method for 
Table 5. Association of summed joint space width (JSW) and summed joint space narrowing (JSN) 
with clinical determinants in hand osteoarthritis patients, at patient level, expressed as β-coefficient 
with 95%CI and p-value.
Summed JSW Summed JSN
Summed osteophytes -0.27 (-0.34 to -0.19), <0.001 0.75 (0.62 to 0.88), <0.001
No. joints self-reported pain -0.14 (-0.23 to -0.05), 0.003 0.30 (0.12 to 0.48), 0.001
No. joints nodes -0.28 (-0.42 to -0.14), <0.001 0.76 (0.50 to 1.03), <0.001
No. joints pain on palpation -0.12 (-0.23 to -0.01), 0.03 0.27 (0.06 to 0.49), 0.01
AUSCAN pain -0.13 (-0.25 to -0.01), 0.03 0.25 (0.02 to 0.49), 0.04
AUSCAN function -0.11 (-0.17 to -0.05), 0.01 0.21 (0.08 to 0.34), 0.002
Grip strength left hand 0.05 (-0.02 to 0.12), 0.14 -0.06 (-0.19 to 0.08), 0.44
Grip strength right hand 0.07 (0.00 to 0.13), 0.07 -0.07 (-0.21 to 0.08), 0.36
HAMIS both hands -0.46 (-0.68 to -0.24), <0.001 1.08 (0.64 to 1.52), <0.001
β-coefficient adjusted for age, sex, BMI, family effect within sibling pairs and mean width of the 
phalanx.
Abbreviations: see table 1.
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JSN showed the same relation with clinical features. An additional advantage of 
JSW measurements performed by the computer software is that it is not subject 
to interpretation differences which can be present amongst human observers. The 
expectation is that quantifying loss of joint space with this method will give fewer 
mistakes in interpretation compared to the grading of joint space narrowing. In 
addition, the JSW can be more easily compared with other JSW in other studies. 
Unfortunately, the present study did not measure the mistakes made by the computer 
where the expert reviewer need to interrupt and should be investigated in the future.
Results shown in table 4 and 5, where same associations of JSW and JSN with 
clinical determinants were found, indicate that the JSW method is not superior to 
the visual grading method to measure joint space. An argument to choose for one 
of these methods could be that one method is easier or more feasible to use than 
the other (e.g. less time-consuming). For example, the positioning of the hand in the 
JSW method is important to derive the most precise joint space width measurements. 
The study of Angwin et al. showed that if the hand was positioned in six different 
arranged positions, the JSW of the MCPJs varied.23 In the visual grading method, the 
effect of positioning could be less important than in the JSW method. In longitudinal 
studies it could be that the JSW method is more sensitive to measure subtle changes 
where the visual grading method is not able to detect these changes and whether 
they are relevant in clinical practice. Bijsterbosch et al. showed that the changes in 
the visual grading method were not related with clinical determinants.5 It could be 
that changes in the JSW method would be related with clinical determinants, but this 
hypothesis needs further investigation. In a longitudinal study in early rheumatoid 
arthritis it was shown that a change in JSW was a more sensitive outcome measure 
than a visual grading method (total Sharp score).26
Several limitations of this study can be addressed. Since radiographs are still 
two-dimensional representations it is not possible to measure joint space width as 
a measure of volume which can more accurately describe the three-dimensional 
structure of a joint. The mean JSW remains the best estimate of the cartilage of the 
joint. The mean JSW could be influenced by other structures such as osteophytes if 
these are projected in the frontal plane. The automatic measurements were reviewed 
by an expert in order to confirm that the joint space width between the true contours 
of the interphalangeal bones was measured. In hand OA, no studies are known where 
the volume of the joint space or cartilage was quantified. In knee OA joints, Duryea et 
al. performed a comparison between quantitative magnetic resonance imaging (MRI) 
(volume and thickness measurements in mm3) with radiography (JSW in mm) in a 
longitudinal study where a relatively weak correlation was found.27 Furthermore, hand 
OA patients in the present study are not representative for the general population, 
since they were selected on familial OA at multiple sites. Previous studies showed 
that these hand OA patients were less affected by their hand complaints than hand 
OA patients in the rheumatology practice.1,28 Bias in the selection of hand joints in 
controls is possible, since patients selected from the cohort with knee complaints may 
be not fully comparable with a randomly selected population. However, since the 
knee complaints were sub-acute (and not chronic), they should not have a higher risk 
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of the presence of hand OA at the moment of their study inclusion than a random 
selected control group. This is supported by the finding that the JSW of controls is 
higher than the hand OA patients in our population. Finally, the hand radiographs 
were obtained with the same study protocol and technician in the majority of 
subjects. Since the knee population consisted mostly of males, hand radiographs of 
EAC-controls were included, however their radiographs were not obtained according 
to the study protocol. This could also lead to a bias in the mean JSW.
In conclusion, automated quantitative analyses of the JSW are a valid method 
to measure JSN in relation with clinical features, such as pain and the presence of 
nodes. The role of measuring the JSW in hand OA patients needs to be investigated 
in longitudinal studies to determine if it can discriminate progression in hand OA 
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Osteoarthritis (OA) is the most common musculoskeletal disorder, characterised 
by degradation of cartilage and changes in subchondral bone leading to pain and 
disability. It is a burden not only for the individual but also for society, increasing in 
relevance with an aging population. The hand is the most frequently involved joint site. 
Treatment options are currently limited to patient education and symptom alleviation. 
This thesis presents the results of the Genetics ARthrosis and Progression (GARP) 
study with emphasis on hand OA. The study population comprises 192 Caucasian 
sibling pairs with symptomatic OA at multiple sites including the hands, knees, 
hips and spine. They are recruited from rheumatologists, orthopaedic surgeons and 
general practitioners. Hand OA is present in the majority of this population. OA status 
was evaluated at baseline and after a follow-up period of 6 years. Part of the study 
population was assessed after a period of 2 years.
We investigated the characteristics of the hand OA subsets thumb base OA, 
erosive OA and nodal OA. Secondly, the long-term disease course of hand OA was 
assessed and determinants of outcome were identified. Also the reliability, validity, 
sensitivity to change and feasibility of outcome measures in hand OA was evaluated. 
Hand oa suBsets
Because of the heterogeneous character of hand OA, different subsets have been 
proposed based on different risk factors, associations and outcomes, although 
evidence is limited. Proposed subsets are interphalangeal joint OA (with and without 
nodes), thumb base OA and erosive OA. There is lack of data on disease outcome 
and pathogenesis of these subsets and it is unclear how these subsets are delineated. 
Characterisation of and differentiation between subsets gives insight in their 
pathogenesis and may contribute to individualised patient management.
Chapter 2 describes levels of pain and disability in two subsets of symptomatic 
hand OA: interphalangeal joint OA and thumb base OA. Patients with only 
interphalangeal joint OA reported the lowest levels of pain and disability followed by 
those with thumb base OA only. Patients affected at both joint sites experienced the 
highest levels of pain and disability. Because pain and disability were associated with 
the number of symptomatic joints we adjusted for this factor. After adjustment the 
level of pain and disability was higher in patients with thumb base involvement than 
in those without involvement of this joint site. This may imply that treatment aiming 
at thumb base symptoms in patients with symptomatic hand OA is important even if 
it coincides with symptoms at the interphalangeal joints. 
In chapter 3 and 4 we focus on erosive hand OA, a radiographic subset based on 
the presence of subchondral erosions mainly affecting the interphalangeal joints. It is 
assumed that erosive OA has a higher burden and worse outcome than non-erosive 
OA, but evidence is limited. Little is known on the risk factors associated with the 
development and progression of erosions in OA. 
We investigated the clinical burden of erosive OA by comparing pain, functioning, and 
health related quality of life (HRQL) between patients with erosive OA and non-erosive 
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OA (chapter 3). It was found that patients with erosive OA experience more pain, report 
more disability, have worse hand mobility and are less satisfied with hand function and 
aesthetics than those with non-erosive OA. HRQL was similar for the patient groups. 
Patients with erosive OA had more nodes, which was also found to be a determinant 
of clinical outcome. Taking into account the number of nodes, only hand mobility and 
patient satisfaction remained different between the groups. These findings demonstrate 
that the clinical burden of erosive OA is higher compared to its non-erosive counterpart. 
However, it seems that this higher burden cannot exclusively be attributed to the erosive 
character but can also be attributed to the presence of nodes. 
Chapter 4 describes the evolution of erosions in hand OA as well as determinants 
of this process over 6 years in 236 hand OA patients from the GARP study. We 
found that erosive evolution took place in 4.4% of the interphalangeal joints at risk, 
corresponding to 25.4% of the patients. This erosive activity was clustered within 
patients meaning that erosive OA is more likely to occur in certain patients than in 
others. Differences in genetic background may explain this predisposition to erosive 
disease. This conclusion is strengthened by the finding that familial factors play a role 
in erosive evolution. Joint space narrowing (JSN) and self-reported pain at joint level 
were independent local predictors for erosive evolution. The latter may imply that 
local inflammation plays a role in the erosive process, since a recent study showed 
a strong dose-response relationship between pain and signs of inflammation on 
ultrasound. These findings give insight in the course of erosive OA and contribute 
to the understanding of its pathogenesis and nature. For clinical practice the 
identification of patients at high risk for development or progression of erosions has 
consequences for treatment since erosive OA is associated with high disease burden.
natural course of Hand oa and determinants 
of outcome
Little is known about the natural history of hand OA and determinants of outcome. 
Knowledge of these topics contributes to better patient information and to the 
development of new therapies. 
Chapter 5 describes the clinical and radiographic course of hand OA in general 
over 6 years in 289 hand OA patients from the GARP study. Also, clinical and 
radiographic determinants of outcome are identified. After 6 years, 40-50% of patients 
experienced increase in pain and disability whereas about a quarter improved. In 
contrast, radiographic progression was an ongoing process which was present in half 
of the patients: 44.9% had progression of osteophytes and 25.9% had progression 
of JSN. Poor clinical outcome was associated with high levels of pain and functional 
limitations at baseline. More pain, structural abnormalities and the presence of erosive 
OA and nodal OA were associated with a higher risk of radiographic progression. 
Change in symptoms and radiographic progression were not related. These findings 
give insight in the long-term disease course of hand OA and factors associated with 
poor outcome. As a consequence the clinician can provide the patient with more 




that the clinical and radiographic course of hand OA are distinct, making development 
of structure modifying treatments with clinical benefit challenging.
The GARP study population consists of patients with OA at multiple sites. Although 
the focus of this thesis is on hand OA, chapter 6 describes clinical and radiographic 
determinants of clinical progression of lower extremity OA over 6 years in 117 patients 
from the GARP study with OA at the knee, hip, or both. Over this period 53% of the 
patients had clinical deterioration defined as worsening of pain and disability (20%) 
or joint replacement (33%). In patients receiving joint prosthesis during the follow-
up period, self-reported pain improved. Worsening of disability over 1 year, limited 
range of motion at baseline and baseline JSN scores were independent predictors for 
clinical progression. These findings contribute to better patient information regarding 
long-term prognosis of lower extremity OA and identification of those patients at risk 
for clinical deterioration.
Hand OA clusters in multiple hand joints as well as with OA at other joint sites, 
especially the knee. Most evidence supporting these concepts is based on cross-
sectional data. We investigated patterns of OA progression within hand joints and 
the relationship between hand OA progression and progression of OA at the knee 
in 236 hand OA patients participating in the GARP study in chapter 7. Radiographic 
progression of hand OA clustered between hand joint groups as well as in a 
symmetrical pattern and in rows but not in rays. At the joint level most progression 
was present in the first carpometacarpal (CMC-1) joint, suggesting that thumb base 
OA may be more progressive that interphalangeal joint OA. Also, there was clustering 
of hand OA progression within sibling pairs. Patients with progression of hand OA 
after 6 years had a higher risk for radiographic change at the knee compared to 
those without hand OA progression. Separate analysis in those with and without 
knee OA at baseline showed similar results. These findings give insight in the complex 
aetiology of hand OA and suggest that systemic factors play a role. Showing that 
there is familial aggregation of hand OA progression is the first step in assessing the 
role of genetic factors in this process.
The role of genetic factors in influencing OA susceptibility is well documented. 
However, few studies assessed the role of OA susceptibility genes in the disease 
course. We investigated whether single nucleotide polymorphisms (SNPs) within 
asporin (ASPN), bone morphogenic protein 5 (BMP5) and growth differentiation 
factor 5 (GDF5) are related to the progression of hand OA over 6 years (chapter 8). 
Subsequently, SNPs with suggestive evidence for association were investigated for 
association with hand OA progression over 2 years. SNP rs13301537 in ASPN was 
associated with radiographic progression of hand OA over 6 years. The minor allele 
of this variant was more common in patients with progression of hand OA than in 
healthy controls. In addition, the mean change in osteophytes and JSN was higher 
in C-allele carriers than for the TT genotype. In the 2-year cohort similar results were 
found. Effects over the long term and short term seem not associated. ASPN inhibits 
both early- and late-stage chondrogenesis trough suppression of transforming 
growth factor β (TGF-β), a central player among growth factors in articular cartilage. 
Excessive ASPN activity reduces TGF-β function to less optimal levels, leading to 
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cartilage degeneration. Our findings suggest that this imbalance between ASPN 
and TGF-β is an ongoing process leading not only to the development but also to 
progression of OA. This interaction between ASPN and TGF-β, leading to suboptimal 
TGF-β levels is a potential target for therapeutic approaches. 
Increasing evidence supports the involvement of both local and systemic inflammation 
in the pathogenesis of OA. In rheumatoid arthritis localised bone mineral density (BMD) 
loss over time is associated with progression of joint damage, indicating inflammatory 
activity. Chapter 11 shows that over a period of 2 years accelerated localised BMD loss 
in the hand is associated with radiographic progression of hand OA. There was no 
difference in BMD change between hand OA patients without progression and patients 
without hand OA. This suggests a role for inflammation in active, progressive hand OA. 
This is in line with the findings in chapter 4 suggesting a role for inflammation in OA 
joints that progress over time as compared to those without changes.
According to the International Classification of Functioning, Disability and Health 
(ICF) patients’ perceptions regarding their disease are part of the personal factors that 
modify disease outcome. Chapter 9 and 10 assessed the relationship between illness 
perceptions and outcome of pain and disability in OA. Over a period of 6 years patients 
perceived their OA as more chronic and less controllable, their understanding of OA 
increased and emotions associated with OA were less negative. Negative patterns of 
illness perceptions were associated with progression of disability (chapter 9) and with 
an increase in self-reported pain (chapter 10), whereas positive patterns of illness 
perceptions were related to a decrease in self-reported pain (chapter 10). Moreover, a 
higher number of symptoms attributed to OA, lower perceived control, and stronger 
perceived consequences at baseline were predictive of high disability after 6 years. 
These findings imply that illness perceptions change over time, that they are related 
to and, most importantly, are predictive of disability. Therefore, interventions aiming 
at changing illness perceptions may influence clinical outcome. 
outcome measures in Hand oa
Research requires well defined and validated outcomes and outcome measures. 
For hand OA a core concept of outcomes and outcome measures is specified in 
the Osteoarthritis Research Society International (OARSI) recommendations. Pain, 
functioning and radiographic abnormalities belong to the inner core set. Importantly, 
outcome measures and instruments need to be valid, reliable and sensitive to change. 
Well established measures are available for self-reported pain, but a standardised 
method to assess pain during physical examination is lacking. One proposed articular 
index is the Doyle Index grading pain in 48 joints or joint groups by pressure on the 
lateral joint margin or by passive joint movement on a four-point scale. In chapter 
12 we showed that the Doyle Index is a reliable, valid and feasible measure for pain 
during physical examination. Besides its use for research purposes, it can be used in 
clinical practice because of the ease of use and limited performance time. 
For structural damage serial radiographs are the recommended outcome measure. 




severity and progression of structural damage in hand OA. However, there is no 
consensus on the preferred method since comparative studies between methods are 
scarce. Therefore, we evaluated the reliability, sensitivity to change and feasibility 
of the Kellgren-Lawrence grading scale (a global score), the OARSI atlas (assesses 
individual radiographic OA features) and the Verbruggen-Veys anatomical phase 
score using three readers from different European centers (chapter 13). We found 
minor differences between the methods. Reliability was high and sensitivity to change 
was good over both 2 and 6 years, Verbruggen-Veys was fastest to perform. There 
were differences in change scores and proportions of progression between readers, 
despite use of methods to enhance consistency. Based on our findings we cannot 
recommend one of the methods. Rather, based on the different character of the 
methods, the choice depends on the study objective. 
Recently a method for the quantitative measurement of joint space width (JSW) 
in hand joints was developed. We assessed the validity of this method by comparing 
JSW in millimetres between 235 hand OA patients from the GARP study and 471 
controls and by assessing the relationship to grading of JSN from 0-3. Also, the 
association with clinical determinants was evaluated (chapter 14). We found that, 
as we hypothesised, the mean JSW in hand OA patients was smaller than in controls 
without hand complaints. The smallest JSW was found for distal interphalangeal 
(DIP) joints and the largest for metacarpophalangeal (MCP) joints. JSW measurement 
and the grading of JSN are both associated with self-reported pain, self-reported 
disability, pain on palpation and the presence of osteophytes, nodes and erosions. 
This implies that JSW measurement is a valid method to evaluate loss of joint space 
in finger joints of hand OA patients. An advantage of the JSW method above the 
JSN method may be that it is more sensitive to subtle changes, which has yet to be 
investigated in longitudinal studies. 
future PersPectives
This thesis increases our knowledge on hand OA subsets and factors involved in 
hand OA progression. Therefore, it contributes to the identification of potential 
targets for the development of new treatments that alter the disease course or even 
prevent its development. In addition, it contributes to better patient information and 
individualised patient management. 
We have shown that the course of symptoms in hand OA is variable over time as 
opposed to radiographic abnormalities that worsened over time. Clinical change and 
radiographic progression were not related. These findings imply that the clinical and 
radiographic course of hand OA are distinct, making development of structure modifying 
treatments with clinical benefit challenging. A reason for lack of association may be 
that the outcome measures used are not sensitive enough. Another reason could be 
that the disease course has a fluctuating character meaning that many measurement 
moments are needed to correctly record changes over time. Advanced techniques 
are required to further assess the relationship between the course of symptoms and 
structural abnormalities such as JSW measurement, ultrasound and MRI. 
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The ultimate goal of our research is to contribute to the development of new 
treatments that alter the disease course or even prevent its development. At 
the moment treatment options are limited to patient education and symptom 
alleviation. This is in part due to lack of understanding of mechanisms involved in 
the disease process and the source of pain. A complicating factor is that hand OA 
is a heterogeneous disease with various subsets and a variable disease course as 
shown in this thesis. Characterisation of these phenotypes and their specific risk 
factors will help in identifying patient groups that benefit from specific treatments. 
An example is erosive OA. In this thesis and other research it is shown that (local) 
inflammation probably plays an important role in its development and progression. 
This implies that anti-inflammatory treatments may have benefit in this phenotype. In 
a trial by Verbruggen et al. it was shown that adalimumab, a TNFα-blocking agent, 
reduced the occurrence of erosive progression compared to placebo. We participate 
in the multicenter international EHOA study, a placebo controlled randomised trial 
investigating the clinical efficacy and effect on structural abnormalities of the TNFα-
blocking agent Etanercept. The first results are expected soon.
Differentiation of hand OA phenotypes and further exploration of the course of 
hand OA requires large patient cohorts including patients with early disease who are 
followed up for a long period of time with frequent evaluation moments. As mentioned 
earlier sensitive outcome measures are needed, such as JSW measurement, ultrasound 
and MRI. Biochemical markers such as cartilage, synovium and bone breakdown 
products as well as cytokines and adipokines can also help. In recent research we 
found that baseline adiponectin levels were associated with progression of hand OA 
over 6 years in the GARP study. In the same population we showed that uCTX-II levels 
over time, a marker for cartilage breakdown, were associated with progression of JSN. 
Because of the need for patient cohorts we started the Hand OSTeoArthritis in 
Secondary care (HOSTAS) study in June 2009. This is a prospective cohort study at 
the outpatient clinic of the Leiden University Medical Center comprising consecutive 
patients with hand OA diagnosed by the treating rheumatologist no longer than 3 
years ago. Clinical data, radiographic data (radiographs and MRI) and blood and 
urine samples are collected. With this and other studies we hope to further unravel 
the complex pathogenesis and disease course of hand OA and thereby continue to 









Artrose is de meest voorkomende musculoskeletale aandoening en wordt gekenmerkt 
door afbraak van kraakbeen en veranderingen in het onderliggende subchondrale 
bot. Dit leidt tot pijn en functionele beperkingen. Het is niet alleen een belasting 
voor het individu maar ook voor de maatschappij, toenemend in relevantie met een 
verouderende populatie. De handgewrichten zijn het meest frequent aangedaan. 
Handartrose is een heterogene aandoening waarbij verschillende subtypen worden 
onderscheiden zoals erosieve artrose. Over het natuurlijk beloop en risicofactoren 
voor achteruitgang over de tijd is weinig bekend. Mede hierdoor zijn de 
behandelmogelijkheden beperkt tot patiëntvoorlichting en symptoombestrijding.
In dit proefschrift worden de resultaten van de Genetica ARtrose en Progessie 
(GARP) studie gepresenteerd, waarbij de nadruk ligt op handartrose. De studiepopulatie 
bestaat uit 192 sibparen (zus-zus, broer-broer, zus-broer) met symptomatische artrose 
van meerdere gewrichten namelijk handen, knieën, heup en/of wervelkolom. Zij zijn 
verzameld via reumatologen, orthopedisch chirurgen en huisartsen. De meerderheid 
van de deelnemers heeft handartrose. De deelnemers werden beoordeeld op baseline 
en na 6 jaar en een deel van hen werd ook nog na 2 jaar beoordeeld. 
Wij onderzochten de kenmerken van handartrose subtypen duimbasis artrose, 
erosieve artrose en artrose met nodi. Ten tweede werd het natuurlijk beloop van 
handartrose op de lange termijn bekeken evenals factoren die van invloed zijn op 
de uitkomst. Verder hebben we de betrouwbaarheid, validiteit en gevoeligheid voor 
verandering van uitkomstmaten in handartrose geëvalueerd. 
Hand oa suBtyPen
Vanwege het heterogene karakter van handartrose worden subtypen onderscheiden 
gebaseerd op verschillen in risicofactoren, associaties en uitkomsten, ook al is er weinig 
bewijs. Subtypen die worden onderscheiden zijn artrose van de interphalangeale 
gewrichten (met of zonder nodi), duimbasis artrose en erosieve artrose. Er is weinig 
bekend over de uitkomst en pathogenese van deze subtypen en hun onderlinge 
verhouding. Differentiatie tussen de subtypen geeft inzicht in de onderliggende 
pathogenese en draagt bij aan behandeling gericht op het individu. 
Hoofdstuk 2 beschrijft de mate van pijn en functionele beperkingen in twee van deze 
subtypen: artrose van de interphalangeale gewrichten en duimbasis artrose. Patiënten 
met alleen artrose van de interphalangeale gewrichten rapporteerden de minste pijn 
gevolgd door patiënten met alleen duimbasis artrose. Degenen met artrose van de 
beide gewrichtsgroepen rapporteerden de meeste pijn en functionele beperkingen. 
Omdat pijn en beperkingen geassocieerd waren met het aantal symptomatische 
gewrichten, hebben we de analyse gecorrigeerd voor deze factor. Na deze correctie 
hadden patiënten met betrokkenheid van de duimbasis meer pijn en beperkingen 
dan degenen zonder betrokkenheid van de duimbasis. Dit betekent dat behandeling 
gericht op de duimbasis in patiënten met symptomatisch handartrose belangrijk is, 
zelfs als het samengaat met klachten van de interphalangeale gewrichten. 
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In hoofdstuk 3 en 4 ligt het focus op erosieve handartrose. Dit is een radiologisch 
gedefinieerd subtype gebaseerd op de aanwezigheid van subchondrale erosies in de 
interphalangeale gewrichten. Het wordt aangenomen dat erosieve artrose een slechtere 
uitkomst heeft dan niet-erosieve artrose, maar bewijs hiervoor is beperkt. Ook is er weinig 
bekend over risicofactoren voor de ontwikkeling en de progressie van erosies bij artrose.
Wij vergeleken pijn, functioneren en kwaliteit van leven tussen patiënten met 
erosieve artrose en niet-erosieve artrose in hoofdstuk 3. Patiënten met erosieve 
artrose ervaren meer pijn en beperkingen in het functioneren, hebben slechte 
handmobiliteit en zijn minder tevreden met hun handfunctie en uiterlijk van hun 
handen dan patiënten met niet-erosieve artrose. Kwaliteit van leven is gelijk tussen 
de groepen. Patiënten met erosieve artrose hebben meer nodi en dit is tevens een 
factor die samenhangt met de uitkomst. Na correctie voor deze factor bleven alleen 
handmobiliteit en patiënt tevredenheid verschillend tussen erosieve en niet-erosieve 
artrose. Deze bevindingen illustreren dat de last van erosieve artrose groter is 
vergeleken met niet-erosieve artrose. Echter, deze hogere last kan niet alleen worden 
toegeschreven aan de erosies maar ook aan de aanwezigheid van nodi. 
Hoofdstuk 4 beschrijft het beloop van erosies in handartrose over 6 jaar in 236 
handartrose patiënten uit de GARP studie, alsmede factoren die aan dit proces bijdragen. 
De vorming en verergering van erosies vond plaats in 4.4% van de interphalangeale 
gewrichten. Dit komt overeen met 25.4% van de patiënten. De erosieve activiteit was 
geclusterd binnen patiënten, wat inhoudt dat de kans op het ontstaan van erosieve 
artrose in bepaalde patiënten groter is dan in anderen. Verschillen in genetische 
achtergrond kunnen deze predispositie voor erosieve handartrose mogelijk verklaren. 
Deze conclusie wordt verder ondersteund door de bevinding dat familiare factoren 
een rol spelen bij erosieve activiteit. Gewrichtsspleetvernauwing en gerapporteerde 
pijn op gewrichtsniveau zijn onafhankelijke voorspellers voor erosieve activiteit. Dit 
kan betekenen dat lokale ontsteking een rol speelt in het erosieve proces aangezien 
een recente studie in handartrose patiënten een sterke dosisrespons relatie vond 
tussen pijn en tekenen van ontsteking bij echografie. Deze bevindingen geven inzicht 
in het beloop van erosieve artrose en dragen bij aan de kennis over de pathogenese 
van dit subtype. Voor de klinische praktijk heeft de identificatie van patiënten met 
een hoog risico op het ontwikkelen of progressie van erosies consequenties voor de 
behandeling aangezien erosieve artrose een hogere ziektelast heeft.
natuurliJk BelooP van Handartrose en 
determinanten van uitkomst 
Er is weinig bekend over het natuurlijk beloop van handartrose en factoren die van 
invloed zijn op de uitkomst van de aandoening. Kennis hierover draagt bij aan het 
verbeteren van patiëntvoorlichting en aan de ontwikkeling van nieuwe behandelingen. 
Hoofdstuk 5 beschrijft het klinische en radiologische beloop van handartrose over 
een periode van 6 jaar in 289 handartrose patiënten uit de GARP studie. Ook werden 
factoren die de uitkomst beïnvloeden geïdentificeerd. Na 6 jaar ervoer 40-50% 




patiënten trad verbetering op. Radiologische progressie werd vastgesteld bij de helft 
van de patiënten: 44.9% had progressie van osteofyten en 25.9% had progressie 
van gewrichtsspleetvernauwing. Slechte klinische uitkomst was geassocieerd met 
veel pijn en beperkingen op baseline. Meer ervaren pijn, structurele afwijkingen 
en de aanwezigheid van erosieve artrose en nodi was geassocieerd met een hoger 
risico op radiologische progressie. Deze bevindingen geven inzicht in het beloop van 
handartrose op de lange termijn en factoren die bijdragen aan een slechte uitkomst. 
Hierdoor kan de clinicus de patiënt beter informatie geven over de prognose. 
Vanuit wetenschappelijk oogpunt impliceren de bevindingen dat het klinische en 
radiologische beloop van elkaar losstaande processen zijn. Dit maakt de ontwikkeling 
van structuur modificerende behandelingen met ook klinisch voordeel een uitdaging.
In de GARP studie hebben de patiënten artrose van meerdere gewrichten. Alhoewel 
het focus van dit proefschrift handartrose is, maken we in hoofdstuk 6 een uitstapje 
naar artrose van de onderste extremiteiten. We beschrijven de klinische en radiologische 
determinanten van klinische progressie van artrose in de onderste extremiteiten over 6 
jaar in 117 patiënten met knieartrose, heupartrose of knie- en heupartrose. Klinische 
achteruitgang was aanwezig in 53% van de patiënten en was gedefinieerd als 
verergering van pijn en beperkingen (20%) of gewrichtsvervanging (33%). Patiënten die 
een gewrichtsprothese kregen tijdens de follow-up periode rapporteerden minder pijn. 
Toename van functionele beperkingen over 1 jaar, bewegingsbeperking van het gewricht 
op baseline en de mate van gewrichtsspleetvernauwing op baseline waren onafhankelijke 
voorspellers voor klinische achteruitgang. Deze bevindingen dragen bij aan verbetering 
van patiëntinformatie over de lange termijn prognose van artrose van de onderste 
extremiteiten en identificatie van patiënten met risico op klinische achteruitgang. 
Hand OA clustert in de handgewrichten en met artrose in andere gewrichten, 
met name de knie. Dit is grotendeels gebaseerd op dwarsdoorsnede onderzoeken. 
Wij onderzochten de patronen van handartrose progressie binnen de handgewrichten 
en de relatie tussen progressie van handartrose en knieartrose in 236 patiënten met 
handartrose uit de GARP studie (hoofdstuk 7). Er was clustering van radiologische 
progressie van handartrose tussen de verschillende handgewrichten. Ook werd gezien 
dat progressie plaatsvond in een symmetrisch patroon en per rij, maar niet per straal. 
Op gewrichtsniveau was progressie meest frequent in het duimbasis gewricht. Dit 
suggereert dat duimbasis artrose een snellere achteruitgang kent dan artrose van de 
interphalangeale gewrichten. Ook was er clustering van handartrose progressie binnen 
sibparen. Patiënten met progressie van handartrose over 6 jaar hadden een hoger risico 
op radiologische veranderingen in de knie vergeleken met degenen zonder progressie 
van handartrose. Analyse in degenen met en zonder knieartrose op baseline liet 
vergelijkbare resultaten zien. Deze bevindingen geven inzicht in de complexe etiologie 
van handartrose en suggereren dat systemische factoren een rol spelen. We hebben 
laten zien dat er familiaire aggregatie is van handartrose progressie. Dit is de eerste 
stap in de beoordeling van de rol van genetische factoren in handartrose progressie.
Het is bekend dat en ook welke genetische factoren de gevoeligheid voor het 
ontwikkelen van artrose beïnvloeden. Echter er zijn weinig studies die de rol van 
deze genen in het beloop van de ziekte hebben bestudeerd. Wij hebben onderzocht 
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of single nucleotide polymorphisms (SNPs) binnen ASPN, BMP5 en GDF, waarvan 
bekend is dat ze geassocieerd zijn met de ontwikkeling van artrose, gerelateerd zijn 
aan progressie van handartrose over 6 jaar (hoofdstuk 8). Vervolgens werden SNPs 
die geassocieerd waren, onderzocht op hun relatie met handartrose progressie over 
2 jaar. SNP rs13301537 in ASPN was gerelateerd aan radiologische progressie van 
handartrose na 6 jaar. Het minor allel van deze variant komt vaker voor in patiënten 
met handartrose progressie dan in gezonde controles. Ook was de gemiddelde 
verandering in osteofyten en gewrichtsspleetvernauwing hoger in C-allel dragers 
dan voor degenen met een TT-genotype. In het 2-jaar cohort werden vergelijkbare 
resultaten gevonden. Effecten over de lange en korte termijn lijken niet met elkaar 
samen te hangen. ASPN remt zowel vroege als late chondrogenese via de suppressie 
van TGF-β, een belangrijke groeifactor in kraakbeen. Overmatige ASPN activiteit 
verlaagt TGF-β tot suboptimaal niveau met als gevolg degeneratie van kraakbeen. 
Onze bevindingen suggereren dat de disbalans tussen ASPN en TGF-β een voortdurend 
proces is wat niet alleen leidt tot de ontwikkeling, maar ook de progressie van artrose. 
Deze interactie tussen ASPN en TGF-β met suboptimale niveaus van TGF-β is een 
potentieel aangrijpingspunt voor nieuwe behandelingen.
Er komt steeds meer bewijs voor de betrokkenheid van zowel lokale als systemische 
inflammatie in de pathogenese van artrose. In reumatoïde artritis is gelokaliseerd 
verlies van botdichtheid geassocieerd met progressie van gewrichtsschade, duidend 
op inflammatoire activiteit. Hoofdstuk 11 laat zien dat verhoogd lokaal verlies van 
botdichtheid over 2 jaar geassocieerd is met radiologische progressie van handartrose 
over deze periode. Er was geen verschil in botdichtheidverandering tussen patiënten 
zonder progressie van handartrose en degenen zonder handartrose. Dit suggereert 
een rol voor inflammatie in actieve, progressieve handartrose. Dit komt overeen met 
de bevindingen in hoofdstuk 4. 
Volgens de International Classification of Functioning, Disability and Health (ICF) 
zijn percepties van patiënten ten aanzien van hun ziekte onderdeel van persoonlijke 
factoren die ziekte-uitkomst beïnvloeden. In hoofdstuk 9 en 10 wordt de relatie 
tussen deze ziektepercepties en de uitkomst van pijn en beperkingen in artrose 
bestudeerd. Over een periode van 6 jaar ervoeren artrosepatiënten hun aandoening 
als meer chronisch en minder controleerbaar, hun ziekte-inzicht nam toe en emoties 
geassocieerd met artrose werden minder negatief. Negatieve ziektepercepties waren 
geassocieerd met verergering van beperkingen (hoofdstuk 9) en toename van 
gerapporteerde pijn (hoofdstuk 10). Positieve ziektepercepties waren gerelateerd 
aan afname in gerapporteerde pijn (hoofdstuk 10). Een groot aantal symptomen dat 
wordt toegeschreven aan artrose, het gevoel van weinig ziektecontrole en ervaren 
van veel consequenties van de ziekte waren voorspellers voor de aanwezigheid van 
veel functionele beperkingen na 6 jaar. Dit betekent dat ziektepercepties veranderen 
over de tijd, dat ze gerelateerd zijn aan en zelfs voorspellend zijn voor functionele 
beperkingen. Daarom kunnen behandelingen gericht op het veranderen van 





Voor onderzoek zijn duidelijk gedefinieerde en gevalideerde uitkomsten en 
uitkomstmaten noodzakelijk. Voor handartrose zijn er kernuitkomsten en 
uitkomstmaten gespecificeerd in de Osteoarthritis Research Society International 
(OARSI) aanbevelingen. Pijn, functioneren en radiologische afwijkingen behoren tot 
de kernuitkomsten. Het is belangrijk dat de uitkomstmaten en meetinstrumenten 
valide, betrouwbaar en gevoelig voor verandering zijn. 
Er zijn goed gedefinieerde maten beschikbaar voor door de patiënt gerapporteerde 
pijn, echter een gestandaardiseerde methode om pijn tijdens lichamelijk onderzoek 
te beoordelen ontbreekt. Een voorgestelde methode is de Doyle Index waarbij pijn 
in 48 gewrichten of gewrichtsgroepen wordt beoordeeld door palpatie of beweging 
van het gewricht op een vierpunt-schaal. In hoofdstuk 12 laten we zien dat de Doyle 
Index een betrouwbare en valide maat is voor pijn tijdens lichamelijk onderzoek. 
Bovendien is het makkelijk en snel uit te voeren. Naast gebruik voor wetenschappelijk 
onderzoek kan de Doyle Index dus ook in de klinische praktijk gebruikt worden. 
Voor gewrichtsschade zijn röntgenfoto’s de aanbevolen uitkomstmaat. 
Verschillende semikwantitatieve radiologische scoremethoden zijn beschikbaar voor 
de beoordeling van de ernst en progressie van gewrichtschade in handartrose. Echter, 
er is geen consensus over welke methode de voorkeur heeft, aangezien er weinig 
vergelijkende onderzoeken zijn. Wij evalueerden de betrouwbaarheid, validiteit en 
uitvoerbaarheid van de Kellgren-Lawrence score (globale score), de OARSI atlas 
(individuele radiologische kenmerken van artrose) en de Verbruggen-Veys anatomische 
fase score met drie beoordelaars uit verschillende Europese centra (hoofdstuk 13). Er 
waren minimale verschillen tussen de methoden. Betrouwbaarheid was hoog en de 
methoden waren gevoelig voor verandering. Verbruggen-Veys was het snelste uit te 
voeren. Er waren verschillen in scores van verandering over de tijd en percentages 
progressie tussen de beoordelaars ondanks methoden om de overeenstemming te 
optimaliseren. Op basis van deze bevindingen is het niet mogelijk een uitspraak te 
doen over welke scoremethode de voorkeur heeft. Vanwege de grote verschillen 
tussen de methoden zou de keuze dus afhangen van het doel van de studie.
Recent is er een methode ontwikkeld voor de kwantitatieve meting van de 
gewrichtsspleet in handgewrichten. In hoofdstuk 14 onderzochten wij de validiteit 
van deze methode door de gewrichtsspleet in millimeters te vergelijken tussen 
235 handartrose patiënten uit de GARP studie en 471 controle personen zonder 
klachten van de handen. Ook werd de relatie tussen deze methode en het graderen 
van gewrichtsspleetvernauwing op een schaal van 0-3 onderzocht evenals de 
associatie met klinische parameters. Zoals we al verwachten was de gemiddelde 
gewrichtsspleet in handartrose patiënten kleiner dan in de controle personen. De 
distale interphalangeale (DIP) gewrichten hadden de smalste gewrichtsspleet en 
de metacarpale (MCP) gewrichten de wijdste. De meting van gewrichtsspleet en 
het graderen van gewrichtsspleetvernauwing waren beiden geassocieerd met 
gerapporteerde pijn en beperkingen, pijn bij palpatie en de aanwezigheid van 
osteofyten, nodi en erosies. Dit betekent dat de meting van gewrichtsspleet een valide 
methode is voor het evalueren van gewrichtsspleetvernauwing in de handgewrichten 
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van handartrose patiënten. Een voordeel van deze methode ten opzichte van de 
gradering van gewrichtsspleetvernauwing is dat het mogelijk gevoeliger is voor 
subtiele veranderingen. Dit moet nader worden onderzocht in longitudinale studies. 
toekomstPercePtieven
Dit proefschrift vergroot onze kennis over handartrose subtypen en factoren die van 
invloed zijn op progressie van handartrose. Hierdoor wordt een bijdrage geleverd aan 
de identificatie van potentiële aangrijpingspunten voor de ontwikkeling van nieuwe 
behandelingen die het ziektebeloop gunstig beïnvloeden of zelfs in staat zijn om 
de ontwikkeling van artrose te voorkomen. Ook draagt dit proefschrift bij aan het 
verbeteren van patiënt informatie en behandeling gericht op de individuele patiënt.
We laten zien dat het beloop van symptomen in handartrose variabel is over de tijd 
terwijl radiologische afwijkingen toenemen over de tijd. Verandering in symptomen 
en toename van radiologische afwijkingen waren niet aan elkaar gerelateerd. Dit 
betekent dat het klinische en radiologische beloop aparte processen zijn waardoor 
de ontwikkeling van structuur modificerende behandelingen met klinisch voordeel 
uitdagend is. Een verklaring voor de afwezigheid van associatie tussen verandering 
in symptomen en structurele afwijkingen kan zijn dat de uitkomstmaten die we 
gebruiken niet gevoelig genoeg zijn. Een andere reden kan zijn dat het ziektebeloop 
fluctueert over de tijd en dat meer meetmomenten nodig zijn om de veranderingen 
over de tijd vast te leggen. Geavanceerde technieken zijn nodig om de relatie tussen 
het beloop van symptomen structuur afwijkingen te onderzoeken, zoals meting van 
gewrichtsspleet ruimte, echografie en MRI.
Het uiteindelijke doel van ons onderzoek is om bij te dragen aan de ontwikkeling 
van nieuwe behandelingen die het ziektebeloop gunstig beïnvloeden of zelfs de 
ontwikkeling van artrose voorkómen. Op dit moment zijn de behandelmogelijkheden 
beperkt tot patiëntinformatie, patiënteducatie en symptoomverlichting. Dit is deels 
het gevolg van ontbreken van inzicht in mechanismen betrokken in het ziekteproces 
en de bron van pijn. Complicerende factor is dat handartrose een heterogene 
aandoening is met verschillende subtypen en een variabel ziektebeloop zoals we 
in dit proefschrift laten zien. Karakterisering van deze subtypen en hun specifieke 
risicofactoren helpt bij de identificatie van patiëntgroepen die baat kunnen hebben van 
specifieke behandelingen. Een voorbeeld is erosieve handartrose. Uit dit proefschrift 
en ander onderzoek blijkt dat (lokale) inflammatie waarschijnlijk een belangrijke rol 
speelt in de ontwikkeling en progressie van erosieve handartrose. Dit betekent dat 
anti-inflammatoire therapie werkzaam zou kunnen zijn in dit type handartrose. In een 
trial van Verbruggen et al. werd gezien dat Adalimumab, een TNFα-blocker, erosieve 
progressie verminderde vergeleken met placebo. Wij participeren in de multicenter 
internationale EHOA studie, een placebo gecontroleerd gerandomiseerd onderzoek 
naar de klinische effectiviteit en het effect op structuur afwijkingen van de TNFα-
blocker Etanercept. De eerste resultaten worden spoedig verwacht.
Voor de differentiatie van handartrose fenotypen en de verder onderzoek naar het 




die voor een lange periode worden vervolgd met frequente evaluatiemomenten. 
Zoals eerder genoemd zijn sensitieve meetinstrumenten nodig zoals meting van 
gewrichtsspleet ruimte, echografie en MRI. Biochemische markers zoals kraakbeen-, 
synovium- en botafbraak producten, cytokines en adipokines zijn ook behulpzaam. 
In recent onderzoek in de GARP studie vonden we dat baseline adiponectine niveaus 
geassocieerd waren met progressie van handartrose over 6 jaar. In dezelfde populatie 
waren uCTX-II niveaus over de tijd, een marker van kraakbeenafbraak, geassocieerd 
met progressie van gewrichtsspleetvernauwing.
Vanwege de noodzaak voor patiëntencohorten zijn we in juni 2009 gestart met de 
Hand OSTeoArthritis in Secondary care (HOSTAS) studie. Dit is een prospectief cohort 
onderzoek op de polikliniek van het Leids Universitair Medisch Centrum met patiënten 
met handartrose vastgesteld door de behandelend reumatoloog. Klinische gegevens, 
radiologische gegevens (röntgenfoto’s en MRI) en bloed- en urinemonsters worden 
regelmatig verzameld. Met dit en ander onderzoek hopen we verder inzicht te krijgen 
in de complexe pathogenese en het beloop van handartrose en daardoor bij te dragen 
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